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 Bioluminescence is the chemical production of light that results when a 
luciferase enzyme catalyzes the luminogenic oxidation of a small-molecule 
luciferin substrate. The numerous luciferases and luciferins nature has evolved 
can be used to illuminate biological processes, from in vitro assays to imaging 
processes in live animals. However, we can improve the utility of 
bioluminescence through modification of these enzymes and substrates. My 
thesis work focuses on developing reporters that expand the bioluminescent 
toolkit and improving our understanding of how bioluminescence works on a 
molecular level. 
 The first part of my thesis focuses on characterizing luciferases and 
luciferins that improve bioluminescence imaging in vivo. Some of our luciferins 
can outperform the natural D-luciferin substrate in live mouse imaging, while 
others are selectively utilized by mutant luciferases in live mouse brain. We also 
engineered luciferins that can selectively report on endogenous enzymatic 
activity in live mice.  
 The second part of my thesis focuses on determining the molecular details 
of how enzymes related to firefly luciferase, long-chain fatty acyl-CoA 
synthetases (ACSLs), can function as latent luciferases. I have determined the 
structure for one of these enzymes and improved its bioluminescent activity with 
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synthetic luciferins enough to image in live mouse brain. I also characterized the 
selectivity in chimerized enzymes that combine firefly luciferase and ACSLs. In 
summary, my work improves the utility of bioluminescence for in vivo use and 
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 Luminous reporters are frequently used to visualize biology. From 
determining localization of a protein in a cell to measuring gene silencing in live 
animals, light-based reporters can provide a real-time view of biology that may be 
otherwise invisible. For imaging at magnifications necessary for individual cells, 
fluorescent reporters are generally used (Ettinger and Wittman., 2014.). 
Alternatively, for imaging deep tissues in live animals, bioluminescence holds 
multiple advantages over other luminous imaging modalities (Close et al., 2010.). 
Bioluminescence’s usefulness for imaging in live animals has pushed numerous 
labs and companies to investigate how they can extend its utility. Elucidating the 
molecular details of how bioluminescence works lays the foundation to build a 
bioluminescent toolkit. 
 Bioluminescence is the chemical production of light that results when an 
ezyme known as a luciferase oxidizes a small-molecule luciferin. This presents 
two different approaches to extending the utility of bioluminescence, either 
modify/create luciferases or modify/create luciferins. Combining engineered 
luciferases with synthetic luciferins allows us to go beyond the confines that 
restricted bioluminesce’s evolution in nature. We find that synthetic luciferins can 
emit more robust light emission in select animal tissues or report on endogenous 
enzymatic activity in live cells or animals (Paley et al., 2013.; Mofford et al., 
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2015.). Orthogonal luciferase-luciferin pairs are also possible and allow us to 
measure more than one process in the same animal (Jones et al., 2017.). 
 Bioluminescence has evolved more than once. Understanding the 
evolutionary trajectory of firefly luciferase (Fluc) from an ancestral long-chain 
fatty acyl-CoA synthetase (ACSL) enzyme presents the opportunity to artificially 
evolve luciferases and luciferins starting with this class of related enzymes. The 
abundance of ACSLs in nature provides many starting points for engineered 
bioluminescent reporters. Since ACSLs process fatty acids and gave rise to Fluc, 
this also suggests that Fluc-based bioluminescence may be appropriated for 
measuring endogenous fatty-acid processing enzymes in live cells or animals, 
including enzymes with pharmacological value (Mofford et al., 2015.). 
Firefly bioluminescence 
To produce light, a luciferase enzyme oxidizes a luciferin substrate to 
access an excited state. This excited-state oxyluciferin releases a photon of light 
when it relaxes to the ground state. In contrast to fluorescence, which requires 
incident light to generate an excited-state emitter, bioluminescent organisms 
achieve light emission through purely chemical means. This makes 
bioluminescence particularly suited to dark environments such as the night sky 
and the depths of the ocean. Bioluminescence has evolved multiple times in 
nature, with distinct luciferases and luciferins that accomplish light emission 
using unique protein and chemical scaffolds (Fallon et al., 2018.; Petushkov et 
al., 2014.; Davis et al., 2016.; Kaskova et al., 2017.; Kaskova et al., 2016.).  
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For example, deep tissue imaging in live animals requires a favorable 
signal-to-noise ratio.  Bioluminescence exhibits no background, leaving the 
robustness of light emission as the key obstacle to its utility. One notable 
exception to the lack of background signal with bioluminescence exists in 
coelenteramide luciferins, which are prone to auto-oxidation. However, their use 
in vivo is further confounded by their emission spectra, which is heavily absorbed 
by hemoglobin. These factors, in addition to the toxicity of coelenteramide 
luciferins, make them poor bioluminescent reporters for deep-tissue imaging. 
Beetle-based bioluminescent reporters do not possess this auto-oxidizing 
tendency, making them better suited to this application. 
Fireflies belong to a family of bioluminescent beetles that have evolved 
multiple distinct luciferases that all use D-luciferin to emit light (Amaral et al., 
2019.). Firefly luciferase (Fluc) and its substrate D-luciferin were characterized 
over half a century ago (White et al., 1963.; White et al., 1965.; McElroy et al., 
1969.) and have been widely adopted for research use. 
Mechanism of beetle bioluminescence 
The mechanism of firefly luciferase proceeds in two general steps: first D-
luciferin is adenylated, then the AMP ester reacts with oxygen to access an 
excited-state molecule of oxyluciferin (Figure 1.1a) (Fraga, 2008.). The finer 
details of the light-emitting reaction as currently understood are as follows 
(Figure 1.2a): 1) the D-luciferin carboxylate attacks the alpha phosphate group of 
ATP to yield pyrophosphate and D-luciferyl-AMP; 2) deprotonation of the C4 
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carbon generates an enolate-stabilized carbanion (Mofford et al., 2014.; Min et 
al., 2011.; and Branchini et al., 2015.); 3) the carbanion reduces molecular 
oxygen by single-electron transfer (SET) to generate superoxide and a C4 radical 
(Mofford et al., 2014.; Min et al., 2011.; Branchini et al., 2015.); 4) the radicals 
combine to form a peroxide attached to the C4 carbon (Mofford et al., 2014.; Min 
et al., 2011.; Branchini et al., 2015.); 5) internal nucleophilic attack of the 
peroxide on the electrophilic carbonyl group displaces AMP, resulting in 
formation of a transient high-energy dioxetanone ring; 6) the oxygen-oxygen 
bond in the dioxetanone ring breaks, resulting in the release of carbon dioxide 
and the generation of an electronically-excited oxyluciferin; 7) the oxyluciferin 
relaxes to the ground state, releasing a photon of light.  
 
 
Figure 1.1. Fluc retains ancestral ACSL activity. A) Fluc catalyzes the 
adenylation and oxidation of D-luciferin to release a photon of light; B) Fluc can 
also ligate coenzyme A to fatty acids. Both reactions involve a key adenylated 






Figure 1.2. Mechanism of beetle bioluminescence. A) D-luciferin is 
adenylated, which makes the C4 carbon more acidic. The carbanion reduces 
molecular oxygen, forming a C4 radical and superoxide. Recombination of the 
radicals forms a peroxide that then attacks the AMP ester to form a strained 
dioxetanone ring. The oxygen-oxygen bond breaks, releasing carbon dioxide and 
forming an excited-state oxyluciferin, which radiatively relaxes to the ground 
state; B) In a “dark” reaction pathway, the C4 radical intermediate can instead 
form dehydroluciferyl-AMP, which is incapable of further oxidation and light 
emission. 
 
The chemistry of light emission is inherent to the luciferin substrate, and 
oxygen plays a critical role. Notably, simply treating a luciferin ester in DMSO 
with base in the presence of oxygen will result in light emission, following the 
general mechanism described above (White et al., 1971.; Seliger and McElroy, 
1962.). The energy needed to access an excited state is provided by breaking an 
oxygen-oxygen bond, a common feature of bioluminescent and 
chemiluminescent reactions. This suggests that enzymes capable of forming an 
AMP ester of luciferin should give rise to luciferase activity, where the 
subsequent light emission chemistry is largely directed by the luciferin ester.  
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It should be mentioned that a non-productive, “dark” reaction can also 
occur (Figure 1.2B). In step 4 of the luciferase mechanism outlined above, there 
is another possible outcome, in which superoxide does not form a C4-peroxide, 
but instead abstracts a hydrogen from the C5 carbon, forming dehydroluciferyl-
AMP and a peroxide anion (Pirrung et al., 2017.). In this case, there is no 
formation of an excited-state oxyluciferin, and no light emission. Furthermore, 
dehydroluciferyl-AMP is a luciferase inhibitor that must be displaced for further 
catalysis to occur. For in vitro luciferase assays, the inclusion of coenzyme A is 
often used to help remove this unwanted inhibitory byproduct, presumably by 
forming the corresponding dehydroluciferyl-CoA. 
Evolution of firefly bioluminescence 
 Bifunctionality of firefly luciferase 
In addition to catalyzing light emission from D-luciferin, Firefly luciferase 
(Fluc) is also able to ligate coenzyme A to fatty acids (Figure 1.1) (Oba et al., 
2003.). This makes Fluc a bifunctional enzyme; it can function as both a 
luciferase and a long-chain fatty acyl-CoA synthetase (ACSL). Enzymatic 
promiscuity to accommodate a range of substrates is a common theme in 
evolution, contributing to the rich diversity of chemistries that living organisms 
require (O’Brien and Herschlag, 1999.; Weng, J-K, 2014.). Fatty acyl-CoA 
synthetases (ACSs) are a diverse class of enzymes found in all kingdoms. These 
enzymes activate fatty acids with ATP, forming an acyl-AMP ester and 
pyrophosphate. In a second step, the AMP moiety is displaced with coenzyme A, 
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yielding a fatty acyl-CoA thioester.  Since cells utilize various different lengths of 
fatty acids, nature has evolved ACSs that are binned into four classes in the 
scientific literature: short chain fatty acyl-CoA synthetases (ACSS) (which 
process fatty acids of chain length 2-3 carbons long), medium chain fatty acyl-
CoA synthetases (ACSM) (which process fatty acids of chain length 4-12 
carbons long), long chain fatty acyl-CoA synthetases (ACSL) (which process fatty 
acids of chain length 12-22 carbons long), and very long chain fatty acyl-CoA 
synthetases (ACSVL) (which process fatty acids of chain length greater than 22 
carbons long) (Watkins, 2008.). 
McElroy et al. noted similarities between the enzymatic activities of Fluc 
and ACSLs as early as 1967, pointing out the shared need for adenylation to 
activate fatty acid and D-luciferin substrates (McElroy et al., 1967.). Fluc shares 
the greatest amino acid sequence identity with ACSL enzymes and even retains 
its ancestral ACSL activity (Oba et al., 2003.). Fluc adenylates and ligates 
coenzyme A to fatty acids of chain length greater than 12 carbons most 
efficiently, which makes it a bifunctional enzyme: a luciferase and an ACSL, 
depending on the substrate (Oba et al., 2003.). Despite the production of 
different products, the overall chemistry of ACSLs and firefly luciferase are quite 
similar in that both involve the formation of an activated AMP-ester intermediate 
from a carboxylic acid. Significant differences occur in the subsequent reactions 
of the adenylated intermediates. When a fatty acid is the substrate, the AMP 
moiety is displaced by CoA to generate a fatty acyl-CoA (Oba et al., 2003.). L-
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luciferin, the enantiomer of D-luciferin, will similarly form a CoA thioester (Fraga 
et al., 2005.; Nakamura et al., 2005.). It is only in the special case of D-luciferin 
that the substrate reacts with oxygen to form an excited-state oxyluciferin 
(Nakamura et al., 2005.). 
Evolution from ancestral fatty acyl-CoA enzyme promiscuity 
Fireflies are not the only bioluminescent beetles. Click beetles also 
evolved luciferases (Oba et al., 2010.). However, click beetle luciferases differ in 
sequence and enzymatic activity when compared to firefly luciferase (Oba et al., 
2010.). Additionally, the location and morphology of the lantern organs differ 
between fireflies and click beetles. Both firefly and click beetle luciferases use the 
same substrate (D-luciferin), but they do not all emit light of the same color 
(Wood et al., 1989.). While most firefly species emit yellow-green light, some 
click beetles emit orange light (Stolz et al., 2003.). Since D-luciferin is the 
common light emitter in the bioluminescent reaction, this means there are 
differences in the environment of the oxyluciferin during its radiative relaxation to 
the ground state. Furthermore, Fluc retains ACSL activity, but click beetle 
luciferases such as the ventral and dorsal luciferases from P. angustus both lack 
ACSL activity (Oba et al., 2010.). These differences could reflect divergence of a 
common luciferase, or convergent evolution of two or more distinct ancestral 
enzymes to achieve light emission with D-luciferin. Complete genomes for 
different bioluminescent beetle species are now available, and analysis of these 
genomes adds credence to the latter theory: the luciferases for fireflies and click 
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beetles both arose from separate duplication events of ancestral ACSLs, which 
independently converged on luciferase activity with D-luciferin (Fallon et al., 
2018.). 
Sequence and structural conservation between firefly luciferase and 
fatty acyl-CoA synthetases 
The structures of firefly luciferase and ACSLs share a common fold. In 
fact, homologous ACSLs were used to infer the unoccupied binding sites of 
luciferin and ATP within the first Fluc crystal structure (Conti et al., 1996.). These 
predictions in the apo-structure were largely confirmed when structures of Fluc 
co-crystallized with oxyluciferin and AMP were later published (Nakatsu et al., 
2006.). Like ACSLs, firefly luciferase consists of a large ~440 amino acid N-
terminal domain and a small ~110 amino acid C-terminal domain connected by a 
short hinge (Conti et al., 1996.). The interface between the two domains contains 
the active site, with the N-terminal domain contributing most of the residues 
responsible for binding the substrate, while the C-terminal domain introduces two 
lysine residues that participate in catalyzing the adenylation and oxidation 
reactions (Sundlov et al., 2012.). The two domains rotate independently of one 
another to mediate the two separate chemistries of adenylation and oxidation 
(Sundlov et al., 2012.). This rotation presents the two alternating lysine residues 
contained within the C-terminal domain (lysine 529 in the adenylation 
conformation and lysine 443 in the oxidation conformation) that mediate the 
adenylation and oxidation reactions and efficiently couples the reactions for 
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robust bioluminescence (Sundlov et al., 2012.). Lysine 529 likely activates ATP 
toward attack by the carboxylate of luciferin, while lysine 443 helps to activate the 
AMP ester of luciferin toward enolization (for the light emitting reaction) or attack 
by CoASH (for the thioesterification reaction) (Sundlov et al., 2012.). These 
lysine residues are conserved in ACS family enzymes and are critical for their 









Figure 1.3. Alignment of firefly luciferase with homologous insect fatty 
acyl-CoA synthetases. Photinus pyralis firefly luciferase (Fluc), Agrypnus 
binodulus luciferase-like protein (AbLL), Drosophila melanogaster long-chain 
fatty acyl-CoA synthetase CG6178, and Pyrophorus angustus luciferase-like 
protein (PaLL) aligned using MUSCLE (Chojnacki et al., 2017.). Coloring 
indicates similarity in sequence, with darker shades of blue representing more 
similarity. Black asterisks under the lysine residues 443 and 529 (Fluc 
numbering) indicate catalytically important residues detailed in the text. The red 
vertical line and corresponding asterisk indicates where the N-terminal domains 
and C-terminal domains meet in the enzymes. Below the alignment are luciferin 
structures and the enzymes that can catalyze light emission from them. 
 
Since Fluc shares sequence identity and enzymatic activity with insect 
ACSLs, Oba et al. initially tested whether D. melanogaster CG6178, a 
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homologous ACSL from the fruit fly, could function as a luciferase and emit light 
with D-luciferin (Oba et al., 2004.). Unfortunately, CG6178 was incapable of 
functioning as a luciferase with the natural substrate. They next tested whether 
chimeras between Fluc and CG6178 are capable of luciferase activity (Oba et al., 
2006.). The C-terminal domain of CG6178 (residues 436-544) was connected to 
the N-terminal domain of Fluc (residues 1-437) to make one of two chimeras. 
This chimera was found to be a functional luciferase. In a second chimera, 
CG6178’s N-terminal domain (residues 1-435) was connected to the C-terminal 
domain of Fluc (residues 438-550). This latter chimera lacked luciferase activity, 
but retained ACSL activity.  
These results illustrate that the N-terminal domain of Fluc is important for 
effective light emission with D-luciferin, but the C-terminal domain can be 
substituted with a corresponding domain from a related adenylating enzyme. In 
another compelling demonstration of the functional closeness of ACSLs to 
luciferase, Oba et al. functionally converted the Agrypnus binodulus luciferase-
like protein AbLL into a luciferase capable of weakly emitting light with D-luciferin 
by mutation to restore a key residue in the binding site (serine 347 in Fluc) (Oba 
et al., 2009.). Interestingly, this serine makes a water-mediated hydrogen bond to 
the benzothiazole nitrogen that is important for the binding and orientation of the 
natural luciferase substrate D-luciferin, but is dispensable for synthetic luciferase 
substrates such as CycLuc2 (Harwood et al., 2011.). With the emerging number 
of ACSLs that bear homology to Fluc and can function as latent luciferases with 
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synthetic luciferins (Mofford et al., 2017.), it would be helpful to revisit the 
chimera experiments performed by Oba et al. in 2006 (Oba et al., 2006.), 
chimerizing domains from multiple ACSLs with Fluc to create luciferases with 
unique substrate preferences and activities. 
Drosophila ACSL CG6178 is a latent luciferase with synthetic luciferins 
 Despite lacking luciferase activity with the natural substrate D-luciferin, 
Mofford et al demonstrated that the insect ACSL CG6178 is a latent luciferase 
when provided synthetic luciferins, specifically CycLuc2 (Mofford et al. 2014.). 
Additionally, CG6178 could catalyze light emission when provided D-luciferin that 
was pre-adenylated (Mofford et al., 2014.). This suggests that CG6178 can 
oxidize D-luciferin, but is prevented from performing the adenylation step that is 
initially required for bioluminescence. Determining the molecular basis for this 
substrate discrimination could thus hold the key to understanding CG6178’s 
selectivity and enhancing its luciferase activity. Determining a structure for 
CG6178 could provide the detail needed to unlock the details of CG6178’s latent 
luciferase activity. As a selective luciferase, CG6178 could be valuable for 
contributing to a growing palette of bioluminescent reporters usable for 
illuminating biology. 
Using bioluminescence as a reporter 
Firefly luciferase accepts modified luciferins 
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In nature, fireflies all use the natural substrate D-luciferin. However, the 
enzyme firefly luciferase can accept a wide range of synthetic luciferins (Kaskova 
et al., 2016.). This flexibility in luciferase’s catalysis has been exploited by labs 
seeking improved reporters to augment the firefly bioluminescent system for 
research use (Figure 1.3B). Based on this willingness to catalyze light emission 
with such a wide range of luciferin analogs, it would be useful to explore more 











Figure 1.4. Natural and synthetic luciferins. Luciferases oxidize their luciferin 
substrates to access an excited-state molecule that emits light. A) Many 
luciferases utilize imidazopyrazinone luciferins, which are directly oxidized by 
their luciferase. Coelenterazine is the substrate for Renilla, Gaussia, and many 
other marine luciferases (Kaskova et al., 2016.). Vargulin is used by Cypridina 
and some fish (Kaskova et al., 2016.). Furimazine is the synthetic 
amidazopyrazinone substrate for NanoLuc (Hall, et al., 2012). B) Beetle 
luciferases all use the same substrate, D-luciferin, which must first be activated 
to an AMP ester before oxidation to the excited-state oxyluciferin (also shown in 
more detail in Figure 1.2). Consequently, D-luciferin is much more stable toward 
oxidation than imidazopyrazinones. Many synthetic modifications are tolerated by 
firefly luciferase.  
In vivo use  
Pioneering work by Contag and coworkers first established that 
bioluminescent bacteria could be imaged in live mice using a sensitive CCD 
camera, and then extended these results to other luciferases (Prescher and 
Contag, 2010). Many different luciferase-expressing cell lines, transgenic 
luciferase-expressing animals, and other bioluminescent reporters are now 
available for noninvasive imaging in live mice as has been extensively reviewed 
elsewhere (Prescher and Contag, 2010.; Dothager et al., 2009.). 
The most common choices of luciferase and luciferin for in 
vivo bioluminescence imaging (BLI) are firefly luciferase and its substrate D-
luciferin. Photon emission from this pair extends into tissue-penetrating red and 
near-infrared wavelengths (Zhao et al., 2005.), the substrate is nontoxic and 
stable in cells and live animals, and bioluminescence can be readily imaged 
several minutes after routine intraperitoneal (IP) injection of the substrate. 
Coelenterazine-utilizing enzymes such as Renilla and Gaussia are less 
commonly used due to the poor tissue penetration of the blue-green light emitted 
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by these marine luciferases (Haddock and Moline, 2010.) and the high cost and 
inherent instability of their imidazopyrazinone-based luciferin, which is prone to 
auto-oxidation (Otto-Duessel et al., 2006.). Typically, these luciferins must be 
prepared immediately prior to use, injected intravenously (IV), and rapidly imaged 
(Gil et al., 2012.; Stacer et al., 2013.; Mezzanotte et al., 2013.).  
The most common method for BLI with D-luciferin is to inject 150 mg/kg 
intraperitoneally (IP), and to image the mice roughly 10 minutes later, when 
emission typically is at its peak. For the average mouse, this is 0.1 mL of a 100 
mM D-luciferin solution. It is not clear how much luciferin actually reaches 
luciferase-expressing cells and tissues. The biodistribution of D-luciferin in the 
mouse is not homogenous, and access to some tissues (e.g., the brain) is 
relatively low (Berger et al., 2008.). 
Synthetic luciferins, due to their chemical modification, are acknowledged 
to possibly influence tissue distribution in ways that differ from D-luciferin. 
Aminoluciferin (Figure 1.4: 2) has been shown to emit 25% greater photon flux 
than D-luciferin from the ubiquitously-expressing transgenic luciferase mouse 
L2G85 when compared at a low IP injection dose of 0.1 mL of 1 mM substrate 
(Shinde et al., 2006.). Aminoseleno-D-luciferin (Figure 1.4: 7) yields lower peak 
photon flux than aminoluciferin after IV injection of a 2.5 mM solution (0.1 mL) 
(Conley et al., 2012.). BODIPY 650/665 X-AL (Figure 1.4: 8) was compared to 
aminoluciferin by injecting a mouse with a 0.1 mM solution (0.1 mL) into 
subcutaneous luciferase-expressing tumor cells (Kojima et al., 2013.). While the 
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light emission was red-shifted, the overall photon flux was lower than 
aminoluciferin and no comparison was made to D-luciferin or using standard IP 
or IV injection methods. 
Shifting the color of bioluminescent light emission often comes at the cost 
of weaker overall signal 
Because infrared light is less absorbed by hemoglobin (Weissleder and 
Ntziachristos, 2003.), much emphasis has been placed on finding ways to 
modulate luciferases to increase light emission in the red and near-IR. While the 
broad emission of firefly luciferase already contains a significant near-IR 
component over 650 nm, shifting the emission to even longer wavelengths would 
in theory enhance our ability to image deeply within living organisms. However, 
luciferase mutants and homologs with red-shifted spectra do not significantly 
increase the total emission of red light from D-luciferin compared to firefly 
luciferase (Viviani et al., 1999.; Branchini et al., 2010.; Liang et al., 2012.). As the 
peak emission is red-shifted, there is a concomitant reduction in light intensity, 
due in part to a lower quantum yield at the longer wavelength. Unfortunately, in 
vivo studies that control for luciferase expression levels have not shown 
improvements in sensitivity for red-shifted luciferases over the standard codon-
optimized firefly luciferase luc2 (Mezzanotte et al., 2013.; Liang et al., 2012.). 
Towards orthogonality 
The noninvasive interrogation of multiple features in living animals can be 
achieved by combining luciferases that use D-luciferin with luciferases that use 
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coelenterazine or other imidazopyrazinones (Figure 1.4) (Stacer et al., 2013.; 
Mezzanotte, et al., 2013.; Maguire et al., 2013.). However, these approaches 
suffer the inherent shortcomings of imidazopyrazinones outlined above. 
Alternatively, the complementary modification of luciferin substrates and 
mutation of luciferases could potentially allow the use of two (or more) selective 
beetle luciferin-luciferase pairs in vivo. Mutagenesis of firefly luciferase can 
improve the utilization and selectivity for synthetic aminoluciferins over D-
luciferin in vitro and in live cells, suggesting that this approach is feasible 
(Harwood et al., 2011.). 
Caged bioluminescent reporters 
Geiger, Miska and coworkers pioneered the concept of bioluminogenic 
substrates that release D-luciferin or 6′-aminoluciferin upon the action of a 
hydrolytic enzyme (e.g., phosphatase, esterase, protease, β-galactosidase, or 
sulfatase) (Miska et al., 1987.; Miska et al., 1988.; Geiger et al., 1992.; Monsees 
et al., 1994.). Prior to enzyme activation, these molecules are not light-emitting 
substrates for luciferase. Enzymatic release of the luciferin substrate therefore 
reports the presence of this enzyme activity. Other workers have extended this 
“caged” or “pro-luciferin” concept to allow in vivo imaging of the enzymatic activity 
of β-galactosidase (Wehrman, et al., 2006.), proteases (Van de Bittner et al., 
2013.; Godinat et al., 2013.), and cytochrome P450s (Roncoroni et al., 2012.) as 
well as the detection of reactive small molecules such as hydrogen peroxide 
(Van de Bittner et al., 2013.; Van de Bittner et al., 2010.). However, in employing 
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this strategy, care must be taken to ensure that the reporter is actually specific 
for the desired analyte and is generally bioavailable (Li et al., 2014.). 
Furthermore, caged luciferins that do not emit light with luciferase could still 
potentially be inhibitors (Miska et al., 1987.) or even non-luminogenic substrates, 
a possibility that has not been universally explored. 
Caged luciferins are generally less soluble than their parent luciferin and 
cannot be supplied at the same high dose typically used for imaging with D-
luciferin. Furthermore, signal is not detected immediately upon release of D-
luciferin or 6′-aminoluciferin, but rather once the released luciferin contacts the 
luciferase enzyme. The construction of caged luciferins that release luciferin 
analogs possessing higher cell permeability, lower Km values for luciferase 
and/or improved pharmacokinetic properties may therefore prove useful for 
increasing the sensitivity of these reporters. 
Typically, caged luciferins have been used in transgenic mice that 
ubiquitously express luciferase (Cao et al., 2004.). In one interesting variant of 
this approach, BLI was used as a proximity reporter for two different cell types – 
an “activator” cell and a “reporter” cell (Sellmyer et al, 2013.). An activator cell 
expressing β-galactosidase converts the pro-luciferin Lugal into D-luciferin. 
Bioluminescence is only observed if the released D-luciferin diffuses out of the 
cell and into a reporter cell expressing firefly luciferase. Thus bioluminescence 




Caged luciferins could also potentially be used to improve delivery of the 
luciferin substrate. For example, esters of D-luciferin have been used in attempts 
to improve cellular delivery (Craig et al., 1991.). However, so far this approach 
has met with limited success, perhaps due to poor rates of esterase cleavage, 
low solubility, and/or the inhibition of luciferase by uncleaved esters. Luciferin 
esters are also inherently more reactive toward oxygen and prone to 
chemiluminescence than the parent luciferin. Developing caged luciferins that aid 
in access of luciferins to the site of luciferase expression would be useful to 
overcome the myriad of challenges that live animal imaging presents, especially 
in such environments as the brain, where D-luciferin is selectively pumped out of 
the blood brain barrier (Zhang et al., 2007.). 
Scope of the thesis 
Fireflies are a type of beetle that evolved the ability to emit light when their 
luciferase enzyme oxidizes their small molecule substrate, D-luciferin. Since 
bioluminescence uses chemistry to achieve light emission, luciferases and 
luciferins can be used as powerful tools to interrogate in vivo processes non-
invasively. Our lab has developed many luciferin molecules, mutant luciferases, 
and enzymes homologous to firefly luciferase to improve the utility of 
bioluminescence while improving our understanding of how it works on a 
molecular level. My thesis work focuses on improving in vivo bioluminescence 




The first part of my thesis will focus on improvement of bioluminescent 
imaging in vivo. The natural D-luciferin substrate fireflies use to emit light is 
limited in its access to select mouse tissues. Some of our synthetic luciferin 
substrates outperform D-luciferin in live mouse brain, as shown in Chapter II 
(Evans et al., 2014.; Mofford et al., 2015.). In Chapter IV, I demonstrate how 
combining these luciferins with mutant luciferases can provide even greater 
improvements in light emission, while also exhibiting selectivity (Adams Jr. et al., 
2016.). Additionally, in Chapter III we developed pro-luciferins, which require 
conversion to luciferin via a secondary enzymatic activity, that selectively report 
on endogenous fatty acid amide hydrolase activity (Mofford et al., 2015.). 
Therefore, my work uncovered improved bioluminescent reporters for in vivo use 
and an approach for longitudinally monitoring endogenous enzymatic activity in 
live animals. 
The second part of my thesis will focus on elucidating the molecular 
requirements for bioluminescence. In Chapters V and VI, we explored the range 
of luciferin modifications tolerated by firefly luciferase and mutants. These 
synthetic luciferins allow us to probe the requirements of bioluminescence 
regarding the substrate. To interrogate the enzyme requirements for 
bioluminescence, we considered enzymes evolutionarily related to Fluc. Fireflies 
evolved their luciferase from an ancestral long-chain fatty acyl-CoA synthetase 
(ACSL) enzyme (Fallon et al., 2018.). Firefly luciferase still retains this ancestral 
activity and our lab revealed nascent luciferase activity in homologous ACSLs 
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(Oba et al., 2003.; Mofford et al., 2014.; Mofford et al., 2017.). We completed the 
first crystal structure for one of these ACSLs, the fruit fly enzyme CG6178, and 
improved its luciferase activity through mutagenesis following its comparison to 
structures of firefly luciferase in Chapter VII. In Chapter VIII, we also 
demonstrated that chimeric luciferase enzymes that combine one of the two 
domains from firefly luciferase and the other domain from one of the related 
ACSLs can all function as luciferases that exhibit in vivo selectivity for synthetic 
luciferins. The lessons learned from engineering luciferins, luciferases, and 
luciferase-like enzymes enhance our understanding of how bioluminescence 
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Summary 
Firefly luciferase is the most widely used optical reporter for noninvasive 
bioluminescence imaging (BLI) in rodents. BLI relies on the ability of the injected 
luciferase substrate D-luciferin to access luciferase-expressing cells and tissues 
within the animal. Here we show that injection of mice with a synthetic luciferin, 
CycLuc1, improves BLI with existing luciferase reporters and enables imaging in 
the brain that could not be achieved with D-luciferin. 
 
Introduction 
Bioluminescence imaging (BLI) with firefly luciferase is a powerful and popular 
method to noninvasively visualize molecular and cellular features in live mice 
(Contag et al., 2002.; Dothager et al., 2009.; Prescher and Contag., 2010.). 
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Firefly luciferase chemically produces light from its small molecule substrate, D-
luciferin. Introduction of these components into cells or whole animals produces 
light that can be captured by sensitive detectors. The inherent simplicity of this 
imaging method has led to its ubiquitous adoption for in vivo monitoring of 
numerous disease states and cellular functions (Contag et al., 2002.; Dothager et 
al., 2009.; Prescher and Contag., 2010.). Improvements to the sensitivity and 
dynamic range of BLI are therefore of immediate and general utility for a wide 
variety of applications. 
 
Here, we show that BLI with an alternative luciferase substrate, CycLuc1 (Figure 
2.1), greatly improves the sensitivity of this optical imaging technique. We find 
that CycLuc1 exhibits superior properties to D-luciferin in vivo, requiring less 
substrate for imaging and providing more intense and persistent light output. 
Moreover, this substrate enabled imaging of luciferase-expressing cells in the 
brains of live mice that could not be observed with D-luciferin. Thus, using 
CycLuc1 in place of D-luciferin expands the scope of bioluminescence imaging 






Figure 2.1. Comparative BLI of tumor xenografts with D-luciferin and 
CycLuc1. A) Photon flux from BALB/c mice harboring 4T1-luc2 tumors. Mice 
were injected i.p. with the indicated dose of D-luciferin or CycLuc1 and imaged 
10 minutes post-injection. All images are plotted on the same scale. Photon 
intensities are shown in units of photons/s/cm2/steradian and quantified in (B). C) 
Quantified light output from 4T1-luc2 cells in BALB/c mice (n = 3) injected i.p. 
with 100 μl of 100 mM D-luciferin (standard BLI conditions), 5 mM D-luciferin, or 








Heretofore, efforts to improve the sensitivity of in vivo BLI have largely focused 
on improving the expression levels of firefly luciferase or identifying mutations 
that red-shift the emitted light to wavelengths that more readily penetrate through 
tissues. Much less attention has been focused on modulating the properties of 
the requisite small molecule luciferin, despite the importance of its cell 
permeability and pharmacokinetic properties in vivo. In standard BLI, relatively 
high concentrations of D-luciferin are required: 150 mg/kg is the typical dose for 
routing i.p. injections, which equates to 0.1 mL of 100 mM D-luciferin for an 
average 20 g. mouse. D-luciferin is also only modestly cell-permeable and 
experiments with radiolabeled substrate have shown that its tissue distribution is 
not homogenous and that uptake into some organs, such as the brain, is low. 
Thus, while D-luciferin yields high light output in vitro and performs well in vivo, it 
may not be the optimal substrate for imaging in the mouse. 
 
No synthetic luciferin has yet shown improvement over the standard imaging 
conditions with D-luciferin in live mice, which likely reflects issues of cell 
permeability, poor biodistribution, reduced efficiency of light emission, and/or no 
net increase in red light (tissue-penetrating) emission over D-luciferin. Recently, 
a variety of new substrates for firefly luciferase have been reported, including 
substrates with alkylated 6’-amino groups. All of these luciferin analogs yield 
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substantially lower levels of light emission than D-luciferin with the wild-type 
firefly luciferase in vitro. However, some substrates, such as the cyclic 
alkylaminoluciferin CycLuc1, exhibit improved light output in live cells relative to 
D-luciferin when compared at low substrate concentrations (e.g., <10 μM). 
Although D-luciferin yields superior photon flux from live cells when supplied at 
higher concentrations, we hypothesized that CycLuc1 could perform relatively 
well in vivo if the actual intracellular concentration of luciferin achieved in the 
mouse is limiting. 
 
Results and Discussion 
To evaluate CycLuc1 in vivo, we first tested its ability to image well-established 
mouse xenograft tumor models. We implanted 4T1-luc2 luciferase-expressing 
breast cancer cells into the right mammary fat pads of BALB/C mice, and imaged 
the mice eight days post-engraftment. Intraperitoneal injection of CycLuc1 
yielded a >10-fold higher bioluminescent signal than could be obtained from D-
luciferin injection at equivalent doses (Figures 2.1 and 2.2). Surprisingly, a 20-
200 fold lower dose of CycLuc1 yielded the same peak photon flux as the 
standard imaging conditions of 150 mg/kg D-luciferin (Figure 2.1C and Figure 
2.3). CycLuc1 doses up to 2000-fold lower than the standard D-luciferin imaging 
conditions could be imaged, while the equivalent concentrations of D-luciferin 
provided either weak or no signal (Figure 2.1). One hour after injection, the 
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relative light emission from CycLuc1 was even more pronounced, primarily due 
to a ten-fold drop in D-luciferin light emission over this period (Figure 2.2). The 
improved performance of CycLuc1 also translated across different cell types, 
mouse strains, and implantation sites. Photon flux from luciferase-expressing 
DB7 breast cancer cells (DB7-luc) implanted in the hind flanks of FVB mice was 
up to 40-fold higher with CycLuc1 versus D-luciferin administration at an 
equivalent dose (Figure 2.4). CycLuc1 also enabled detection of luciferase-
expressing CMT-64 lung cancer cells implanted into the hind flank of C57BL/6 
mice, one of the most widely used mouse strains, providing increased signal 




        
 
Figure 2.2. Comparative BLI of tumor xenografts with D-luciferin and 
CycLuc1 after 1 hour. BALB/c mice harboring 4T1-luc2 tumors were injected 
i.p. with the indicated dose of D-luciferin (top images) or CycLuc1 (bottom 
images) and imaged 1 h post injection. All images are plotted on the same scale. 
Red circles outline the regions of interest (ROIs) used to quantify photon flux 
(below). In the bar graphs, photon flux values were calculated for all ROIs, and 
the fold increase in bioluminescent signal achieved with CycLuc1 relative to D-
luciferin (at varying concentrations) is plotted. Error bars represent the standard 






Figure 2.3. Bioluminescence images of 4T1-luc2 cells in BALB/c mice 
injected i.p. with 100 μl of 100 mM D-luciferin (standard BLI conditions) or 
the indicated dose of CycLuc1. 
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Figure 2.4. BLI of DB7-luc cells in FVB mice. DB7-luc cells were implanted 
into the right flanks of FVB mice prior to imaging with D-luciferin (5 mM-500 μM) 
or CycLuc1 (5 mM-500 μM). A) Representative images from mice treated with 5 
mM solutions are shown at peak emission intensities (top panels), one hour post-
injection (middle panels), and two hours post-injection (bottom panels). All 
images are plotted on the same relative scale, and the red circles outline the 
regions of interest (ROIs) used to quantify relative photon flux from the animals. 
B) The fold increase in bioluminescent signal achieved with CycLuc1 relative to 
D-luciferin (at various concentrations) is plotted. Error bars represent the 




Figure 2.5. BLI of CMT-64-luc cells in C57BL/6 mice. CMT-64-luc cells were 
implanted into the right flanks of FVB mice prior to imaging with D-luciferin (5 
mM-500 μM) or CycLuc1 (5 mM-500 μM). A) Representative images for mice 
treated with 5 mM solutions are shown at peak emission intensities (top panels), 
one hour post-injection (middle panels) and two hours post-injection (bottom 
panels). All images are plotted on the same relative scale, and the red circles 
outline the regions of interest (ROIs) used to quantify relative photon flux from 
the animals. B) The fold increase in bioluminescent signal achieved with 
CycLuc1 relative to D-luciferin (at various concentrations) is plotted. Error bars 
represent the standard error of the mean. 
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Next, to compare the distribution and trafficking of CycLuc1 and D-luciferin in 
vivo, we utilized a transgenic mouse that expresses luciferase in most tissues 
(L2G85-FVB). Consistent with previous studies, intraperitoneal injection of D-
luciferin revealed access to tissues throughout the mouse, albeit with the highest 
photon flux confined to the abdominal cavity near the site of injection (Figure 
2.6). In contrast, i.p. injection of CycLuc1 revealed a bioluminescent signal that 
was ten-fold higher in intensity and escaped from the abdominal cavity to give a 
broad distribution that was maintained for up to two hours (Figure 2.6). 
Comparison of intravenous injections was even more striking: CycLuc1 signal 
peaked at 4-5 min post-injection and then yielded a steady signal that was up to 
100-fold greater than that of D-luciferin, and persisted for more than 60 min 
(Figures 2.7 and 2.8). By contrast, with D-luciferin the signal peaked immediately 






Figure 2.6. Comparison of intraperitoneally-injected D-luciferin and 
CycLuc1 in luciferase-expressing transgenic mice. A) Photon flux from 
L2G85-FVB mice injected i.p. with 100 μl of 5 mM CycLuc1 (left) or D-luciferin 
(right) and imaged over time. Photon intensities are shown in units of 
photons/s/cm2/steradian and plotted on logarithmic scales. (B-C) Total photon 
output from L2G85-FVB luc mice treated with (B) CycLuc1 or (C) D-luciferin from 
above. The apparent bioluminescent half-lives are shown. Data are 







Figure 2.7. Comparison of tail vein-injected D-luciferin and CycLuc1 in 
luciferase-expressing transgenic mice. L2G85-FVB mice were injected i.v. 
with 100 μl of 5 mM (A) CycLuc1 or (B) D-luciferin. For (A-B), photon intensities 
are shown in units of photons/s/cm2/steradian and plotted on logarithmic scales. 
C) Total photon output from L2G85-FVB luc mice treated with CycLuc1 (i.v.) or 
(D) D-luciferin (i.v.). The apparent half-life of bioluminescent signal (t1/2) is shown. 
(Note: the animals were placed on the imaging bed immediately after injection 





Figure 2.8. Biodistribution of D-luciferin and CycLuc1 in luciferase-
expressing transgenic mice. Mice were injected with 100 μl of 5 mM (A) 
CycLuc1 or (B) D-luciferin and dorsal images were acquired until the 
bioluminescent signal returned to background levels (180 min for D-luciferin, 240 
min for CycLuc1). Images were also acquired following intravenous (i.v.) injection 
of 100 μl of 5 mM (C) CycLuc1 or (D) D-luciferin. For (A-D), photon intensities are 
shown in units of photons/s/cm/steradian and plotted on logarithmic scales. 
 
 
In light of these exciting results, we next asked whether CycLuc1 could improve 
bioluminescence signals in the brain. The blood-brain barrier limits the access of 
many small molecules to this tissue, and thus imaging in the brain is particularly 
challenging. To evaluate the ability of CycLuc1 to access brain tissue, we imaged 
mice that had been treated with adeno-associated virus 9 (AAV9) to express 
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codon optimized luc2 luciferase in the brain striatum. We found that i.p. injection 
of CycLuc1 provided an 8.1 ± 1.5 fold higher signal than the standard 150 mg/kg 
D-luciferin, despite a 20-fold lower imaging dose of CycLuc1 (Figures 2.9 and 
2.10). Thus, CycLuc1 can readily cross the blood-brain barrier and access deep 
brain tissues. Next, we crossed Dat (also known as Slc6a3) Cre driver mice with 
Rosa26 floxed-stop luciferase reporter mice. Dat-Cre drives reporter expression 
at low levels from the endogenous Rosa26 promoter in dopaminergic neurons, 
primarily in the substantia nigra, one of the deepest brain tissues. Injection of 
these mice with D-luciferin failed to yield any measurable brain signal in vivo 
(Figures 2.9 and 2.11). In sharp contrast, we found that CycLuc1 not only 
enabled imaging in these same mice but that homozygous mice with two copies 
of the Rosa26-luc allele could be readily distinguished from heterozygous mice 








Figure 2.9. Comparison of D-luciferin and CycLuc1 in the brain. A) Photon 
flux from mice expressing AAV9-CMV-luc2 in the brain striatum ten minutes after 
i.p. injection with 100 μl of 5 mM CycLuc1 or 100 mM D-luciferin (n = 5). Error 
bars are S.E.M. ****P < 0.0001 (t-test). B) Photon flux from Dat-Cre+/-Rosa26-
luc+/- (n = 5) and Dat-Cre+/-Rosa26-luc+/+ (n = 5) mice after i.p. injection with 100 
μl of 5 mM CycLuc1. *** P < 0.001 (t-test). No quantifiable photon flux was 








Figure 2.10. Comparison of photon flux from AAV9-luc2 mice. Five female 
FVB mice were treated with adeno-associated virus 9 (AAV9) as described in the 
Methods to express codon-optimized luc2 luciferase in the brain striatum. Nine 
weeks after surgery, the mice were injected i.p. with the standard imaging dose 
of D-luciferin (0.1 ml of 100 mM) and imaged ten minutes post-injection. The next 
day, the same five mice were injected i.p. with 0.1 ml of 5 mM CycLuc1 and 
imaged ten minutes post-injection. Both images are plotted on the same scale, 
and the red circles outline the regions of interest (ROIs) used to quantify relative 




       
 
Figure 2.11. Comparison of photon flux from Dat-luc mice. Dat-luc mice were 
injected i.p. with the standard imaging dose of D-luciferin (0.1 ml of 100 mM) and 
imaged ten minutes post-injection. The next day, the same mice were injected 
i.p. with 0.1 ml of 5 mM CycLuc1 and imaged ten minutes post-injection. The first 
two mice are heterozygous for the Rosa26-luc allele, the third is homozygous. 
Both images are plotted on the same scale, and the red circles outline the 
regions of interest (ROIs) used to quantify relative photon flux. ROI4 was used to 
measure background signal. The top images were autoscaled by the Living 
Image software. In the bottom images, the same data is displayed with the 




The improved sensitivity of BLI with CycLuc1 has immediate ramifications for 
biological studies in mice. Simply replacing the obligatory injection of D-luciferin 
with CycLuc1 improves the sensitivity of bioluminescent detection, while retaining 
the use of existing luciferase reporters. CycLuc1 reduces the amount of substrate 
required for BLI and allows imaging at low doses where D-luciferin provides weak 
or no signal. Furthermore, CycLuc1 allows detection of low-level luciferase 
expression in deep brain tissues that cannot be detected with D-luciferin, and 
thus opens up new applications for noninvasive imaging in the brain. One 
potential contributor to the improved in vivo performance of CycLuc1 is a red-shift 
in the emitted photons to more tissue-penetrating wavelengths (Figure 2.12). 
However, the percentage of Cy5.5-filtered flux from the brains of live AAV-treated 
mice is actually slightly higher for D-luciferin than CycLuc1 (9.4% vs. 8.1%; 
Figure 2.13), perhaps reflecting the red-shift in luciferase emission previously 
reported at 37 °C in vivo (Zhao et al., 2005.). Moreover, a change in emission 
wavelength alone cannot explain the differences we observed in tissue 
distribution, signal persistence, or the ability to image at very low substrate 
concentrations where CycLuc1 is favored (Figure 2.13). In vivo, these same cells 
yield greater photon flux with CycLuc1, even in tumors that are located near the 
surface and/or proximal to the site of substrate injection. This suggests that the 
delivery of D-luciferin to luciferase-expressing cells in vivo is limiting, and that the 
cell permeability, lower Km, and bioavailability of CycLuc1 play important roles in 






Figure 2.12. Live cell bioluminescence with CycLuc1 and D-luciferin 
through a Cy5.5 filter. Bioluminescence imaging of (A) DB7-luc, (B) 4T1-luc2, 
and (C) CMT-64-luc cells treated with the indicated concentration of CycLuc1 
(light blue bars) or D-luciferin (dark blue bars). D) Light output from 50,000 4T1-
luc cells treated with 1 mM D-luciferin or CycLuc1. Photons were collected either 
with an open filter (light blue bars) or after passage through a Cy5.5 filter (dark 
blue bars). The percent filtered light captured in each case is shown in (E), *** P 
< 0.001 (t-test). For (A-E), error bars represent the standard error of the mean for 




                       
 
Figure 2.13. Photon flux from AAV9-luc2 mice through a Cy5.5 filter. Mice 
were imaged as described for Figure 10, with and without a Cy5.5 emission filter 
(695-770 nm bandpass). The ratio of Cy5.5-filtered photon flux to unfiltered 
photon flux is expressed as a percentage (D-luciferin: 9.4 ± 0.3 %; CycLuc1: 8.1 
± 0.2 %). Error bars are S.E.M. (n = 5 mice for each luciferin). ** P < 0.01 (t-test). 
 
Conclusion 
In conclusion, CycLuc1 improves in vivo BLI using existing luciferase reporters, 
yet requires much less substrate for imaging. Transgenic luciferase-expressing 
mice treated with CycLuc1 demonstrated that the analog has broad access to 
mouse tissues, and more persistent light emission than with D-luciferin by either 
i.p. or i.v. injection. In the brain, CycLuc1 provided stronger BLI signals than D-
luciferin, and even enabled detection of luciferase expression that could not be 
imaged with D-luciferin. Based on these results, CycLuc1 can be recommended 
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for immediate use in BLI, while future adaptation of related synthetic luciferins 
and mutant luciferases is expected to allow even greater improvements in the 
sensitivity, selectivity, and scope of in vivo bioluminescence reporters. 
 
Materials and Methods 
Contributions 
M.S.E. and J.A.P. imaged tumors and L2G85-FVB mice, G.R.R. synthesized 
CycLuc1, M.A.P. imaged cultured cells, J.P.C. bred Dat mice, S.T.A. and J.P.C. 
imaged AAV9 and Dat mice, N.A. contributed to the development of AAV9 
and Dat mouse models and manuscript editing, S.C.M. designed CycLuc1, and 
S.C.M. and J.A.P. led the study and wrote the manuscript. 
General 
D-luciferin and CycLuc1 were synthesized as previously described. Luciferase 
expressing 4T1 cells, CMT-64 cells, and DB7 cells were provided by the Contag 
laboratory (Stanford University). 
Mice 
Pathogen-free BALB/c, FVB/N, C57BL/6, and luciferase-expressing transgenic 
mice (FVB-Tg(CAG-luc, -GFP)L2G85Chco/FathJ) were obtained from either 
Charles River or the Jackson Laboratory and housed in UC Irvine’s AAALAC-
accredited animal-care facility. All mice used were littermates or age-matched (6-
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12 weeks of age) females, were provided access to food and water ad libitum, 
and housed in the animal facilities at UC Irvine. All procedures with these mice 
were approved by the Animal Care and Use Committee at UC Irvine (protocol 
#2011-2987 to J.A.P.). FVB/NJ, B6.SJL-Slc6a3tm1.1(cre)Bkmn/J(“Dat-Cre”), and 
FVB.129S6(B6)-Gt (ROSA)26Sortm1(Luc)Kael/J(“Rosa26-luc”) mice were purchased 
from the Jackson Laboratory and were maintained and used according to the 
guidelines of the Institutional Animal Care and Use Committee of the University 
of Massachusetts Medical School (docket #A978-12 to N.A.). Dat-Cre mice were 
mated with floxed-stop Rosa26-luc mice to generate white Dat-cre+/-Rosa26-luc+/- 
and Dat-Cre+/-Rosa26-luc+/+ mice. Offspring were genotyped by PCR. 
Tumor cell inoculations 
Mice were inoculated subcutaneously with 1 x 106 luciferase-expressing CMT-64 
or DB7 cells in serum-free RPMI media. Tumors were allowed to establish for 1-2 
weeks before imaging. To establish 4T1 tumors, aliquots of the cells were mixed 
1:1 by volume with Matrigel (usually 5 x 105 cells in 50 μl serum-free DMEM 
media plus 50 μl Matrigel per injection) and transplanted into the orthotopic 
second or fourth mammary fat pads (left or right side) of mice. Eight days post-
engraftment, the mice were injected i.p. with 100 μl of either D-luciferin or 






To image tumor cells in vivo, mice were injected i.p. with 100 μl of luciferin stocks 
(in PBS). The animals were anesthetized with isoflurane (2% in 1 l/min oxygen), 
and bioluminescence images were acquired using the IVIS Lumina system (a 
Xenogen Product from Caliper Life Sciences, now Perkin-Elmer). Images were 
acquired every 2 min for 30 min (10 s exposure/image). The mice were also 
imaged 1 h post-injection and 2 h post-injection (10 s exposure/image). Images 
were analyzed using Living Image software. Regions of interest (ROIs) were 
drawn around each cell mass, and the total number of photons within each ROI 
were recorded. ROI size was held constant across all images. Prior to imaging 
with CycLuc1, the mice were stratified using standard BLI conditions (100 μl i.p. 
injection of 100 mM D-luciferin in PBS). 
To analyze the biodistribution of D-luciferin and CycLuc1 in vivo, the compounds 
were injected (100 μl of 5 mM solutions in PBS) i.p. or i.v. into luciferase-
expressing FVB transgenic mice. The mice were imaged over time as described 
above, and quantitative analyses of the light emission were performed using 
Living Image software as above. 
Construction of AAV-CMV-luc2 
Codon-optimized luc2 luciferase from pGL4 (Promega) was cloned into the 
EcoR1-Sal1 sites of a pAAV-CMV vector (gift of Guangping Gao). The plasmid 
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was packaged into AAV serotype 9 by the University of Massachusetts Medical 
School Viral Vector Core. 
AAV9-CMV-luc2 vector striatal injections 
FVB/NJ mice (5 females, 6 weeks old, Jackson Laboratory, Bar Harbor, ME) 
were anesthetized with 250 mg/kg tribromoethanol prior to surgery, placed on a 
stereotactic frame and injected with 0.25 μl 1e13 GC AAV9-CMV-Luc2 by 
micropump syringe (Nanofil, World Precision Instruments) at the lateral edge of 
the striatum/cortex border (anterior 1 mm, lateral 3 mm, and ventral 2 mm from 
bregma). Imaging was performed at least two weeks after AAV injection. 
Brain imaging 
Bioluminescence imaging luciferase-expressing mice was performed as 
described above in the University of Massachusetts Medical School Small Animal 
Imaging Core using an IVIS 100 imaging system and analyzed with Living Image 
software and Graphpad Prism 6. 
Supplementary Material 
Refer to Web version on PubMed Central for supplementary material. 
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8684-8687. 
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Summary 
Firefly luciferase is homologous to fatty acyl-CoA synthetases. We hypothesized 
that the firefly luciferase substrate D-luciferin and its analogs are fatty acid 
mimics that are ideally suited to probe the chemistry of enzymes that release 
fatty acid products. Here, we synthesized luciferin amides and found that these 
molecules are hydrolyzed to substrates for firefly luciferase by the enzyme fatty 
acid amide hydrolase (FAAH). In the presence of luciferase, these molecules 
enable highly sensitive and selective bioluminescent detection of FAAH activity in 
vitro, in live cells, and in vivo. The potency and tissue distribution of FAAH 
inhibitors can be imaged in live mice, and luciferin amides serve as exemplary 
reagents for greatly improved bioluminescence imaging in FAAH-expressing 







Firefly luciferase is best known for its light emission chemistry with D-luciferin, but 
it is also a long-chain fatty acyl-CoA synthetase (ACSL) that can bind fatty acid 
substrates such as arachidonic acid (Figure 3.1) (Oba et al., 2003.). Conversely, 
we have recently shown that an ACSL from the fruit fly Drosophila 
melanogaster is a latent luciferase that can emit light with a synthetic luciferin 
(Mofford et al., 2014). In both cases, adenylation of a carboxylic acid is the first 
step in catalysis. Furthermore, both enzymes can bind fatty acids ranging from 
octanoic acid to arachidonic acid, suggesting that D-luciferin and aminoluciferin 
analogs (Reddy et al., 2010.; Adams et al., 2014.;Mofford et al., 2014) are acting 
as fatty acid mimics. Based in part on this observation, we hypothesized that 
luciferins are ideally suited to probe the chemistry of enzymes that release fatty 
acid products. 
Fatty acid amide hydrolase (FAAH) is a serine hydrolase that limits the lifetime 
and sphere of action of fatty acid amide second messengers by hydrolysis to 
their corresponding fatty acids (Figure 3.1) (Blankman and Cravatt, 2013.; 
Cravatt et al., 1996.). Most notably, arachidonoyl ethanolamine (anandamide) is 
a locally generated agonist for the cannabinoid receptor CB1. Inhibition of FAAH 
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prolongs the action of anandamide and is therefore an attractive drug target for 
the treatment of pain, anxiety, and cannabinoid dependence (Blankman and 
Cravatt, 2013.). Many FAAH inhibitors are being developed as potential 
therapeutics, and there is great interest in detecting FAAH activity in vivo (Shoup 
et al., 2015.). Current techniques to assay FAAH inhibitors in mice primarily 
require sacrificing the mouse, homogenizing the tissues, adding radioactive lipid 
substrates, and HPLC analysis of the products (Long et al., 2011.). This places 
large demands on time and quantities of mice required to evaluate inhibitors and 
furthermore cannot give longitudinal data from the same animal. Some inroads 
have been made with PET imaging probes for FAAH, but these are specialized 
and expensive tools with low throughput and signal-to-noise that lack the 





Figure 3.1. Enzyme mechanisms and luciferin structures. A) Firefly luciferase 
catalyzes light emission from D-luciferin. B) Firefly luciferase is also a fatty acyl-
CoA synthetase. C) FAAH cleaves anandamide to arachidonic acid. D) Luciferin 
amides could allow bioluminescence imaging of FAAH activity. 
 
FAAH readily accepts a wide range of saturated and unsaturated fatty acid 
amides in addition to anandamide (Cravatt et al., 1996.; Boger et al., 2000.) and 
has been shown to hydrolyze ethanolamides, primary amides, and methyl 
amides (Cravatt et al., 1996.; Boger et al., 2000.; Patricelli and Cravatt., 
1999.). We therefore hypothesized that FAAH could hydrolyze luciferin amides to 
their respective carboxylates, resulting in the formation of a luminogenic 
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luciferase substrate (Figure 3.1). Here we show that luciferin amides allow 
exquisitely selective and sensitive imaging of endogenous FAAH activity in live 
cells and in live mice. FAAH is both necessary and sufficient for bioluminescence 
to occur and is the only enzyme activating these probes. The performance of 
FAAH inhibitors can be imaged in live mice, and inhibitors that cross the blood-
brain barrier can be readily distinguished from those that cannot. Moreover, the 
amount of luciferin amide probe needed to perform this imaging is >1000-fold 
lower than typical D-luciferin imaging conditions but nonetheless improves overall 
signal from the brain. Thus, luciferin amides also excel at delivering luciferins into 
FAAH-expressing cells and tissues. 
Results and discussion 
To test our initial hypothesis, we synthesized four luciferin amides (Figure 3.1) by 
the condensation of electrophilic nitriles (Reddy et al., 2010.; Mofford et al., 
2014.) with a D-cysteine amide. Without a free carboxylate, these luciferin 
analogs are not light-emitting substrates for purified firefly luciferase (Figures 3.2 
and 3.3). Pretreatment of the luciferin amides with recombinant rat FAAH 
(Mofford et al., 2014) restores luminescent activity and could be specifically 
blocked by incubation with FAAH inhibitors such as PF3845 (Figures 3.2 and 3.3) 
(Ahn et al., 2009). The presence of FAAH or FAAH inhibitors has no effect on 
light emitted from the parent luciferins (Figures 3.2 and 3.3). Thus, luciferin 




Figure 3.2. FAAH inhibitor structures and FAAH inhibitor screen. A) FAAH 
inhibitor structures. B) Photon flux from the indicated luciferin analog (10 μM) 
normalized to emission in the presence of FAAH with no FAAH inhibitor. The 




Figure 3.3. Luciferin amides report on rat FAAH activity in vitro. A) Photon 
flux from the indicated luciferin analog (10 μM) in the absence of FAAH or 
presence of FAAH with and without a FAAH inhibitor. B) Direct comparison of 
each luciferin amide after treatment with rFAAH without inhibitor from (A). C) 
Dependence of photon flux on the concentration of rFAAH (30-579) after 30 min. 
incubation with the indicated luciferin amide at pH 7.4., ambient temperature. All 
assays were performed in triplicate and are represented as the mean ± SEM. 
 
 
We next sought to determine whether luciferin amides were specific to FAAH and 
sensitive enough to enable the detection of FAAH activity in live cells. Chinese 
hamster ovary (CHO) cells are known to express FAAH (Okamato et al., 
2005.), an integral membrane protein (Blankman and Cravatt., 2013.), but at 
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levels insufficient to detect with fluorescence-based assays (Ramarao et al., 
2005.). In contrast, treatment of luciferase-expressing CHO cells with luciferin 
amides resulted in robust bioluminescence (Figures 3.4A and 3.5). Potentially, in 
the complex environment of the cell, luciferin amides could be cleaved by 
proteases or other serine hydrolases. However, treatment with PF3845, which 
specifically inhibits FAAH but no other serine hydrolases (Ahn et al., 
2009.), blocked emission from luciferin amides but had no effect on luciferase 
activity in the presence of the parent luciferin (Figure 3.4A). Furthermore, 
inhibitors of other serine hydrolases had no effect, and we evaluated the potency 
of a wide range of FAAH inhibitors in the natural context of live cell membranes 
(Figures 3.6 and 3.7). Lacking an ionized carboxylate, the luciferin amides also 
served as excellent luciferin delivery vehicles in these FAAH-expressing cells, 
yielding higher bioluminescence signals than their parent luciferins at 
concentrations <100 μM (Figure 3.5). CycLuc1-methyl amide achieved higher 
maximal photon flux than CycLuc1-amide, presumably because uncleaved 
CycLuc1-amide can ultimately inhibit luciferase, while CycLuc1-methyl amide 





        
Figure 3.4. Luciferin amides report on FAAH activity in live mammalian 
cells. A) Relative photon flux from live luciferase-expressing CHO cells treated 
with the indicated luciferins and luciferin amides (125 μM) in the absence (black 
bars) or presence (red bars) of the FAAH inhibitor PF3845. The data are 
normalized to the uninhibited sample for each luciferin (black bars). B) Relative 
flux from live luciferase-expressing HeLa cells treated with the same set of 
substrates after transfection with empty pcDNA3.1 vector (black bars), 
pcDNA3.1-hFAAH (blue bars), or pcDNA3.1-hFAAH and treatment with the 
FAAH inhibitor PF3845 (red bars). The data are normalized to the uninhibited 
hFAAH-transfected sample for each luciferin (blue bars). All assays were 





Figure 3.5. Luciferin amides report on FAAH activity in live cells and 
improve signal over parent luciferins. A) Live CHO cells transfected with 
luciferase were incubated with 1 μM PF3845 for five minutes and then imaged 
with varying concentrations of the indicated luciferin analog. B) Live HeLa cells 
co-transfected with either luciferase and human FAAH or luciferase and empty 
vector were incubated with 1 μM PF3845 for five minutes and then imaged with 
varying concentrations of the indicated luciferin analog. The assay was 
performed in triplicate and is represented as the mean ± SEM. Curves were fit to 




                                 
Figure 3.6. Luciferin amides report on inhibitor potency in live cells. A) Live 
CHO cells transfected with luciferase were incubated with varying concentrations 
of FAAH inhibitor for five minutes and then imaged with CycLuc1-methyl amide 
(10 μM). B) Live HeLa cells co- transfected with luciferase and human FAAH 
were incubated with varying concentrations of FAAH inhibitor for five minutes and 
then imaged with CycLuc1-methyl amide (10 μM). The assays were performed in 
triplicate and are represented as the mean ± SEM. Data was fit by nonlinear 
regression to log(inhibitor) vs. response (three parameters) to determine relative 
IC50 values. CHO cell IC50 values: PF3845, 12 nM; URB597, 2.7 nM; URB937, 






Figure 3.7. Luciferin amides report on FAAH activity in live CHO cells. Live 
CHO cells transfected with luciferase were incubated with 1 μM of the indicated 
serine hydrolase inhibitor for five minutes and then imaged with the indicated 
luciferin analog (10 μM). All assays were performed in triplicate and are 
represented as the mean ± SEM. FAAH inhibitors: PF3845, PF750, PF622, 
URB597, URB937, OL135, and AZ513; MAGL inhibitors: JZL184 and KML29; 




                
Figure 3.8. Luciferin primary amides can inhibit luciferase in vitro. A) 
Purified firefly luciferase treated with 7.81 μM D-luciferin alone or in the presence 
of 10 μM or 25 μM D-luciferin amide. B) Purified luciferase treated with 7.81 μM 
CycLuc1 alone or in the presence of 10 μM or 25 μM of CycLuc1-amide, 
CycLuc1-methyl amide, or CycLuc1–ethyl ester. The assay was performed in 
triplicate, is represented as the mean ± SEM. Each amide was compared to 






HeLa cells do not express FAAH (Dickason-Chesterfield et al., 2006.; Day et al., 
2001.), and luciferin amides do not yield bioluminescence in luciferase-
expressing HeLa cells (Figure 3.4B). Transfection of HeLa cells with human 
FAAH enabled bioluminescence with luciferin amides (Figures 3.4B and 3.5). 
Specific inhibition of the transfected FAAH with PF3845 blocked bioluminescence 
(Figure 3.4B) and the potency of FAAH inhibitors could be evaluated in these 
FAAH-transfected live cells (Figure 3.6). FAAH has been shown to cleave some 
fatty acid esters (Patricelli and Cravatt, 1999.), and we find that it indeed also 
contributes to the cleavage of CycLuc1 ethyl ester (Figure 3.9). However, unlike 
CycLuc1 amides, the ethyl ester of CycLuc1 is not exclusively cleaved by FAAH 




                          
Figure 3.9. CycLuc1 ethyl ester supports bioluminescence from both live 
CHO and HeLa cells. A) Live CHO cells transfected with luciferase were 
incubated with 1 μM PF3845 for five minutes and then imaged with varying 
concentrations of either CycLuc1 or CycLuc1 ethyl ester. B) Live HeLa cells co-
transfected with either luciferase and human FAAH or luciferase and empty 
vector were incubated with 1 μM PF3845 for five minutes and then imaged with 
varying concentrations of either CycLuc1 or CycLuc1 ethyl ester. The assay was 
performed in triplicate and is represented as the mean ± SEM. Curves were fit to 







In mice, FAAH is highly expressed in the brain (Long et al., 2011.). We thus 
expected that luciferin amides would result in strong brain bioluminescence in 
luciferase-expressing mice if able to access this tissue. We used adeno-
associated virus 9 (AAV9) to express luciferase only in the brain striatum (Evans 
et al., 2014.). The amides are less water-soluble than the parent carboxylates, 
necessitating a lower imaging dose. Nonetheless, CycLuc1-amide yielded 
dramatically higher photon flux in these mice than the parent luciferin CycLuc1 or 
the conventional substrate d-luciferin (Figure 3.10). A 400-fold lower dose of 
CycLuc1-amide was markedly superior to the standard imaging dose of d-
luciferin (Figure 3.10). Even 1000-fold lower doses yielded higher brain 





Figure 3.10. Bioluminescence from mice that express luciferase in specific 
tissues after treatment with luciferins and luciferin amides. CycLuc1-amide 
compared to d-Luciferin for bioluminescence imaging in live mice expressing 
luciferase in (A) the brain or (B) the heart and leg muscles. Quantification is 





Figure 3.11. CycLuc1 amide increases total photon flux from the brain at 
1000-fold lower dose than D-luciferin. Mice striatally injected with AAV9-CMV-
luc2 were treated with 0.4 μmol/kg CycLuc1-amide or 400 μmol/kg D-luciferin. 
Quantification was normalized to D-luciferin signal for each mouse and is 
represented as the mean ± SEM for n=3 mice.  
 
Pretreatment with PF3845 (Figure 3.2), which has been demonstrated to inhibit 
only FAAH in mice (Ahn et al., 2009.), completely blocked brain bioluminescence 
when using luciferin amides (Figure 3.12). Tail-vein injection of AAV9-CMV-luc2 
primarily transduces heart (Inagaki et al., 2006.) and leg muscles (Figure 3.10), 
tissues where FAAH activity has been reported to be absent (Evans et al, 
2014.). In these mice, luciferin amides yielded dramatically lower photon flux than 
could be achieved with their parent luciferins (Figure 3.10). By contrast, CycLuc1 
ethyl ester was on par with equal doses of the parent luciferin in the heart and leg 
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muscles, but ineffective in the brain (Figure 3.10). These differences likely reflect 
the location of the liberating enzymatic activity and biodistribution of the more 
hydrophobic ester. 
To visualize FAAH activity throughout the mouse, we next turned to transgenic 
mice that express luciferase in all tissues (Cao et al., 2004). When D-luciferin or 
CycLuc1 is introduced into these mice, the weakest light emission is from the 
head, and bioluminescence is dominated by superficial tissues (Figures 3.13 and 
3.14). In marked contrast, injection of CycLuc1-amide revealed the strongest 
bioluminescence signals from the brain and kidneys (Figure 3.13), tissues known 
to have high FAAH activity (Long et al., 2011.). Ventral bioluminescence was less 
well-defined, which may reflect rapid transit of released luciferin out of FAAH-
expressing tissues such as the liver (Figure 3.14). Pretreatment of mice with 
PF3845 completely blocked bioluminescence from luciferin amides in the brain 
and in all peripheral tissues (Figures 3.13, 3.15, and 3.16) but had no effect on 
bioluminescence from the parent luciferins (Figure 3.17). The aminoluciferin 
amides (Figure 3.1) readily sense FAAH activity in vivo (Figure 3.14), and can be 
imaged at extremely low doses (as low as 8 nmol/kg; Figure 3.18). Although D-
luciferin amide senses FAAH activity in vitro and in live cells, it works poorly in 
live mice and cannot sense FAAH activity in the brain (Figure 3.14). This is 
consistent with our contention that the improved biodistribution properties of 
aminoluciferins and low Km values render them superior for use as luminogenic 
sensors in vivo (Adams et al., 2014.). Interestingly, CycLuc1-methyl amide did 
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not exhibit an advantage over CycLuc1-amide in the mouse (Figure 3.14). 
Presumably, inhibition of luciferase by uncleaved luciferin primary amides is not 
an issue at the substrate concentrations achieved in vivo. 
 
 
Figure 3.12. Inhibition of FAAH by PF3845 results in loss of signal from 
CycLuc1-amide in the brain. Mice striatally injected with AAV9-CMV-luc2 were 
imaged with CycLuc1-amide alone or after pre-treatment with 10 mg/kg PF3845. 
Quantification is represented as the mean ± SEM for n=3 mice and was 




       
 
Figure 3.13. Luciferin amides report on FAAH activity in live mice that 
ubiquitously express luciferase. A) Bioluminescence imaging with CycLuc1 or 
CycLuc1-amide in ubiquitously expressing transgenic luciferase mice treated with 
vehicle only or the indicated FAAH inhibitor. B) Total flux from the brain and 
kidneys quantitated as a function of inhibitor concentration and normalized to the 
vehicle-only signal, represented as the mean ± SEM for n = 3 mice. Data were fit 
by nonlinear regression to determine relative IC50 values in the brain (PF3845, 
0.14 mg/kg; URB597, 0.40 mg/kg; URB937, ND) and kidneys (PF3845, 0.03 





Figure 3.14. Bioluminescence from mice that ubiquitously express 
luciferase after treatment with luciferins and luciferin amides. A) Dorsal view 
of FVB-Tg(CAG-luc) mice injected with the indicated substrate. B) Ventral view of 





Figure 3.15. Ventral view of ubiquitously-expressing luciferase mice treated 
with CycLuc1 amide. Mice were pre-treated with vehicle only (18:1:1 
PBS:Kolliphor:ethanol), or the indicated FAAH inhibitors. Quantification was 
normalized to the average vehicle-only signal and is represented as the mean ± 
SEM for n=3 mice. Data was fit by nonlinear regression to determine relative 





                     
Figure 3.16. Mice ubiquitously-expressing luciferase treated with high 
inhibitor dose. Mice were pre-treated with vehicle only (18:1:1 






Figure 3.17. FAAH inhibitors do not affect parent luciferins. A) Dorsal view of 
live FVB- Tg(CAG-luc) mice, injected with the indicated inhibitor and treated with 
CycLuc1. B) Ventral view of mice in (A). Quantification is represented as the 
mean ± SEM for n=3 mice. Each inhibitor was compared to vehicle only by t-test. 




         
 
Figure 3.18. CycLuc1-amide can be imaged at doses as low as 8 nmol/kg 
and signal is not saturated at 1 μmol/kg. A) Dorsal view of FVB-Tg(CAG-luc) 
mice injected with the indicated concentration of CycLuc1 amide. B) Ventral view 
of mice in (s). Quantification is represented as n=1 mouse per substrate dose.  
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Finally, we sought to determine whether luciferin amides could be used to 
evaluate the tissue distribution of prospective FAAH inhibitors, which can have 
important effects on their efficacy (Clapper et al., 2010.). URB937 is a brain-
impermeable FAAH inhibitor that differs from the global FAAH inhibitor URB597 
by a single hydroxyl group (Figure 3.2) (Clapper et al., 2010.). Bioluminescence 
imaging with CycLuc1-amide confirmed that URB597 inhibits FAAH activity in 
both peripheral and brain tissues (Figures 3.13, 3.15 and 3.16), whereas no 
inhibition of FAAH activity is detected in the brains of URB937-treated mice 
(Figure 3.13). 
Many bioluminescent sensors have been described based on “caged” pro-
luciferins that can release a luciferin upon the action of an enzyme or reactive 
small molecule (Adams and Miller, 2014.; Van de Bittner et al., 2013.). The labile 
moiety is distinct from the luciferin and often separated by a self-immolative linker 
(Carl et al., 1981.). A limitation of this approach is that the luciferin itself is not 
contributing to specific recognition or selectivity; the best one can hope for is that 
its presence is innocuous. Our approach embraces the inherent fatty acid 
mimetic properties of luciferin analogs to create sensors for enzymes that release 
fatty acids. The power of this approach is borne out in the exquisite specificity 
and sensitivity of luciferin amides for FAAH even in vivo, simply by replacing an 
oxygen atom with nitrogen (Figure 3.1). Furthermore, we find that luminogenic 
sensors based on high-affinity, cell-permeable aminoluciferins perform better in 
mice than those based on d-luciferin. As the number of structurally distinct 
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luciferin analogs grows (Adams and Miller, 2014.; Mofford et al., 2014), we 
anticipate there will be additional opportunities to build sensors based on the 
inherent properties of the luciferin itself. 
Conclusion 
In summary, we have found that luciferin amides are highly sensitive and 
selective reporters of FAAH activity. These sensors readily translate from in 
vitro assays to live cells to in vivo imaging to report on the activity of a single 
enzyme in its natural context. The bioluminescence approach described herein 
reveals otherwise invisible endogenous enzymatic activity in live cells and mice 
and more broadly allows imaging of the biodistribution consequences of subtle 
modifications to a prospective therapeutic inhibitor in vivo (e.g., ability to cross 
the blood-brain barrier). Further refinement and modification of the structure of 
the luciferin (Adams and Miller, 2014.; Mofford et al., 2014) and the scissile bond 
could potentially allow extension of this bioluminescence detection approach to 
other enzymes (Long and Cravatt, 2011.; Bandiera et al., 2014.).Finally, luciferin 
amides are excellent reagents for increasing the sensitivity of bioluminescence 
imaging in FAAH-expressing cells and tissues, such as the brain, and allow 
orders of magnitude lower imaging doses than the natural luciferase substrate. 
 




D.M.M. devised experiments, performed in vitro assays, cell-based experiments, 
mouse imaging and analysis, and manuscript preparation. S.T.A. Jr. performed 
AAV deliveries via surgery, AAV deliveries via tail vein injection, and mouse 
imaging and analysis. G.S.K.K.R. and G.R.R. synthesized luciferins. S.C.M. 
devised experiments and helped with manuscript preparation. 
General 
Chemicals for synthesis were obtained from Aldrich unless otherwise noted. D-
luciferin was obtained from Anaspec for in vitro work and from Gold Bio for 
mouse work. Serine hydrolase inhibitors were purchased from Cayman. CycLuc1 
was synthesized as previously described (Reddy et al., 2010). Protein 
concentrations were determined using Coomassie Plus (Thermo Scientific). 
Immobilized glutathione (Thermo Scientific) was used for glutathione S-
transferase (GST)-tagged protein purification. Kolliphor® EL was obtained from 
Sigma Life Sciences (Stock # C5135) Data were plotted and analyzed with 
GraphPad Prism 6.0. High resolution mass spectral data were recorded on a 
Waters QTOF Premier spectrometer (University of Massachusetts Medical 
School Proteomics and Mass Spectrometry Facility). Bioluminescence assays 
were performed on a Xenogen IVIS-100 system in the Small Animal Imaging 
facility. Data acquisition and analysis were performed with Living Image software. 
Data are reported as total flux (p/s) for each region of interest (ROI). For in vitro 
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and cellular assays, the ROIs correspond to each well of a 96-well plate. For in 
vivo assays, the ROIs correspond to the indicated region of a mouse.  
Plasmid Constructs  
Human and rat FAAH genes (hFAAH and rFAAH) were purchased from the 
Mammalian Gene Collection of Thermo Fisher Scientific (clone IDs: hFAAH 
5728192, rFAAH 7370226). Residues 30-579 of the rFAAH gene were PCR-
amplified and cloned into the EcoRI and NotI sites of pGEX6P-1, resulting in 
removal of the N-terminal transmembrane domain (Mileni et al., 2008.). Full 
length hFAAH was PCR-amplified and cloned into the KpnI and NotI sites of 
pcDNA3.1 to yield pcDNA3.1- hFAAH.  
Protein Expression and Purification  
Rat FAAH (30-579) and firefly luciferase were expressed as GST-fusion proteins 
using the pGEX6P-1 vector in the E. coli strain JM109. Cells were grown at 37°C 
until the OD600 reached 0.5-1, induced with 0.1 mM IPTG, and incubated at 
20°C overnight. Cells were pelleted at 5000 rpm in a Sorvall 2C3C Plus 
centrifuge (H600A rotor) at 4°C for 15 min, then flash frozen in liquid nitrogen. E. 
coli pellets from 1 L of culture were thawed on ice, resuspended in 25 mL lysis 
buffer (50 mM Tris [pH 7.4], 500 mM NaCl, and 0.5% Tween 20) containing 1 
mM phenylmethylsulfonyl fluoride, and disrupted by sonification (Branson 
Sonifier). Dithiothreitol (DTT) was added at 10 mM, and the resulting cell lysate 
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was clarified by centrifugation at 35,000 rpm in a Beckman 50.2 Ti rotor for 60 
min at 4°C. The supernatant was batch-bound to immobilized glutathione for 1 hr 
at 4°C, and the beads were washed with lysis buffer containing 10 mM DTT, 
followed by wash buffer (50 mM Tris [pH 8.1], 250 mM NaCl, and 10 mM DTT) 
and storage buffer (50 mM Tris [pH 7.4], 0.1 mM EDTA, 150 mM NaCl, 1 mM 
TCEP). Twenty units of PreScission Protease (GE Healthcare) were added, and 
incubated overnight at 4°C to cleave the GST-fusion and elute the untagged 
protein into storage buffer.  
Purified Protein rFAAH Activity Assays  
FAAH inhibitors were prepared at 4 μM in substrate buffer (20 mM Tris [pH 7.4], 
0.1 mM EDTA, 8 mM MgSO4, and 4 mM ATP). Luciferins and luciferin amides 
were prepared at 40 μM in substrate buffer. Luciferase and rFAAH were 
prepared at 400 nM in enzyme buffer (20 mM Tris [pH 7.4], 0.1 mM EDTA, 1 mM 
TCEP, and 0.8 mg/mL BSA). In a black 96-well plate (Costar 3915), 25 μL FAAH 
inhibitor or substrate buffer was added to three wells each. rFAAH (25 μL) or 
enzyme buffer was added to the inhibitor and incubated at ambient temperature 
for 5 minutes. Luciferin or luciferin amide (25 μL) was then added to each well 
and incubated at ambient temperature for 20 minutes. Luminescence was then 
initiated by adding 25 μL of luciferase. Imaging was performed one minute after 
luciferase addition and integrated for 2-20s  
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at a final concentration of 1 μM FAAH inhibitor, 10 μM luciferin, 100 nM rFAAH, 
and 100 nM luciferase.  
Purified rFAAH Dose-Response Assays  
Purified rFAAH was prepared at concentrations ranging from 8 μM to 3.91 nM in 
enzyme buffer. Luciferin amides were prepared at 20 μM in substrate buffer. 
Luciferase was prepared at 400 nM in enzyme buffer. In a black 96-well plate 
(Costar 3915), 50 μL of each luciferin amide was added per well. rFAAH (25 μL) 
was then added to the amide and incubated at ambient temperature for 30 
minutes. Luminescence was then initiated by adding 25 μL of luciferase. Imaging 
was performed one minute after luciferase addition for 2-20s at a final 
concentration of 2000 nM to 0.977 nM rFAAH, 10 μM luciferin amide, and 100 
nM luciferase.  
Luciferin Amide Inhibitor Assays with Purified Luciferase  
Luciferin amides were prepared at 40 μM or 100 μM in substrate buffer. 
Luciferins were prepared at concentrations from 1000 μM to 0.488 μM in 
substrate buffer. Luciferase was prepared at 200 nM in enzyme buffer. In a black 
96-well plate (Costar 3915), 25 μL luciferin amide or substrate buffer was added 
to three rows each. Luciferin (25 μL) was added to the luciferin amide. 
Luminescence was then initiated by adding 50 μL of luciferase. Imaging was 
performed one minute after luciferase addition for 2-20s at a final concentration 
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of 0 μM, 10 μM, or 25 μM luciferin amide, 250 μM to 0.122 μM luciferin, and 100 
nM luciferase.  
Cell Culture  
Chinese hamster ovary (CHO) cells and HeLa cells were grown in a CO2 
incubator at 37°C with 5% CO2 and were cultured in F-12K Nutrient Mixture 
(GIBCO) and Dulbecco's Modified Eagle's Medium (DMEM) (GIBCO) 
respectively. Both media were supplemented with 10% fetal bovine serum and 
100 U/mL penicillin/streptomycin.  
Transfections  
CHO cells were transfected with codon-optimized firefly luciferase (luc2) as 
previously described (Mofford et al., 2014.). HeLa cells were transfected with 
pcDNA3.1-luc2 plasmid (Mofford et al., 2014.) and either pcDNA3.1- hFAAH or 
empty pcDNA3.1 vector. Transient transfections were performed at RT using 
Lipofectamine 2000 on cells plated at 60%–75% confluency in 96-well black 
tissue culture- treated plates (Costar 3916). For CHO cells, 0.075 μg DNA/well of 
pcDNA3.1-luc2 was transfected; for HeLa cells, 0.0375 μg DNA/well each of 
pcDNA3.1-luc2 and either pcDNA3.1- hFAAH or empty pcDNA3.1 was 
transfected. Assays were performed in triplicate 24 hrs after transfection.  
Live Cell FAAH Activity Assays  
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Transfected cells were washed with HBSS. For substrate dose-response curves, 
the cells in 96- well plates were incubated with 50 μL of 2 μM FAAH inhibitor in 
HBSS or HBSS only at ambient temperature for 5 minutes. Then, 50 μL of 2x 
substrate was added to each well to achieve final substrate concentrations 
ranging from 125 μM to 0.061 μM. For inhibitor dose-response curves, the cells 
in 96-well plates were incubated with 50 μL of 2x FAAH inhibitor in HBSS at 
ambient temperature for 5 minutes (final inhibitor concentrations ranging from 10 
μM to 0.21 pM). Then, 50 μL of 2x substrate was added to each well to a final 
luciferin concentration of 10 μM. Imaging was performed three minutes after 
addition of substrate.  
Mice  
All of the experiments involving mice were conducted in accordance with the 
Institutional Animal Care and Use Committee of The University of Massachusetts 
Medical School (docket #A-2474- 14). Female FVB mice and luciferase-
expressing transgenic mice (FVB-Tg(CAG-luc,- GFP)L2G85Chco/FathJ) were 
purchased from Jackson Laboratories (Bar Harbor, ME).  
Striatal injection of AAV9-CMV-luc2 into FVB mice was performed as previously 
described (Evans et al., 2014.).  
Tail-vein injection of AAV  
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FVB mice were injected in the lateral tail vein with 1x1011 particles of AAV9-
CMV-luc2 luciferase (Evans et al., 2014.) suspended in sterile filtered PBS at a 
final volume of 200 μL. The mice were held under a heat lamp to warm the tail for 
better visualization of the lateral tail vein due to vasodilation and then placed into 
a Tailveiner (Braintree Scientific, Braintree, MA). The tails were cleaned with a 
70% isopropyl alcohol wipe and injection was performed using a 27.5 gauge 
needle. Once the needle was withdrawn, the tail was compressed with sterile 
gauze to ensure complete homeostasis. The mice were monitored afterwards for 
recovery of normal behavior before returning to their colony. Imaging was 
performed weeks to months after AAV injection.  
Substrate and FAAH Inhibitor Preparation for Mouse Injection  
All FAAH inhibitors were prepared by direct dissolution into 18:1:1 
PBS:Kolliphor:ethanol and sterile filtering through a 0.22 μm syringe filter. Each 
inhibitor was injected intraperitoneally (i.p.) at 5 μL/g mouse. Inhibitors were 
prepared at 2 mg/mL, 0.2 mg/mL, 0.02 mg/mL, and 0.002 mg/mL to achieve final 
concentrations of 10 mg/kg, 1 mg/kg, 0.1 mg/kg, and 0.01 mg/kg respectively. 
Due to limited solubility, URB597 was prepared at 0.4 mg/mL and injected at 10 
μL/g to achieve a dose of 4 mg/kg.  
D-luciferin (100 mM) and CycLuc1 (5 mM) were prepared by direct dissolution 
into PBS and were sterile filtered through a 0.22 μm syringe filter. All other 
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luciferins were prepared by diluting a 50 mM DMSO stock into PBS and sterile 
filtering through a 0.22 μm syringe filter. CycLuc1 ethyl ester was not soluble in 
PBS and was therefore prepared by diluting the 50 mM DMSO stock into 18:1:1 
PBS:Kolliphor:ethanol. Each substrate was injected i.p. at 4 μL/g mouse.  
Substrates were prepared at 100 mM (D-Luciferin), 5 mM (CycLuc1), 250 μM 
(substrates for AAV mice), and 100 μM (substrates for FVB-Tg[CAG-luc] mice) to 
achieve final concentrations of 400 μmol/kg, 20 μmol/kg, 1 μmol/kg, and 0.4 
μmol/kg respectively.  
Bioluminescence Imaging of Mice  
Each mouse was weighed to determine substrate and/or FAAH inhibitor dosing 
and anesthetized using 2.5% isoflurane in 1 L/min oxygen. FAAH inhibitors were 
injected i.p. at 5 μL/g mouse 30 minutes prior to luciferin injection. Luciferin 
substrate was injected i.p. at 4 μL/g mouse and mice were imaged dorsally at 10 
minutes and ventrally at 13 minutes.  
Synthetic Procedures and NMR Data 
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Firefly Luciferase Mutants Allow Substrate-Selective Bioluminescence 
Imaging in the Mouse Brain 
Adams Jr., et al. (2016) Angew Chem Int Ed Engl., 55(16): 4943-4946. 
 
Summary 
Bioluminescence imaging is a powerful approach to visualize specific events 
occurring inside live mice. Animals can be made to glow in response to the 
expression of a gene, the activity of an enzyme, or the growth of a tumor. But 
bioluminescence requires the interaction of a luciferase enzyme with a small 
molecule luciferin, and its scope has been limited by the mere handful of natural 
combinations. Here we show that mutants of firefly luciferase can discriminate 
between natural and synthetic substrates in the brains of live mice. Using adeno-
associated viral (AAV) vectors to express luciferases in the brain, we find that 
mutant luciferases that are inactive or weakly active with D-luciferin can light up 
brightly when treated with the aminoluciferins CycLuc1 and CycLuc2 or their 
respective FAAH-sensitive luciferin amides. Further development of selective 
luciferases promises to expand the power of bioluminescence and allow multiple 





Mice do not ordinarily glow in the dark. But if you introduce the enzyme firefly 
luciferase and the small molecule D-luciferin, they will glow in much the same 
way as a firefly does. Detection of the light emitted from these animals can be 
used to spy on specific events that would otherwise be invisible, such as gene 
expression and enzyme activity (Prescher and Contag, 2010.; Adams and Miller, 
2014.). One limitation of this powerful technique has been the paucity of 
distinguishable luciferins and luciferases, restricting our ability to visualize 
multiple events in the same live animal using bioluminescence. 
 
Firefly luciferase is particularly well suited to in vivo imaging (Adams and Miller, 
2014.). The wavelength of the emitted light extends well into the red and near-
infrared wavelengths that pass most easily through living tissues. Furthermore, 
the luciferin substrate is stable, easily administered, and offers several strategies 
to create luminescent probes (Adams and Miller, 2014.; Takakura et al., 2015.; 
Mofford et al. 2015.; Porterfield et al. 2015.). In efforts to expand upon the 
bioluminescent palette of the firefly while retaining its inherent benefits, we have 
synthesized new luciferin analogs and mutated the luciferase enzyme (Reddy et 
al., 2010.; Harwood et al., 2011.; Mofford et al. 2014.). We found that mutant 
luciferases can discriminate between D-luciferin and aminoluciferin analogs in 
vitro and in live cells (Harwood et al., 2011.; Mofford et al. 2014.). However, part 
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of the basis for this discrimination is a loss of substrate affinity, and it has been 
unclear how this discrimination would manifest in the context of live animals 
(Evans et al., 2014). 
Here we perform bioluminescence imaging in the brain, and show that in this 
challenging environment, firefly luciferase mutants can discriminate between the 
natural substrate D-luciferin and synthetic luciferin analogs. We find that a 
balance of substrate selectivity and substrate affinity must be achieved to 
maintain high photon flux in vivo, more restrictive conditions than exist in vitro. 
Nonetheless, simple point mutations of luciferase are capable of discriminating 
between substrates. This work will help guide the development of additional 
luciferase-luciferin pairs that can be used to shed light on the molecular basis of 
disease and drug action in live animals. 
We recently reported that the combination of three active-site mutations (R218K, 
L286M, and S347A) yielded a luciferase with 10,000-fold selectivity for a 
synthetic aminoluciferin substrate over the natural substrate D-luciferin (Figure 
4.1) (Mofford et al., 2014). However, this selectivity came at the cost of an 
increased apparent Km compared to the individual mutants and the wild-type 
luciferase. A higher Km is not an issue for bioluminescence assays performed in 
vitro, but it could pose a problem for in vivo imaging, where substrate access is 
limiting (Evans et al., 2014). 
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Figure 4.1. Location of mutated residues in firefly luciferase’s active site 
and comparison of synthetic luciferins to D-luciferin. A) Crystal structure of 
firefly luciferase bound to a luciferyl-adenylate analog (PDB 4G36, rendered in 
PyMol). Mutations to R218, L286, and S347 in the luciferin binding pocket have 
allowed tuning of substrate specificity. L342 does not contact the core luciferin 
structure and is distal from the structural differences between D-luciferin, 




Figure 4.2. Substrate structures and mechanistic overview of firefly 
bioluminescent chemistry. Structures of D-luciferin, CycLuc1, CycLuc2, and 
CycLuc1-amide (A); Proposed mechanism of the luciferase reaction, shown with 
CycLuc2 in place of D-luciferin: B) Adenylation of the substrate is the key 
enzymatic chemistry required for bioluminescence. C) Subsequent light emission 
chemistry from the adenylate is largely driven by the chemistry accessible to this 
intermediate within the enzyme pocket: a) deprotonation of C4; b) single electron 
transfer to oxygen from the resonance-stabilized C4 anion; c) radical 
recombination with superoxide; d) displacement of AMP; e) decarboxylation of a 





Light emission from a luciferin substrate requires activation by ATP to form an 
adenylated intermediate (Figure 4.1, Figure 4.2). Although residues in the ATP 
binding site make no direct contact with the core luciferin scaffold, the ATP 
binding site can influence (and be influenced by) luciferin binding. High ATP 
concentration exacerbates the product inhibition that is observed with 
aminoluciferins (Figure 4.3). The apparent Km value for ATP depends on the 
luciferin substrate and is much lower for CycLuc1 and CycLuc2 compared to D-
luciferin (Table 4.1, Figure 4.3). Taking advantage of this behavior can thus 
conceivably be used to distinguish between luciferins. Mutation of leucine 342, 
part of the GYGLTE motif found in many adenylate-forming superfamily members 
(Weimar et al., 2002.), can greatly increase the apparent Km values for both D-
luciferin and ATP yet retain high maximal luciferase activity (Branchini et al., 
2003.). We found that the L342A mutation confers substrate selectivity which 
compares favorably to the previously reported R218K mutant (Figures 4.3, 4.4, 
and 4.5). The change in apparent Km values for aminoluciferins is muted 
compared to D-luciferin (Table 4.1). Combination of the two mutations into a 
single luciferase results in further selectivity over D-luciferin (Table 4.1, Figure 
4.4). Although not as selective as the R218K/L286M/S347A luciferase (Mofford 
et al. 2014), the R218K/L342A double mutant yields the highest maximal 
sustained photon flux with a synthetic luciferin to date, and no longer suffers 




Figure 4.3. Substrate selectivity of the mutant luciferases: role of [ATP]. A) 
Burst kinetic data for WT and mutant luciferases with D-luciferin, CycLuc1, and 
CycLuc2 and varying [ATP], measured after rapid injection as described in the 
Experimental Methods. B) Sigmoidal dose-response fit to peak photon emission 




       
Table 4.1. Apparent Km values for luciferins and ATP with wild-type and 
mutant luciferases. NA = poor fit of data to a sigmoidal dose-response curve. 
     
              
Figure 4.4. Photon flux from purified wild-type (WT) and mutant luciferases 
treated with high and low concentration of luciferin substrate (imaged as 





Figure 4.5. Substrate selectivity of the mutant luciferases: role of [luciferin]. 
A) Burst kinetic data for WT and mutant luciferases with varying concentration of 
D-luciferin, CycLuc1, and CycLuc2 measured after rapid injection as described in 
the Experimental Methods. B) Sustained photon emission for each luciferase and 
luciferin as a function of [luciferin], measured on the IVIS as described in the 
Experimental Methods. 
 
To evaluate the performance of these three luciferase mutants in vivo, each 
codon-optimized mutant was cloned into an adeno-associated viral (AAV) 
plasmid under the control of a CMV promoter (Evans et al. 2014.), and packaged 
into AAV9 vectors (Gao et al., 2004.; Clearley and Wolfe, 2006.). The AAV9-
luciferase viruses were then used to transduce FVB mice in the brain striatum 
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(Evans et al., 2014.). Unlike the use of luciferase-expressing tumor cells, this 
viral gene delivery method allows luciferase expression in endogenous mouse 
cells, for the life of the mouse (well over a year). As we have previously 
described for AAV9 transduction with the WT luciferase, each luciferase-
expressing mouse was imaged after i.p. injection with a phosphate-buffered 
saline (PBS) solution of each luciferin (Mofford et al., 2015.; Evans et al., 2014.). 
These experiments were performed in the exact same set of mice, imaged with 
each substrate on sequential days. 
 
Results and discussion 
For all of the mutant luciferases, brain bioluminescence was dramatically 
reduced when using D-luciferin compared to CycLuc1 and CycLuc2 (Figure 4.6). 
With the L342A luciferase, D-luciferin gave no signal, while both aminoluciferins 
gave signal that was >50-fold over background. For the R218K luciferase, D-
luciferin signal was 3-fold over background, but CycLuc1 and CycLuc2 were 40-
50 fold brighter still. However, combining the R218K and L342A mutations did 
not yield synergism in vivo. 
Although no photon flux above background was observed with D-luciferin for the 
double-mutant, the photon flux was also substantially lower for CycLuc1 and 
CycLuc2 than for the individual point mutants (Figure 4.7). Thus, at least in the 
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brain, the double mutant was less useful as a selective luciferase for these 
substrates compared to L342A or R218K alone. 
  
 
Figure 4.6. Mutant luciferase performance in the brains of live mice. A) 
Photon flux from a single AAV-transduced mouse compared after imaging with 
the indicated luciferase and luciferin (D-luciferin, 400 μmol/kg; CycLuc1, 20 
μmol/kg; CycLuc2, 10 μmol/kg; CycLuc1-amide, 1 μmol/kg; CycLuc2-amide, 0.4 
μmol/kg); B) Photon flux from the region of interest (ROI), n = 3 mice for each 
mutant luciferase. * p <0.05; ** p < 0.01; ns = not significant by t-test. 
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Figure 4.7. Mouse imaging with R218K/L342A luciferase. A) Photon flux from 
a single mouse transduced in the brain striatum with AAV9-CMV-
luc2(R218K/L342A) after i.p. injection with the indicated luciferin (D-luciferin, 400 
μmol/kg; CycLuc1, 20 μmol/kg; and CycLuc2, 10 μmol/kg); B) Photon flux from n 
= 2 mice. 
 
Luciferin amides, sensors for the enzyme fatty acid amide hydrolase (FAAH), 
potentially offer a way to deliver luciferins into the brain more effectively (Mofford 
et al, 2015.; Mofford and Miller., 2015.). Because of high FAAH activity in the 
brain, the amides are converted into their respective luciferins, and imaging can 
be performed with very low doses of the luciferin amide (Mofford et al., 2015.). 
We therefore tested whether the amides of CycLuc1 and CycLuc2 (Figure 4.1) 
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could be used to detect AAV transduction in the brain with the mutant luciferases 
(Figure 4.3). Remarkably, i.p. injection of just 0.4 µmol/kg CycLuc2-amide 
allowed imaging of L342A luciferase in the brain with a signal that was >400-fold 
over background, equivalent or better than its performance with WT luciferase 
(Figure 4.8). By contrast, 400 µmol/kg D-luciferin failed to yield any detectable 
signal (Figure 4.6). Luciferin comparison at low equimolar doses further revealed 
the relative potency of each analogue (Figure 4.9). 
 
           
Figure 4.8. Mouse imaging with wild-type (WT) luciferase. Photon flux from 
mice transduced in the brain striatum with AAV9-CMV-luc2 after i.p. injection with 
the indicated luciferin (D-luciferin, 400 μmol/kg; CycLuc1, 20 μmol/kg; and 
CycLuc2, 10 μmol/kg). Each mouse was separately imaged, on sequential days, 





Figure 4.9. Comparison of luciferin analogs at equimolar dose after i.p. 
injection with A) CycLuc1, CycLuc1-amide, CycLuc2, and CycLuc2-amide at 0.4 
μmol/kg; and B) CycLuc1, CycLuc2, and D-luciferin at 4 μmol/kg. D-luciferin at 80 
μmol/kg is also shown for reference. Radiance of all images is represented on 
the same scale bar to the right. 
 
Firefly luciferase exhibits a great deal of structural plasticity, and accepts an 
almost bewildering array of molecules as substrates (Adams and Miller., 2014.; 
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Mofford et al., 2014.). Although we demonstrate here that mutant luciferases can 
strongly discriminate against D-luciferin in vivo, the inherent promiscuity of firefly 
luciferase has posed a challenge for the construction of truly orthogonal 
luciferases. That is, we can identify mutated enzymes that will emit light with 
CycLuc2 but not D-luciferin, but as of yet the converse has not been achieved. 
For most of the selective luciferases described thus far, we do not believe that 
the changes to the luciferin and luciferase are mirroring the classic “bump-hole” 
approach used for engineering ligand-receptor interactions (Belshaw et al., 
1995.; Shah et al. 1997.). Rather, the primary basis for substrate selectivity is 
likely a loss of affinity for the core features of D-luciferin. Because aminoluciferins 
bind with higher affinity, they remain viable substrates. Going forward, one 
approach to more selective luciferases is to take advantage of homologous 
enzymes that are inherently more selective than firefly luciferase, and may 
therefore offer guidance as to how more precise substrate selectivity can be 
achieved (Mofford et al., 2014.). Here we also show that the interplay between 
the luciferin and ATP binding sites can play a role in discriminating between 
luciferins. Although leucine 342 is located far from the 6’-hydroxyl of D-luciferin 
(i.e. the site of the CycLuc1 and CycLuc2 modifications), mutation of this residue 
allows substrate selectivity in the brain. Future mechanistic work in vitro will be 
aimed at establishing the molecular basis for this interplay and uncovering how 
ATP binding affects the product inhibition seen with many luciferin analogs 
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(Figure 4.3). Perhaps ATP can rebind luciferase prior to release of the 
oxyluciferin product, resulting in a trapped complex. 
 
Conclusion 
Using AAV-delivered reporters, we have a platform on which to evaluate 
luciferases, luciferins, and luciferin-based sensors in different animal models and 
tissues (Mofford et al., 2015; Limberis and Wilson, 2006.; Zincarelli et al., 2008.; 
Tarantal and Lee, 2010.; Orabi et al., 2015.). Despite the ability of the L342A 
luciferase to emit light given sufficient quantities of D-luciferin and ATP in vitro, in 
the context of the live mouse brain we do not detect a signal. On the other hand, 
strong brain bioluminescence is observed from the L342A luciferase when using 
the aminoluciferins, but not with the double mutant R218K/L342A, despite its 
higher peak performance in vitro. Based on these results, a prudent design 
consideration (and proxy) for in vivo use, it is also important to keep in mind the 
role substrate modification has on the ability of the molecule to access particular 
tissues in the live animal (Mofford et al., 2015.). Together, we expect that the 
judicious application of mutant luciferases and modified luciferins will greatly 





Materials and Methods 
Contributions 
S.T.A. Jr. devised experiments, performed AAV deliveries in mice, performed 
mouse imaging and analysis, and prepared manuscript. D.M.M. devised 
experiments, performed in vitro work, live cell assays, and helped with 
manuscript preparation. G.S.K.K.R. designed and synthesized synthetic 
luciferins. S.C.M. devised experiments and helped with manuscript preparation. 
Compounds. D-luciferin was purchased from Gold Bio. CycLuc1, CycLuc2, 
CycLuc1-amide, 1,and D-cysteine amide were synthesized as previously 






 (S)-2-amino-3-mercaptopropanamide (D-cysteine amide, 7 mg, 0.0596 mmol) 
was dissolved in 50 mM aqueous sodium phosphate buffer (pH 8, 2 mL) and 
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degassed using argon. This solution was added to 1 (10 mg, 0.049 mmol) in 2 ml 
of degassed methanol. The reaction was stirred for 2 h, and then diluted with 
sodium phosphate buffer and extracted with ethyl acetate (2 x 30 mL). The 
combined organic layers were washed with water (3 x 30 mL) and dried 
(Na2SO4), filtered and evaporated to afford CycLuc2-amide 2 as a yellow solid 
(12 mg, 81%). 1H-NMR (400 MHz, CDCl3): δ 7.71 (s, 1H), 6.72 (s, 1H and br s, 
1H; overlapping), 5.68 (br s, 1H), 5.25 (t, 1H, J = 9.2 Hz), 3.75 (d, 2H, J = 10.0 
Hz), 3.51 (t, 2H, J = 8.0 Hz), 3.10 (t, 2H, J = 8.0 Hz), 2.86 (s, 3H). 13C-NMR (100 
MHz, CDCl3): δ 173.5, 166.8, 153.7, 153.6, 146.5, 137.7, 132.9, 120.0, 96.1, 
78.9, 55.8, 35.26, 35.18, 28.2. HRMS (ESI+) Calcd for C14H15N4OS2 : 
319.0687, Found: 319.0677. 
Plasmid Constructs 
Wild-type and R218K mutant luciferase genes were prepared as previously 
described (Takakura et al., 2015.; Mofford et al., 2015.). The L342A and 
R218K/L342A mutant luciferases were generated using the Q5 site-directed 
mutagenesis kit (NEB) using the WT or R218K luciferase, respectively, as 
template. 
Enzyme Expression and Purification 
Wild-type and mutant luciferases were expressed and purified as GST-fusion 
proteins from the pGEX6P-1 vector as previously described.3 Briefly, JM109 
cells were grown at 37 °C until the OD600 reached 0.5-1, induced with 0.1 mM 
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IPTG, and incubated with shaking at 20 °C overnight. Cells were pelleted at 5000 
rpm, then flash frozen in liquid nitrogen. The E. coli pellets from 1 L of culture 
were thawed on ice, resuspended in 25 mL lysis buffer (50 mM Tris [pH 7.4], 500 
mM NaCl, and 0.5% Tween 20) containing 1 mM phenylmethylsulfonyl fluoride, 
and disrupted by sonification (Branson Sonifier). Dithiothreitol (DTT) was added 
at 10 mM, and the resulting cell lysate was clarified by centrifugation at 35,000 
rpm for 60 min at 4 °C. The supernatant was batch-bound to immobilized 
glutathione (Thermo Scientific) for 1 hr at 4 °C, and the beads were washed with 
lysis buffer containing 10 mM DTT, followed by wash buffer (50 mM Tris [pH 8.1], 
250 mM NaCl, and 10 mM DTT) and storage buffer (50 mM Tris [pH 7.4], 0.1 mM 
EDTA, 150 mM NaCl, 1 mM TCEP). Twenty units of PreScission Protease (GE 
Healthcare) were added, and incubation continued overnight at 4 °C to cleave 
the GST-fusion and elute the untagged enzyme. Protein concentrations were 
determined using Coomassie Plus (Thermo Scientific). 
Purified Protein Luminescence Assays - IVIS 
Luminescence assays were performed as previously described (Mofford et al., 
2015.). Briefly, luminescence was initiated by adding 30 μL of purified luciferase 
in enzyme buffer (20 mM Tris [pH 7.4], 0.1 mM EDTA, 1 mM DTT, and 0.8 
mg/mL BSA) to 30 μL 2x substrate in substrate buffer (20 mM Tris [pH 7.4], 0.1 
mM EDTA, 8 mM MgSO4, and 4 mM ATP) in a black 96-well plate (Costar 3915). 
Imaging was performed one minute after enzyme addition using a Xenogen IVIS-
100 at a final enzyme concentration of 10 nM and final substrate concentrations 
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ranging from 0.122 to 250 μM. Data acquisition and analysis was performed with 
Living Image software. Data are reported as total flux (p/s) for each ROI 
corresponding to each well of the 96-well plate. The data were plotted using 
GraphPad Prism 6.0 and fit to a sigmoidal dose-response curve by non-linear 
regression. The cooled CCD in the IVIS has high quantum efficiency at the 
emission wavelengths of all substrates, and is the same detector used for in vivo 
imaging. However, these data do not reflect the initial rate and can be affected by 
product inhibition. 
Luciferin Burst Kinetics Assays 
Using a Promega GloMax-Multi Detection System, 50 μL of purified enzyme in 
enzyme buffer was rapidly injected into a white 96-well plate (Costar 3912) 
containing 50 μL of 2x substrate in substrate buffer to a final enzyme 
concentration of 0.2 nM and a final luciferin substrate concentration ranging from 
0.122 to 250 μM. Measurements were taken every 0.5 s for 1 s pre-injection and 
60 s post-injection. Data are reported as Relative Light Units (RLU) and were 
fitted to a sigmoidal dose-response curve by non-linear regression to determine 
apparent Km values (GraphPad Prism 6.0). Because the photomultiplier tube 
(PMT) in the GloMax has reduced sensitivity to red light, the photon emission of 
CycLuc1 and CycLuc2 are understated relative to D-luciferin. These data were 





ATP Burst Kinetics Assays 
D-Luciferin was prepared at 400 μM in 20 mM Tris, [pH 7.4]. CycLuc1 and 
CycLuc2 were prepared at 40 μM in 20 mM Tris, pH 7.4. Separately, ATP was 
prepared in 20 mM Tris, pH 7.4 in two-fold serial dilutions from 16,000 μM down 
to 7.81 μM, with MgSO4 present in two-fold excess at concentrations from 
32,000 μM to 15.63 μM. WT and mutant luciferases were prepared at 0.4 nM in 
enzyme buffer lacking EDTA. In a white 96-well plate (Costar 3912), 25 μL of the 
luciferin solution and 25 μL of the ATP-Mg solution were combined. Using a 
Promega GloMax-Multi Detection System, 50 μL of luciferase solution was 
rapidly injected to achieve a final luciferase concentration of 0.2 nM, a final 
luciferin concentration of 100 μM for D-luciferin and 10 μM for CycLuc1 and 
CycLuc2 (for WT, R218K, and L342A luciferases), and a final ATP concentration 
ranging from 4,000 μM to 1.95 μM, with Mg in two-fold excess. For the 
R218K/L342A mutant, which has higher apparent Km values for the luciferins, 
final concentrations of 1 mM D-luciferin and 100 μM CycLuc1 and CycLuc2 were 
used. Measurements were taken every 0.5 s for 1 s pre-injection and 60 s post-
injection. Data are reported as Relative Light Units (RLU). Dose-response curves 
were plotted with data at the peak of the burst (0.5 s post injection) using 
GraphPad Prism 6.0 and fit to a sigmoidal curve by nonlinear regression to 
calculate the Km(app) for ATP with each luciferase/luciferin pair. Because the 
photomultiplier tube (PMT) in the GloMax has reduced sensitivity to red light, the 
photon emission of CycLuc1 and CycLuc2 are understated relative to D-luciferin. 
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These data were not corrected for wavelength and were only used to determine 
apparent Km values. 
Mice 
FVB/N mice were purchased from the Jackson Laboratory. All procedures 
involving these mice were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Massachusetts Medical School (protocol 
A-2714). 
Construction of AAV-CMV-luc2 
Mammalian codon-optimized luc2 luciferase from pGL4.1 (Promega) was 
mutated using a Quickchange mutagenesis kit (Agilent), and then cloned into the 
EcoRI-SalI sites of a pAAV-CMV plasmid. The AAV-CMV-luc2 mutant plasmids 
were packaged into AAV serotype 9 by the University of Massachusetts Medical 
School Viral Vector Core. 
AAV9-CMV-luc2 vector striatal injections 
Three female FVB/NJ mice per luciferase mutant were purchased from the 
Jackson Laboratory. Striatal injections were performed at 6 weeks of age. A 
chemical hand warmer under a gel pad wrapped in paper towel was placed onto 
a stereotactic frame. Each mouse was anesthetized with 90 mg/kg ketamine and 
4.5 mg/kg xylazine (ketamine/xylazine mix) before surgery. Once anesthetized, 
they were placed on a stereotactic frame and had the hair on their scalp removed 
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by an application of super glue, followed by pulling the hair off as a single 
section. Three alternate betadine and 70% ethanol washes of the denuded area 
were performed with a new cotton-tipped applicator for each application. 
Sterilized forceps were used to raise the skin on the scalp, then sterilized surgical 
scissors were used to make a 1 cm incision anterior to posterior within the 
denuded area covering the bregma suture. The site of injection was acquired at 
the lateral edge of the striatum/cortex border (stereotactic coordinates: anterior 1 
mm, lateral 3 mm and ventral 2 mm from bregma). The needle was left in place 
for one minute, then the mutant luciferase containing AAV vector (1 μL of 2.5e12 
GC/ml AAV9-CMV-Luc2 in PBS) was injected into the mouse at a rate of 125 
nl/min using a micropump-controlled syringe (NanoFil, World Precision 
Instruments). After injection, the needle was left in place for one minute before 
withdrawing. The incision was sutured using 3 simple interrupted stitches of 
dissolving suture material. The mouse was then treated with 0.05 mg/kg 
buprenorphine i.p. before returning to its cage, and again every 6 hours for 48 
hours post-surgery. The cages remained on a heat pad at 37 degrees Celsius 
until mice regained righting reflex. Bioluminescence imaging was performed at 






Preparation of luciferins for brain imaging 
D-luciferin (100 mM), CycLuc1 (5 mM), and CycLuc2 (2.5 mM) were all prepared 
by dissolving dry compound directly into PBS. The respective amides were 
prepared by first dissolving dry compound into DMSO to a concentration of 50 
mM, followed by dilution in PBS to a final concentration of 250 μM (CycLuc1-
amide) or 100 μM (CycLuc2-amide). Once dissolved, all substrate stocks were 
filtered through a 0.2 μm filter (Millipore) prior to injection into mice. 
Brain imaging 
Mice were imaged in the University of Massachusetts Medical School Small 
Animal Imaging Core using an IVIS 100 imaging system. The animals were 
anesthetized with isoflurane (2% in 1 L/min oxygen), then injected i.p. with 4 μl of 
luciferin stock in PBS per gram of body mass. Images were acquired as 60 
second exposures at 15 minutes after i.p. injection and analyzed using Living 
Image software. Regions of interest (ROIs) were drawn around the region 
covering the brain, and the total flux within each ROI was recorded. ROI sizes 
were identical across all images. Graphs and statistics were generated using 







Rapid Access to a Broad Range of 6’-Substituted Firefly Luciferin 
Analogues Reveals Surprising Emitters and Inhibitors 
Deepak K. Sharma, Spencer T. Adams Jr., Kate L. Liebmann, and Stephen C. 
Miller. (2017) Org. Lett., 19(21): 5836-5839. 
Spencer T. Adams Jr. performed in vitro experiments and prepared figures 5.2, 
5.3, 5.4, 6.6 and Table 5.1. 
Summary 
Light-emitting firefly luciferin analogues contain electron-donating groups in the 
6’-position, but the scope of known 6’-substitution remains narrow. A two-step 
route to a broad range of 6’-substituted luciferin analogues was developed to fill 
this void and enable a more extensive study of the 6’-functionality.This chemistry 
allowed direct access to “caged” amide and bright azetidine analogues, but also 




The natural substrate for firefly luciferase, d-luciferin, contains an electron-
donating hydroxyl group in the 6′-position that is crucial for bioluminescence 
(Figure 5.1) (Adams and Miller, 2014.). Synthetic analogues containing amine or 
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alkylamine donors are also luminogenic and can offer advantages for in vivo 
imaging (Evans et al., 2014.; Kuchimaru et al., 2016.). However, to date most 
firefly luciferin substrates and “caged” sensors have been synthesized from 6-
amino or 6-hydroxy benzothiazoles, placing inherent restrictions on the nature of 
the electron-donating 6′-functionality (Adams and Miller, 2014.; Woodroofe et al., 
2008.; Reddy et al., 2010.; Jathoul et al., 2014.; Takakura et al., 2015.; Mofford 
et al., 2015.; Heffern et al., 2016.; Steinhardt et al., 2017.). As such, only a 
relatively narrow range of 6′-substituted luciferin analogues are known, limiting 
our understanding of the chemistry of bioluminescence and ability to take full 
advantage of this imaging modality. In order to further investigate the role of this 
vital component, we explored the derivatization of 6-fluoro and 6-bromo-2-cyano-
benzothiazoles via nucleophilic aromatic substitution and Buchwald–Hartwig 
amination, respectively. We found that this chemistry allowed access to new 
classes of luciferase substrates, inhibitors, and their precursors, with immediate 
applications for biocompatible chemistry and bioluminescence imaging. 
 




           
Figure 5.1. Firefly luciferase substrates all have hydroxy, amino, or 
alkylamino electron donors. Examples include d-luciferin, 6′-aminoluciferin, 
CycLuc1, and AkaLumine. 
 
We envisioned that 6-halo-2-cyanobenzothiazoles could be modified at the 6-
position by nucleophilic aromatic substitution or palladium catalysis (Grimm and 
Lavis, 2011.). One concern was that the activated nitrile is prone to react with 
nucleophiles. Indeed, fear of this possibility initially dissuaded us from exploring 
this route, in favor of reductive alkylation and other synthetic strategies (Reddy et 
al., 2010.; Mofford et al., 2014.). Nonetheless, this chemistry could offer access 
to a wide variety of analogues not readily accessible by other approaches. 
Results and discussion 
We first synthesized 6-fluoro-2-cyanobenzothiazole 3 (Scheme 5.1) and 
performed SNAr reactions with a variety of cyclic secondary amines that could be 
challenging or tedious to synthesize by the conventional N-alkylation approach 
(Scheme 5.2). Of particular interest, azetidine-substituted fluorophores have 
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been reported to have higher quantum yields than those of analogous dyes 
(Grimm et al., 2015.). Although the desired 6-substituted-2-cyano-
benzothiazoles 4–9 could be isolated in most cases, the yields from the SNAr 
route were low (<20%; Scheme 5.2). The reaction with azetidine was particularly 
problematic (2% yield). Primary amines and weakly nucleophilic amines such as 
thiomorpholine dioxide failed to give any desired product. However, displacement 
with methanethiol was successful (48% yield), giving access to a new class of 
analogue that was expected to be fluorescent (Barr and Holewinski, 2002.; 
Granzhan et al., 2007.). The corresponding sulfoxide and sulfone could be 
prepared by oxidation with Oxone and mCPBA, respectively (Scheme 5.2). The 
thiophenol analogue could also be prepared, albeit in low yield (13%). 
We next turned to Buchwald–Hartwig amination of 14, synthesized from 6-
bromo-2-chlorobenzothiazole by heating with KCN in DMSO, or alternatively in 
higher yield at room temperature using DABCO as a catalyst (Scheme 5.3) 
(Hauser et al., 2016.). Palladium-catalyzed amination using xantphos as a ligand 
(Kranenburg et al., 1995.; Yin and Buchwald, 2002.) allowed synthesis of the 
morpholine analogue in 71% yield vs 12% for the SNAr reaction (Scheme 5.4). 
Additionally, the thiomorpholine dioxide analogue was obtained in 74% yield, and 
the azetidine, in 33% yield (low, but vastly improved over 2%). Boc-piperazine 








Scheme 5.1. (a) Bromine, potassium thiocyanate, acetic acid, rt, 21h then 
adjusted to pH 8 using NH4OH; (b) t-butyl nitrite, CuCl2, CH3CN, rt, 2h, then 65°C 
for 1h; (c) potassium ethyl xanthogenate, DMF, 100°C, 4h; (d) SO2Cl2, rt, 2h; (e) 
Method A: KCN, DMSO, 90°C, 8h or Method B: KCN, DABCO, DMSO:H2O (9:1), 
rt, overnight; (f) Nucleophile, K2CO3, DMF, 60°C, 4h; (g) mCPBA, DCM, rt, 12h; 





                    
Scheme 5.2. Nucleophilic aromatic substitution of 6-fluoro-2-





   
Scheme 5.3. Synthesis of piperazine luciferins. (i) (a) Method A: KCN, DMSO, 
90°C, 8h; Method B: KCN, DABCO, DMSO: H2O (9:1), rt, overnight. (b) 
nucleophile, Pd2dba3, xantphos, Cs2CO3, dioxane, 95-100°C. (c) D-cysteine, pH 




                      
Scheme 5.4. Buchwald-Hartwig substitution of 6-bromo-2-
cyanobenzothiazole with a wide variety of partners. 
 
Buoyed by the success of this approach, we then sought access to entire classes 
of 6′-modifications heretofore unknown in luciferin analogues, in order to more 
broadly explore the range of electron-donating groups (EDGs) that could be 
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accommodated in luciferin substrates or caged sensors. For example, no 6′-
arylamino luciferin analogues have been reported. Excitingly, Buchwald-Hartwig 
amination with xantphos allowed ready access to a wide variety of 6-arylamino 
derivatives (Scheme 5.4, 17–30). Furthermore, secondary and tertiary “caged” 6-
amide analogs could also be synthesized directly in good yields under these 
conditions (31–35) (Yin and Buchwald, 2002.). Although simple 6′-amidoluciferins 
are all potential sensors for amidases, only the 6′-acetamide has been previously 
described (White et al., 1966.). We extended this chemistry to carbamates and 
ureas such as 2-oxazolidone 39, benzyl carbamate 36, dimethylurea 37, and 
trimethylurea 38. The thiophenol derivative 13 could be prepared in improved 
yield. Primary amines could also be coupled (40–42), enabling the direct 
synthesis of derivatives that previously required functional group protection (42). 
The new 6-substituted nitriles were all readily converted into their respective 
luciferin analogues 3a-41a by reaction with D-cysteine (Schemes 5.1 and 5.3). 
However, it should be noted that these nitriles are also of direct interest for their 
mild biocompatible condensation with N-terminal cysteines and related 
aminothiols (Ren et al., 2009.; Van de Bittner et al., 2013.; Godinat et al., 2013.; 
Ramil et al., 2016.). 
A set of 36 new luciferin analogues was then evaluated in burst bioluminescence 
assays with purified firefly luciferase (Figures 5.2-4; Table 5.1) (Mofford et al., 
2014.; Harwood et al., 2011.). This assay was used to determine whether the 
new analogues have the capacity for light emission. Unsurprisingly, monoalkyl 
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amine 40a was the brightest, while azetidine 4a led the new cyclic secondary 
amines (Figures 5.2 and 5.5). Although disparate structures such as azepane 7a 
(Kakiuchi et al., 2017.), thiomorpholine 9a, piperazine 16b and 
trifluoroethylamine 41awere all good emitters, the thiomorpholine dioxide 
analogue 15awas unexpectedly only weakly luminescent (Figures 5.2A; 5.3-4), 
despite its fluorescence (Table 5.2). Potentially, accommodation of the bulky 
sulfone group requires twisting of the amine within the enzyme pocket, lowering 
the quantum yield. Such differences could be exploited for the development of 
orthogonal luciferase substrates (Harwood et al., 2011.; Mofford et al., 2014b.; 
Adams et al., 2016.; Jones et al., 2017.) and for the creation and modulation of 






Figure 5.2.  Bioluminescence emission from WT luciferase with luciferin 
analogs. A) alkylamino luciferins; B) putative “caged” luciferins; C) arylamino 
luciferins; D) arylamino luciferins incubated with R218K mutant luciferase. Note 




                            
Figure 5.3. Burst bioluminescence emission from WT firefly luciferase with 
luciferin analogues. A) Log scale shows dramatically lower emission from 
thiomorpholine dioxide 15a compared to other cyclic amines. B) Non-canonical 
luciferin analogues 20a and 37a compared to 15a on a linear scale. 
 
                    
123 
 
               
Figure 5.4. Burst bioluminescence emission from R218K mutant firefly 
luciferase with luciferin analogues on A) log scale and B) linear scale. The 
mutant enzyme improved emission from 8a and non-canonical luciferin 






Figure 5.5. Newly-synthesized luminogenic substrates. 
 





Table 5.1. Peak bioluminescence emission wavelengths for selected 
luciferins. 
Measurements were performed as previously described (Harwood et al., 2011.; 
Mofford et al., 2014.). ND = not determined. 
 
In contrast to alkylamines, the presence of arylamine EDGs in dyes is generally 
associated with negligible fluorescence (Grimm and Lavis, 2011.; Granzhan et 
al., 2007.; Kitamura et al., 2007.; Peng et al., 2016.). However, fluorescence can 
be observed in rigid, viscous, or nonpolar environments (Table 5.2) (Granzhan et 
al., 2007.; Chen et al., 2003.; Kosower, 1982.; Ren et al., 2016.). We suspected 
that the luciferase active site might serve as a suitably rigid environment for 
luminescence. Although most of the aniline analogues were essentially non-
luminescent, the subset of ortho-substituted anilines, expected to experience 
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hindered rotation, was indeed emissive: 2,6-dimethylaniline 20a, 
indoline 29a and 2-ethylaniline 18a (Figures 5.5.2C and 5). Furthermore, a 
substantial increase in luminescence for 20a was observed with a mutant 
luciferase that is known to better accommodate many synthetic luciferins 
(Figures 5.2D and 5.4), suggesting that further enhancement of 6′-arylamine 
luminescence is possible by alteration of the substrate pocket. 
Interestingly, not all “caged” analogs are completely dark (Figures 5.2B, 5.3, and 
5.4). In particular, the dimethylurea derivative 37a was luminescent and brighter 
than 15a (Figures 5.5.3 and 4). Several carboxamide analogues also had weak 
emission (>1,000-fold weaker than D-luciferin, but still >10-fold over 
background). In contrast, all of the new thio analogues are dark, despite the 
fluorescence of the S-methyl analogue 10a (Table 5.2) (Barr and Holewinski, 
2002.; Granzhan et al., 2007.). Indeed, thioethers 10a and 13a are potent 
luciferase inhibitors, as are the non-emissive aryl amines (Figure 5.6). On the 
other hand, the thiomethyl sulfoxide 11a and sulfone 12a are only weakly 
inhibitory, suggesting a potential strategy for constructing bioluminescent sensors 







Table 5.2. Fluorescence properties of selected luciferin analogues. 
Excitation wavelength was 351 nm in PBS and dioxane, 359 nm in methanol. An 
observed lack of fluorescence is indicated by a QY of 0 and “-” for emission 
wavelength. Grayed out boxes indicate no measurements were carried out. 
aExcitation wavelength was 384 nm in PBS and methanol. 





                     
Figure 5.6. Inhibition of firefly luciferase by luciferin analogs. Purified firefly 
luciferase (10 nM) was treated with D-luciferin (250 μM) in the presence of the 




Finally, we evaluated the new panel of luciferin analogues (Figure 5.5) as 
substrates for luciferase in live Chinese hamster ovary (CHO) cells (Figure 
5.7, Figure 5.8). Unlike the in vitro assay, this requires the luciferin analogue to 
cross the cell membrane. The brightest of the new substrates in this context was 
the allylamine 40a (Figure 5.9). None of the new dialkylamines was brighter than 
CycLuc2, but the azetidine, azepane, and thiomorpholine analogues 4a, 7a, 
and 9a yielded higher photon flux than D-luciferin or the 6′-dimethylamino 
analogue (Reddy et al., 2010.). The polar morpholine and piperazine 
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analogues 8a and 16b are substantially weaker emitters in cells, perhaps 
reflective of their relatively poor permeability across the cell membrane, and in 
the case of piperazine, a higher Km than the more lipophilic aminoluciferins 
(Table 5.3). In cells expressing the R218K luciferase, bioluminescence emission 
from D-luciferin could be exceeded by many of the alkyl aminoluciferins. 
Impressively, this includes the unconventional 2,6-dimethylaniline derivative 20a, 
even though it is a relatively weak emitter. 
 
 
Figure 5.7. Comparison of bioluminescence from selected luciferin 
analogues in live CHO cells (10 μM). Live CHO cells expressing (A) wild-type 





Figure 5.8. Comparison of bioluminescence from selected luciferin 
analogues in live CHO cells at multiple concentrations. Live CHO cells 
expressing A) wild-type firefly luciferase or B) R218K mutant luciferase were 
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Figure 5.9. Dose-response of D-luciferin versus 40a with WT firefly 
luciferase in CHO cells. Live CHO cells expressing WT firefly luciferase treated 






Table 5.3. Apparent Km values for selected luciferin analogues. 
Conclusion 
In summary, we have developed a two-step synthesis of luciferin analogues from 
a common intermediate. The essential 6′-donating group can be easily modified, 
enabling investigation of its role and supporting the development of many new 
substrates, inhibitors, and potential probes. Novel 6′-aniline analogues can be 
inhibitors or luminescent substrates, depending on the nature of the aryl 
substituent, and also hold potential as sensors of oxidative species (Takakura et 
al., 2015.; Peng et al., 2016.). Furthermore, numerous other “caged” luciferins 
can be directly accessed, and importantly not all are dark. This work thus pushes 
133 
 
the boundaries of what can be considered a luciferin and suggests new avenues 
to exploit this light-emitting chemistry for detecting and imaging chemical 
reactivity and biological processes. 
Methods and Procedures 
Contributions 
D.K.S. designed and synthesized luciferins, characterized their photophysical 
qualities and prepared the manuscript. S.T.A. Jr. performed purified enzyme 
assays, determined wavelengths of bioluminescent light emission with luciferins, 
and helped with manuscript preparation. K.L.L. performed live cell experiments 
and helped with manuscript preparation. S.C.M. devised experiments and helped 
with manuscript preparation. 
General 
All reactions were performed in well-dried round bottom flasks with rubber septa 
under argon atmosphere, unless otherwise noted. D-luciferin was purchased 
from Gold Bio. Chemical reagents and solvents were purchased from Aldrich, 
Frontier Scientific, Matrix, Oakwood, Synthonix, Toronto Chemical Research, 
Chem-Impex, or TCI and used as received. Flash column chromatography was 
carried out on a CombiFlash RF automated chromatography system using 
RediSep RF Gold silica columns. Thin-layer chromatography (TLC) was 
performed using silica gel (60 F-254) coated aluminum plates (EMD Millipore), 
and spots were visualized by exposure to ultraviolet light (UV). NMR spectra 
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were acquired on Varian Mercury 400 MHz or Bruker Avance III HD 500 MHz 
NMR instruments. High-resolution mass spectra (HRMS) were recorded on a 
Thermo Scientific Orbitrap Velos Pro mass spectrometer coupled with a Thermo 
Scientific Accela 1250 UPLC and an autosampler using electrospray ionization 
(ESI) in the positive mode. UV absorbance was measured on a Varian Cary 50 
Bio UV-Visible Spectrophotometer. Fluorescence data were recorded on a 
Horiba Scientific FluoroMax-4 using FluorEssence software. Solvents used for 
fluorescence spectra: PBS, 1X (Corning Cellgro), Methanol ≥ 99.9% pure (Sigma 
Aldrich), Dioxane 99+% pure (Acros Organic). Bioluminescence imaging assays 
were performed on a GloMax luminometer (Promega) or IVIS-100 (Xenogen, 
now Perkin-Elmer). GraphPad Prism ver. 7.0a (GraphPad Software, Inc.) was 
used to analyze data and generate graphs. 
Luciferin Burst-Kinetics Assays 
Wild-type and R218K mutant firefly luciferase were expressed and purified as 
previously described.1,2 Using a GloMax Luminometer (Promega), 50 μl of 
enzyme buffer [20 mM Tris (pH 7.4), 0.1 mM EDTA, 0.8 mg/mL BSA, and 1 mM 
TCEP] containing firefly luciferase (2 nM) was rapidly injected into each well of a 
white 96-well plate (Costar 3912) containing luciferin analogue (500 μM) in 
substrate buffer [20 mM Tris (pH 7.4), 0.1 mM EDTA, 8 mM MgSO4, and 4 mM 
ATP (AP Bio)], to a final enzyme concentration of 1 nM and luciferin analogue 
concentration of 250 μM. The peak emission occurring 0.5 s after injection was 
reported in Relative Light Units (RLU) and not corrected for the wavelength 
135 
 
sensitivity of the photomultiplier tube. To determine apparent Km values for 
emissive analogues, a two-fold dilution series of each substrate was prepared 
(final substrate concentrations ranging from 250 μM down to 0.122 μM). Peak 
emission occurring 0.5 s after injection of luciferase (0.1 nM final concentration) 
was fitted to a sigmoidal dose-response curve by non-linear regression in 
GraphPad Prism 7. All assays were performed in triplicate. 
Luciferase Inhibition Assay 
Fifty microliters of enzyme buffer [20 mM Tris (pH 7.4), 0.1 mM EDTA, 0.8 
mg/mL BSA, and 1 mM TCEP] containing firefly luciferase (20 nM) was pipetted 
into each well of a 96-well plate containing 250 μM D-luciferin and 10 μM luciferin 
analogue in substrate buffer [20 mM Tris (pH 7.4), 0.1 mM EDTA, 8 mM MgSO4, 
and 4 mM ATP (AP Bio)]. Luminescence measurements were taken one minute 
after substrate addition in an IVIS-100, in triplicate. The data was analyzed with 
Living Image Software ver. 4.3.1 and reported as total flux (p/s). 
Cell Assays 
Chinese hamster ovary (CHO) cells were maintained at 37°C and 5% CO2 in F-
12K medium (Gibco) containing 10% fetal bovine serum and 100 units/ml 
penicillin/streptomycin. Cells were seeded in black 96-well plates (Costar 3916) 
at 15,000 cells/ml. Twenty-four hours post-seeding, the cells were transiently 
transfected with pcDNA3.1 WT luc2 or R218K luc2, as previously reported, at 
0.075 μg DNA/well using Lipofectamine 2000 (Invitrogen).2 Assays were 
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performed in triplicate 48 hours after transfection. Luciferin substrates were 
diluted in Hank’s balanced salt solution (HBSS) to 100 μM, 10 μM, and 1 μM. 
Transfected CHO cells were washed with HBSS and incubated with 60 μl/well of 
100, 10, or 1 μM substrate. Imaging was performed one minute after substrate 
addition in an IVIS-100. Data acquisition and analysis were performed with Living 
Image® software. Data are reported as total flux (p/s) for each ROI 
corresponding to each well of the 96-well plate, and plotted and analyzed with 
GraphPad Prism 7.0. 
Relative Quantum Yield Measurement 
Absorbance spectra were recorded at five different concentrations with 
absorbance between 0.01-0.10 for each sample. Fluorescence spectra were 
recorded on a Horiba Scientific FluoroMax-4. Relative quantum yields were 
calculated from plots of absorbance vs. integrated fluorescence and were 
referenced to that of 6'-aminoluciferin measured under the same conditions. 
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Sulfonamides are an Overlooked Class of Electron Donors in Luminogenic 
Luciferins and Fluorescent Dyes 
Deepak K. Sharma, Spencer T. Adams Jr., Kate L. Liebmann, Adam Choi, and 
Stephen C. Miller. (2019) Org. Lett., 21(6): 1641-1644. 
Spencer T. Adams Jr. performed in vitro experiments and prepared figures 6.2 
(the bioluminescence curves in the top half) and 6.3-6.5. 
 
Summary 
Many fluorophores, and all bright light-emitting substrates for firefly luciferase, 
contain hydroxyl or amine electron donors. Sulfonamides were found to be 
capable of serving as replacements for these canonical groups. Unlike “caged” 
carboxamides, sulfonamide donors enable bioluminescence, and sulfonamidyl 
luciferins, coumarins, rhodols, and rhodamines are fluorescent in water.  
 
Introduction 
There is only one natural substrate for firefly luciferase: D-luciferin. The light-
emitting chemistry of this molecule is not unique, as a broad range of synthetic 
substrates have now been shown capable of supporting bioluminescence (Miller 
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et al., 2018.; Zhang et al. 2018.; Hall et al., 2018.). However, most luminogenic 
examples are push−pull chromophores that contain hydroxyl, amine, or 
alkylamine electron donors (Figure 6.1). Here, we show that a new class of 
sulfonamidyl luciferin analogues are fluorescent molecules that are luminogenic 
substrates for firefly luciferase. Furthermore, we find that sulfonamidyl analogues 
of coumarin and xanthene dyes are also bright fluorophores. Sulfonamides are 
thus an overlooked class of electron donors that can be incorporated into both 
fluorescent and bioluminescent probes.  
 
              
Figure 6.1. Examples of luciferins and xanthenes. 
Results and discussion 
In recent work to explore and expand the range of accessible luciferin analogues, 
we found that Buchwald–Hartwig amination of 6-bromo-2-
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cyanobenzothiazole 1 with Xantphos and Cs2CO3 allowed ready access to a 
wide variety of 6-substituted luciferin precursors (Sharma et al., 2017.). When 
these reaction conditions were applied to methanesulfonamide, attack at the 
electrophilic nitrile occurred instead, resulting in the imide 2 (Scheme 6.1). 
Fortunately, simply replacing the ligand and base with tBuXPhos(5) and 
K3PO4 allowed the synthesis of 3 to proceed in 67% yield. Condensation with D-
cysteine yielded the 6′-methanesulfonamide (mesyl) luciferin analogue 3a. 
 
   




In sharp contrast to 6′-acylamino luciferin analogues which are “caged” 
derivatives with little to no bioluminescent emission (Sharma et al., 2017.) we 
found that 3a is luminogenic (Figure 6.2). This marked difference could be due in 
part to the lower pKa of sulfonamides. Consistent with this hypothesis, 3a 
exhibits pH- dependent fluorescence (pKa of 7.8), suggesting that light emission 
occurs from the sulfonamide anion. Furthermore, the N-methylated sulfonamide 
analogue 4a exhibits negligible bioluminescence, and its weakened fluorescence 





Figure 6.2. Bioluminescence and fluorescence of 3a-4a. Top: Rapid injection 






Table 6.1. Fluorescence properties for selected sulfonamidyl luciferins. 
aExcitation wavelength used for RQY study was 335 nm. 
bExcitation wavelength used for RQY study was 325 nm. 
ND = Not determined. 
 
To further probe the scope of sulfonamide luminescence behavior, we 
synthesized a large panel of ∼40 sulfonamidyl luciferin analogues (Schemes 6.2-
6.6). Because firefly luciferase also has fatty acyl-CoA synthetase activity (Oba et 
al., 2003.; Mofford et al., 2014.; Mofford et al., 2017.), sulfonamides with aliphatic 
chains were expected to extend into the elongated binding pocket (3a−15a). 
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Bulky analogues were synthesized to probe the steric scope of accepted 
substrates (16a−34a), and electronic modifications were made to further probe 
the importance of the sulfonamide pKa on its emissive properties (35a−44a).  
 
Scheme 6.2. Synthesis of sulfonamidyl luciferin nitrile precursor. a) 
Methane sulfonamide, Pd2dba3, xantphos, Cs2CO3, dioxane, 95-100°C.  
 
Scheme 6.3. Synthesis of sulfonamidyl luciferins 3-15. a) Alkyl sulfonamide, 





Scheme 6.4. Synthesis of sulfonamidyl luciferins 16-23. a) Cyclic 
alkylsulfonamide or dialkylsulfamide, Pd2dba3, tBuXPhos, K3PO4, dioxane, 95-





Scheme 6.5. Synthesis of sulfonamidyl luciferins 24-42. a) Aryl or fluorinated 






Scheme 6.6. Synthesis of sulfonamidyl luciferins 43 and 44. a) Fluorosulfonic 
anhydride, triethylamine, 0°C to rt, 3 h; b) D-cysteine, pH 8 buffer.  
 
The modest light emission of 3a could be greatly improved upon (Figure 6.3). 
Generally, more lipophilic derivatives performed better as luminogenic 
substrates, but interestingly, there is a substantial drop off in luminescent activity 
for the hexylsulfonamide 14a compared to that of the butyl, pentyl, and octyl 
analogues (9a, 12a, 15a). Bulky phenethyl, 2,6- dimethylphenyl, and mesityl 
analogues (25a, 31a, 32a) are also bright emitters. Intriguingly, the maximal 
emission from 31a is ∼10% of that achieved with D-luciferin (Figure 6.4). 
Furthermore, the decay in luminescence from the sulfonamides 1 min after 
substrate injection is only ∼3-fold from the initial rate, similar to D-luciferin, rather 
than ∼10−100-fold as observed for many aminoluciferin analogues (Figures 6.2 
and 6.4) (Mofford et al., 2014.; Reddy et al., 2010.). Surprised by the brightness 
of many sulfonamides, we performed LC/MS to verify that there is no 
contaminating D-luciferin or aminoluciferin (Supporting Information).  
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Figure 6.3. Sulfonamidyl luciferins (top) and their relative light emission 




             
Figure 6.4. Burst luciferase assays. A solution containing 0.5 nM firefly 
luciferase was rapidly injected into 250 μM substrate as described in the 
methods. Top: D-luciferin compared to a range of sulfonamidyl luciferins (from 
brightest 31a to weakest 3a and 14a). Bottom: Sulfonamidyl luciferin 31a 
compared to D-luciferin, aminoluciferin, monoalkylated aminoluciferin CycLuc1, 




We measured the pH sensitivity of fluorescence for a subset of these new 
analogues (Table 6.1). Compared to 3a, the pKa values for benzenesulfonamide 
27a and trifluoropropyl (TFP) sulfonamide 41a are decreased from 7.8 to 7.4, 
and these analogues exhibited the highest quantum yields. On the other hand, 
the pKa values for 9a, 25a, and 32a were increased to 8.6, 8.2, and 8.6, 
respectively, yet they remain good luminogenic luciferase substrates. This 
suggests that deprotonation can occur within the active site for all of these 
analogues. For reference, the pKa of D-luciferin is 8.7 (Morton et al., 1969.).  
Bioluminescence from most of the sulfonamides occurred at a wavelength similar 
to that of D-luciferin (547−555 nm). However, 3a and 9a emit at 636 and 642 nm, 
respectively (Figure 6.5). This difference appears to derive from a subtle 
orientation and/or protonation effect within the enzyme pocket and not the pKa 
value per se, as this red-shift is not observed for similar analogues 12a and 15a. 
Furthermore, some of the sulfonamides, such as 29a and 41a, give bimodal 
emission. D-Luciferin is known to exhibit similarly environmentally sensitive 
emission, including examples of bimodal emission (Harwood et al., 2011.; 





Figure 6.5. Bioluminescence emission spectra from selected sulfonamidyl 
luciferins (collected as described in the methods). Several substrates give 
bimodal emission or have apparent shoulder peaks. Peak emission wavelengths 
are 636 nm (3a); 642 nm (9a); 555 nm (12a); 628 nm (14a); 555 nm (15a); 553 




In live cells, the brightest substrates include the mesityl and n-butyl sulfonamides 
32a and 9a (Figures 6.6 and 6.7). Surprisingly, n-octyl sulfonamide 15a gave 
weaker than expected emission based on the in vitro results (Figure 6.3), 
suggesting that its ability to access the intracellular luciferase is restricted, 
perhaps through sequestration in cell membranes and/or engagement with other 
cellular targets. In cell lysates, the relative performance of 15a was substantially 
improved. Notably, sulfonamidyl luciferin analogues do not suffer from the 
product inhibition normally associated with alkylated aminoluciferins in cell 
lysates (Figure 6.6) (Harwood et al., 2011.), consistent with their behavior using 




                     
Figure 6.6. Bioluminescence of sulfonamidyl luciferins in live (top) and 





Figure 6.7. Live cell bioluminescence imaging of sulfonamidyl luciferins in 
CHO cells. Each substrate was used at 1, 10, and 100 micromolar, respectively, 
in triplicate, as described in the methods. Each panel represents a different 




Because all of the sulfonamidyl luciferins are fluorescent, it was surprising to find 
few documented examples of fluorophores with sulfonamide donors. Shibata et 
al. have reported two rhodamines containing 2,4-dinitrobenzenesulfonamide 
donors, designed as “caged” sensors for thiols, neither of which exhibited 
appreciable fluorescence (Shibata et al, 2008.). Nitrobenzenesulfonamide 
coumarin and cresyl violet dyes are similarly nonfluorescent, presumably due to 
electron-transfer quenching (Zhang et al., 2011.). Toluenesulfonamide-
substituted coumarin, cresyl violet, and rhodamine dyes have been reported, but 
their fluorescence properties have scarcely been investigated (Zhang et al., 
2011.; Dakanali et al., 2005.; Grimm and Lavis, 2011.; Reddy et al., 1986.).  
The lack of reported sulfonamidyl dyes may be due to the perception that they 
will not be fluorescent, coupled with the need for deprotonation. To determine 
whether sulfonamide donors can be utilized more broadly in fluorescent scaffolds 
other than luciferin analogues, we synthesized TFP sulfonamidyl coumarin 45, 
which should have a low pKa and no electron- transfer quenching (Figure 6.8). In 
water at physiological pH, 45 is 89% as bright as the aminocoumarin, with a 
similar extinction coefficient and emission that is red-shifted by 15 nm (Table 
6.2). Next, we synthesized sulfonamidyl rhodol 46 and rhodamine 47. The bis-
sulfonamide rhodamine 47 is colorless in ethanol, and the monosulfonamide 
rhodol 46 nearly so, suggesting they exist predominantly as the spirolactone 
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(Figure 6.1). However, in water, we expected they would deprotonate to a ring-
opened, anionic form. Indeed, the pKa of rhodol 46 is 5.9, slightly lower than that 
of fluorescein (Figure 6.9). TFP-rhodol 46 has an extinction coefficient of 56400 
M−1 cm−1 at 499 nm and fluoresces at 526 nm with a quantum yield of 0.78 
(Table 6.3). Impressively, this is brighter than most rhodols with dialkylamine 
donors (Peng and Yang, 2010.; Grimm et al., 2015.). Moreover, the bis-TFP 
rhodamine 47 is also fluorescent, with a quantum yield of 0.40 and extinction 
coefficient of 51 000 M−1 cm−1, suggesting that sulfonamides could also be 
incorporated into related red-shifted scaffolds such as oxazines (Pauff and Miller, 
2011.) and azasilines (Choi and Miller, 2018.), as well as sulfone (Liu et al., 
2016.), phosphorus (Chai et al., 2015.; Zhou et al., 2016.; Grzybowski et al., 
2018.), and Si-substituted rhodamines (Grimm et al., 2017.) and rhodols (Jia et 




          
Figure 6.8. Properties of fluorophores with sulfonamide donors (depicted in 









Figure 6.9. Fluorescence properties of trifluoropropyl (TFP) sulfonamidyl 
rhodol 46 (left panels) and rhodamine 47 (right panels). Top: excitation and 
emission spectra (summarized in Table 6.3). Middle: pH-dependence of 
fluorescence. Bottom: Curve fitting yields apparent pKa values of 5.9 for 46 and 




Table 6.3. Fluorescence properties of TFP Rhodol 46 and Rhodamine 47. 
Conclusion 
In summary, sulfonamide electron donors do not behave like “caged” 
carboxamides but instead expand the scope of luminogenic molecules beyond 
the canonical hydroxyl and amino-substituted analogues. The relative brightness 
of sulfonamide-substituted fluorophores suggests that further improvements in 
bioluminescence from sulfonamidyl luciferins can be achieved through mutation, 
and the ability to easily tune the molecular properties of sulfonamidyl luciferins 
can aid in the construction of selective new luciferin−luciferase pairs (Mofford et 
al., 2014.; Harwood et al., 2011.; Jones et al., 2017.) as well as specific 
bioluminescent sensors that can take advantage of this new functionality(Mofford 
et al., 2015.; Heffern et al., 2016.). Furthermore, sulfonamide donors have been 
previously overlooked for incorporation into fluorescent probes, opening up new 





Protocols and Methods 
Contributions 
D.K.S. designed and synthesized luciferins, characterized their photophysical 
qualities and prepared the manuscript. S.T.A. Jr. performed purified enzyme 
assays, determined wavelengths of bioluminescent light emission with luciferins, 
and helped with manuscript preparation. K.L.L. performed live cell experiments 
and helped with manuscript preparation. A.C. designed and synthesized dyes 
and helped with manuscript preparation. S.C.M. devised experiments and helped 
with manuscript preparation. 
General 
All reactions were performed in well-dried round bottom flasks with rubber septa 
under an argon atmosphere, unless otherwise noted. Chemical reagents and 
solvents were purchased from Aldrich, Frontier Scientific, Matrix, Oakwood, 
Synthonix, Toronto Chemical Research, Chem- Impex, Enamine, 
1ClickChemistry Inc., Synquest Laboratories, Santa Cruz Biotechnology or TCI 
and used as received. Fluorescein ditriflate (Grimm et al., 2011.) and 6-bromo-2-
cyanobenzothiazole (Sharma et al., 2017.) (compound 1) were synthesized as 
previously described. Flash column chromatography was carried out on a 
CombiFlash Rf automated chromatography system using RediSep Rf Gold silica 
columns. Thin- layer chromatography (TLC) was performed using silica gel (60 F-
254) coated aluminum plates (EMD Millipore) and spots were visualized by 
exposure to ultraviolet light (UV). NMR spectra were acquired on a Bruker 
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Avance III HD 500 MHz NMR instrument. High-resolution mass spectra (HRMS) 
were recorded on a Thermo Scientific Orbitrap Velos Pro mass spectrometer 
coupled with a Thermo Scientific Accela 1250 UPLC and an auto sampler using 
electron spray ionization (ESI) in the positive mode. Absorbance was measured 
on a Varian Cary 50 Bio UV- Visible Spectrophotometer. Fluorescence data were 
recorded on a Horiba Scientific FluoroMax-4 using FluorEssence software. 
Solvents used for fluorescence spectra were ethanol (Decon), dioxane 
(Oakwood), and PBS (Corning Cellgro). LC-MS analyses were performed on an 
Agilent Technologies 6130 quadrupole LC/MS connected to an Agilent diode 
array detector using an Agilent ZORBAX SB-C18 Rapid Resolution HT 2.1 x 50 
mm column, 1.8 micron particle size, with a mobile phase of water/acetonitrile 
including 0.1% formic acid. In vitro bioluminescence assays were performed on a 
Promega GloMax Discover luminometer. Cellular bioluminescence assays were 
performed on a Xenogen IVIS 100. GraphPad Prism 7.0a (Graph Pad Software, 
Inc.) was used to analyze data and generate graphs.  
In Vitro Luciferase Assay  
Luciferin analogues were prepared by dilution of 50 mM DMSO stocks into 
substrate buffer (20 mM Tris HCl pH 7.4, 0.1 mM EDTA, 8 mM MgSO4, and 4 
mM ATP). The final volume added into each well of a white 96-well plate (Costar 
3912) was 60 μl. The plates were then loaded into a Promega GloMax Discover 
instrument, where each well was injected with 60 μl of 1 nM recombinant firefly 
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luciferase (Harwood et al., 2011.; Mofford et al., 2014.) in enzyme buffer (20 mM 
Tris HCl pH 7.4, 0.1 mM EDTA, 0.8 mg/mL BSA, and 1 mM TCEP), followed by 
measuring the bioluminescent light output at 0.5 second intervals for one minute. 
Note that once the luciferase is added, both the enzyme and substrate are at half 
their originally prepared concentrations.  
Fluorescence and Relative Quantum Yield Measurement for Sulfonamidyl 
Luciferins  
Absorbance spectra were recorded at five different concentrations with 
absorbance between 0.01-0.10 for each sample. Extinction coefficients were 
calculated from the slope of absorbance versus concentration. Relative quantum 
yields were calculated from plots of absorbance vs. integrated fluorescence and 
were referenced to that of 6'-aminoluciferin measured under the same conditions. 
Fluorescence spectra were recorded in PBS at different pH values, and pKa 
values were determined from plots of pH vs. integrated fluorescence.  
Bioluminescence Emission Wavelength Measurement  
Luciferin analogues were prepared at 20 μM by dilution from a 50 mM DMSO 
stock into substrate buffer (20 mM Tris HCl pH 7.4, 0.1 mM EDTA, 8 mM 
MgSO4, and 4 mM ATP). Recombinant firefly luciferase was prepared at 200 nM 
in enzyme buffer (20 mM Tris HCl pH 7.4, 0.1 mM EDTA, 0.8 mg/mL BSA, and 1 
mM TCEP). A quartz cuvette containing 1.5 mL of the enzyme solution was 
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placed into a FluoroMax fluorometer. Into the quartz cuvette, 1.5 mL of the 
respective luciferin analogue in substrate solution was injected into the luciferase 
enzyme solution, and the resulting emission was scanned from 400-800 nm with 
a 10 nm emission slit and closed excitation slit.  
CHO Cell Bioluminescence Assays  
Chinese hamster ovary (CHO) cells were maintained at 37°C and 5% CO2 in F-
12K medium (Gibco) containing 10% fetal bovine serum and 100 units/mL 
penicillin/streptomycin as previously reported. CHO cells were grown to ~80% 
confluence, then trypsinized, seeded in black 96-well plates (Costar 3916) at 
15,000 cells/mL, and returned to the incubator overnight. Twenty-four hours post-
seeding, the cells were transiently transfected with pCDNA3.1-WTLuc2 at 0.075 
μg DNA/well using Lipofectamine 2000 (Invitrogen), as previously reported. 
Assays were performed in triplicate 48 hours after transfection in a Xenogen 
IVIS-100. Substrates were diluted in Hank’s balanced salt solution (HBSS) to 100 
μM, 10 μM, and 1 μM. Each 96-well plate of transfected CHO cells was gently 
washed with HBSS and overlaid with 60 μl/well of 100, 10, or 1 μM substrate. 
Bioluminescence imaging was performed one minute after addition of substrate. 
Lysed cell assays were performed as previously described (Harwood et al., 
2011.; Mofford et al., 2014.). Data acquisition and analysis were performed with 
Living Image software, and reported as total flux (p/s) for each ROI 
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corresponding to each well of the 96-well plate. Data were plotted and analyzed 
with GraphPad Prism 7.0.  
Photophysical Properties of TFP Rhodol (46) and Rhodamine (47)  
Compounds were diluted from a 10 mM DMSO stock into 0.1 M NaOH. The 
diluted solution was allowed to equilibrate in the dark at room temperature for 15 
minutes before a second dilution was made. The second dilution was allowed to 
equilibrate in the dark at room temperature for another 15 minutes before the 
absorption or fluorescence signal was read. Absorbance spectra were recorded 
at five different concentrations with absorbance between 0.01-0.10 for each 
sample. Extinction coefficients were calculated from the slope of absorbance 
versus concentration. Quantum yields were determined from plots of absorbance 
versus integrated fluorescence, using fluorescein and Rhodamine 6G as 
reference standards. To determine pKa values, dyes 46 and 47 were diluted from 
a 10 mM DMSO stock into the appropriate buffers (pH 4 – 5.4, 0.2 M citrate; pH 
5.8 – 7.8, 0.1 M phosphate; pH 8.4 – 8.6, 0.1 M Bicine/Tris) to a final 
concentration of 5 μM and allowed to equilibrate in the dark for 15 minutes. 







FruitFire: a Luciferase Based on a Fruit Fly Metabolic Enzyme 
Spencer T. Adams, Jr., Markus F. Bohn, Celia A. Schiffer, and Stephen C. 
Miller. Currently preparing for submission. 
Summary 
The fruit fly enzyme CG6178 shares high sequence identity with firefly luciferase, 
but is incapable of catalyzing bioluminescence with firefly luciferin. Recently, we 
found that it has weak luciferase activity when supplied with synthetic luciferin 
analogues such as CycLuc2. To better understand the basis for this substrate 
discrimination and to engineer the enzyme to be a more robust luciferase, we 
determined the structure of CG6178 using x-ray crystallography. We then 
mutated select residues in the active site to create FruitFire, which exhibits a 
lowered Km for CycLuc2, 20-fold improved activity, and even some weak light 
emission with D-luciferin. When expressed in mice, FruitFire enabled 
bioluminescence imaging in the brain using the pro-luciferin CycLuc2-amide. The 
conversion of a fruit fly fatty acyl-CoA synthetase into a luciferase capable of in 







Fruit flies, like the majority of insects, do not glow in the dark. But why not? 
Fireflies and other bioluminescent beetles use luciferase enzymes to oxidize the 
small-molecule substrate D-luciferin for light emission. The fruit fly Drosophila 
melanogaster expresses a long-chain fatty acyl-CoA synthetase (ACSL), 
CG6178, which is 41% identical to firefly luciferase (Fluc) (Oba et al., 2004.). We 
previously demonstrated that this enzyme harbors latent luciferase activity when 
supplied a suitable synthetic luciferin, such as CycLuc2 (Figure 7.1) (Mofford et 
al., 2014.). Although this latent luciferase activity is relatively weak, it suggests 
that fatty acyl-CoA synthetases (ACSs) can inform us about the molecular details 
of what makes beetle luciferases different from their ancestral enzymes. Further, 







Figure 7.1. Firefly luciferase and CG6178 are bifunctional. Firefly luciferase 
(Fluc) is a luciferase that catalyzes light emission from D-luciferin (A) and 
CycLuc2 (B). Fluc is also a long-chain fatty acyl-CoA synthetase, ligating 
coenzyme A to long-chain fatty acids (C). CG6178 catalyzes light emission from 
CycLuc2 (B), but not D-luciferin (A). CG6178 natively functions as an ACSL (C). 
Thus, both enzymes are bifunctional. 
 
Fluc is a two-domain protein, with a substrate-binding channel that lies at 
the interface of its larger N-terminal domain and smaller C-terminal domain 
(Figure 7.2) (Conti et al., 1996.). Fluc is able to catalyze light emission from 
luciferins and attach coenzyme-A to fatty acids, making it a luciferase and an 
ACS, respectively (Oba et al., 2003.). In the bioluminescent reaction, D-luciferin 
is first adenylated, then this AMP ester reacts with oxygen to form an excited-
state oxyluciferin (Figure 7.1A) (McElroy et al., 1996.; White et al., 1971.; 
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DeLuca, M., 1976.; Wood, K.V., 1995.). The oxyluciferin then relaxes to the 
ground state, emitting a photon of light (McElroy et al., 1996.; White et al., 1971.; 
DeLuca, M., 1976.; Wood, K.V., 1995.). Similarly, when Fluc binds fatty acids of 
appropriate length, it adenylates them (Figure 7.1B) (Oba et al., 2003.). However, 
once the fatty acid is adenylated, coenzyme A displaces AMP from the acyl 
adenylate, forming a fatty acyl-CoA ester (Oba et al., 2003.). Although the N-
terminal domain is primarily responsible for substrate recognition, the C-terminal 
domain is necessary for efficient bioluminescence (Oba et al., 2006.). The C-
terminal domain facilitates light emission by alternating between two alternating 
conformations (rotating 140° relative to the N-terminal domain) to present two 
different lysine residues that are important for efficiently coupling the adenylation 






Figure 7.2. Firefly luciferase is a two-domain protein. Structure of Photinus 
pyralis luciferase (4G36; Sundlov et al., 2012.) shown with the N-terminal domain 
colored blue and the C-terminal domain colored red. A flexible hinge connects 
the two domains (not highlighted). Substrates bind at the interface of the two 
domains. 
 
CG6178 is an insect ACSL that shares 42% identity with Fluc on the 
amino-acid level (Figure 7.3) (Oba et al., 2003.). Given the significant sequence 
homology and shared evolutionary history between Fluc and ACSLs, this fruit-fly 
enzyme has garnered attention from labs seeking to identify and characterize 
novel luciferase enzymes. Characterization of CG6178 revealed that the enzyme 
is a luciferase capable of catalyzing light emission from synthetic luciferins, but 
not the natural substrate D-luciferin (Oba et al., 2003.; Mofford et al., 2014.). To 
understand the molecular basis for CG6178’s latent luciferase activity and 




Figure 7.3. CG6178 shares 42% amino-acid identity with firefly luciferase. 
Firefly luciferase sequence (UniProt accession number: Q27758) aligned with 
CG6178 sequence (UniProt accession number: Q97CC6) using Clustal under 
MUSCLE settings (Edgar, R.C., 2004.). Asterisks indicated residues later 
targeted for mutagenesis. Asterisk color corresponds to residue coloring in 
Figure 7.5. 
 
Here we report the crystal structure of CG6178, which shares the same 
overall fold as firefly luciferase, but has a steric protrusion constricting the 
substrate binding site. Through the introduction of point mutations to residues 
that comprise this bump, we improved the luciferase activity in this fruit fly 
enzyme. The mutated CG6178, which we now dub “FruitFire,” has increased 
bioluminescent activity with CG6178’s preferred substrate (CycLuc2), catalyzes 
light output with the synthetic luciferin CycLuc2-amide robust enough for 




Results and discussion 
X-ray data was collected at the APS 23-ID beamline and the initial solution was 
generated using Fluc (PDB 4G36) as a search model (Sundlov et al., 2012.). Our 
structure was determined at 2.48 Angstrom resolution with a crystallographic R-
value of 0.19 and an R-free value of 0.24 (Table 7.1). The structure contains 534 
out of 544 residues. The first residue and the last 6 residues are all exposed on 




    
Table 7.1. Crystallographic Statistics for CG6178 Structure. 
As expected, the CG6178 structure shares the same overall fold with 
firefly luciferase (Figure 7.4). As calculated with PyMol, our CG6178 structure 
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exhibits an RMSD of 1.45 Å with Fluc (PDB ID: 4G36) (Sundlov et al, 2012). 
Efforts to co-crystallize CG6178 with either CycLuc2 or D-luciferin were 
unsuccessfull. However, ATP dramatically improved crystallizability. Within our 
structure, we see density for an adenylated moiety. However, the identity of the 
ligand is ambiguous. In Figure 7.5, we show the electron density maps for either 
an adenylated fatty acid or an adenylated polyethylene glycol molecule, both of 
which fit equally well. Therefore, we modeled luciferin into CG6178’s active site 
by superimposing its structure onto a co-crystal structure of Fluc with a non-
hydrolyzable bisubstrate analog DLSA, then visualized CG6178’s active-site 
residues that surrounded this substrate’s predicted binding location. CG6178’s 
active site residues differ from the ones in Fluc (Figure 7.6).  





                      
Figure 7.4. Firefly luciferase and CG6178 share an overall fold. Fluc (PDB ID: 
4G36; Sundlov et al., 2012.) (N-terminal domain in light blue and C-terminal 
domain in dark blue) and CG6178 (N-terminal domain in beige and C-terminal 
domain in brown) were aligned using UCSF Chimera (Petterson et al., 2004) and 
are represented in two poses rotated approximately 180° about the vertical axis. 
The structures are well-conserved among the two proteins. 
 
   
 
Figure 7.5. The identity of the ligand bound to the CG6178 structure is not 
clear. Though the density for CycLuc2 generated negative density (not shown), a 
long alkyl chain (left panel) or polyethylene glycol chain (right panel) extended 
from the AMP moiety are equally supported by our model. Sigma values set to 





Figure 7.6. Active site residues selected for mutagenesis. CG6178’s 
structure (panel B) was superimposed over Fluc co-crystallized with DLSA (panel 
A) to identify residues for mutagenesis. The alignment was used to show the 
predicted location of luciferin in CG6178’s active site and the surrounding 
residues.The colors shown correspond with the residues’ location in the 
sequence alignment in Figure 7.3. Figure prepared using UCSF Chimera 
(Petterson et al., 2004). 
 
Based on these differences, we initially created 11 CG6178 mutants in an 
attempt to improve the enzymes luciferase activity (residues chosen for 
mutagenesis are asterisked in Figure 7.3 and the specific mutations and 
combinations of these residues are shown in Figure 7.7, panel C.). Once these 
mutants were created, they were tested for their performance in vitro compared 
to wild-type CG6178 with both CycLuc2 and D-luciferin. The best performing 
mutant among the 11 mutants involved the residues 342-S-E-S-T-L-S-347 
mutated to mimic the sequence in Fluc to 342-T-E-T-T-S-A-347. Despite some of 
the other mutants improving the activity of CG6178 relative to wild-type, the 
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combination of mutating this region along with other active site residues did not 
provide an additive benefit to the activity of CG6178. 
       
 
Figure 7.7. Activity of CG6178 active site mutants with CycLuc2 and D-
luciferin. Residues asterisked in Figure 7.3 and shown in Figure 7.6 were 
mutated in various combinations and tested in vitro for their performance with 
CycLuc2 (panel A) or D-luciferin (panel B). The specific residues mutated in each 
mutant are indicated in the table in panel C. 
 
Within the region that provided the greatest improvement in activity from 
the initial mutant screen, CG6178 residues 344-347 create a protrusion that 
constricts the active site relative to firefly luciferase (Figure 7.8). We hypothesize 
that substrates with aliphatic fatty acid side-chains can readily traverse this 
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narrow constriction, but D-luciferin cannot, or at least not in a conformation 
suitable for attack of its carboxylate on ATP during the adenylation step. This 
discrimination is not an issue for CG6178 to perform its native ACSL activity. It is 
not immediately clear why CycLuc2 would perform better than D-luciferin in this 
respect. However, CycLuc2 is a more hydrophobic and rigid substrate that may 
enable some deformation of the active site that is not possible with D-luciferin. 
Removal of the constriction in CG6178’s active site could therefore be beneficial 
for the luciferase activity of CG6178 with both CycLuc2 and D-luciferin. 
 
 
Figure 7.8. Comparison of firefly luciferase’s and CG6178’s active sites 
highlights differences. Fluc (PDB ID 4G36; Sundlov et al., 2012) (shown in 
green) and CG6178 (shown in blue) were aligned using UCSF Chimera 
(Petterson et al., 2004.) and surfaces shown to compare the substrate binding 
pocket: (A) with luciferase’s co-crystallized bisubstrate analog of D-luciferin 
adenylate (DLSA) shown and (B) without the compound shown. The red arrow in 
(A) shows where CG6178 has a protrusion that impinges the active site in the 
region occupied for the substrate to access ATP during the adenylation step of 
catalysis. 
 
Failure to adenylate D-luciferin precludes light emission with this 
substrate, and indeed there is evidence that CG6178 is incapable of adenylating 
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D-luciferin. The sidechain of leucine 346 that creates CG6178’s protrusion 
(highlighted in Figure 7.9A) aligns with the sidechain of serine 347 in firefly 
luciferase.  Serine 347’s side-chain hydroxyl group makes a hydrogen-bonding 
interaction with the benzothiazole nitrogen via an intermediate water molecule in 
firefly luciferase and is a key residue for efficient catalysis of bioluminescence 
(Nakatsu et al., 2006.). However, previous work has shown that simply mutating 
the leucine residue 347 in CG6178 to serine as suggested from the sequence 
alignment was insufficient to enable CG6178 to efficiently emit light with D-
luciferin (Oba et al., 2009.). Furthermore, mutation of serine 347 in firefly 
luciferase has a detrimental effect on bioluminescence from D-luciferin, but is 
well tolerated by aminoluciferins (Harwood et al., 2011.). To test our hypothesis 
that this bump limits the luciferase activity of CG6178, we generated four mutants 
of CG6178 that contained mutations to the leucine and flanking residues and 
tested their ability to improve the luciferase activity of CG6178 with its preferred 
substrate CycLuc2 and with the natural D-luciferin substrate. A table in Figure 7.9 
details the mutant sequences we selected (Alignment of relevant Fluc and 
CG6178 sequences in Figure 7.9C and corresponding CG6178 mutant 
sequences in Figure 7.9D). These sequences were chosen to reduce the size of 
the bump in CG6178’s active site using alanines and/or to restore a serine side 
chain that functionally mimics the serine residue in firefly luciferase. Mutants 1-3 
retain the same residues as wild-type CG6178 for residues 344 and 345, but 
mutate 346 (the lysine primarily causing the bump) and residue 347 (serine in the 
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wild-type sequence). The fourth mutant mutates all residues to mimic the 
sequence from wild-type firefly luciferase. 
 
 
Figure 7.9. Mutant strategy for improving the luciferase activity of CG6178. 
CG6178’s (A) and Fluc’s (B) (PDB 4G36; Nakatsu et al., 2012.) active site 
surfaces modeled with UCSF Chimera (Petterson et al., 2004.). The residues 
that contribute to CG6178’s protrusion are highlighted in A and the corresponding 
residues that align with them in Fluc are highlighted in B and in sequence form in 
C. Mutant sequences for the bump residues are detailed in D. 
 
 
To test the whether these CG6178 mutants had improved the enzyme’s 
bioluminescent activity, we initially assayed purified protein over a range of 
concentrations with D-luciferin and CycLuc2 (Figure 7.10). We found that three of 
the four CG6178 mutant enzymes improved the luciferase activity of CG6178 
with CycLuc2, with the best performing mutant increasing light emission by 20-
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fold at 250 µM substrate concentration (saturating luciferin concentration). 
Further, the CG6178 mutants also lowered the Km for luciferin CycLuc2 from 15 
μM for the wild-type enzyme to 2.13 μM for the “STSA” mutant (Table 7.2), 
suggesting the mutants would be more useful in contexts where substrate access 
is limiting, such as in vivo. Mutant 3 exhibited the best performance overall and 






Figure 7.10. In vitro performance of CG6178 mutants. Wild type CG6178 and 
the 4 mutants detailed in Figure 6D were incubated with either D-luciferin or 
CycLuc2 over a range of concentrations from 0.122 µM to 250 µM. Panel A 
contains graphs of both substrates with each enzyme, while panel B only 
contains graphs for D-luciferin, showing the response of the dimmer substrate 
with a lower scale. Due to the different scales used for each dose-response, 
panels C and D show the relative performance of CycLuc2 and D-luciferin at 





Table 7.2. In vitro Km vales for wild type CG6178 and mutants. Data from 
figure 7 was analyzed using nonlinear regression to calculate Michaelis 
constants. Compared to wild type CG6178, Fruitfire (highlighted in red) has a 
lower Km.  
 
We next tested whether these mutants would permit light emission with D-
luciferin. Mutant 2, which exhibited poorer luciferase activity than wild-type 
CG6178 with CycLuc2, did not catalyze light emission from D-luciferin. However, 
mutants 1, 4, and FruitFire were each able to catalyze weak but measurable light 
emission with D-luciferin in a dose-dependent manner (7.10B and 7.10D). The 
relative emission with D-luciferin is approximately 3 orders of magnitude lower 
than CycLuc2, with FruitFire again exhibiting the highest activity. 
Following the successful improvement of bioluminescent light intensity and 
lower Km for CycLuc2 in CG6178 through mutagenesis, we wanted to determine 
if the same results applied to live cells. We transfected Chinese hamster ovary 
(CHO) cells with either wild-type luc2, wild-type CG6178, or Fruitfire, then 
incubated them with serially diluted D-luciferin or CycLuc2 from 250 µM to 0.122 
µM concentration with 96 well plates, imaged with the IVIS-100 imaging system 
to measure the dose-response of the enzyme-substrate pairs in cells. Compared 
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to wild-type CG6178, FruitFire exhibited a lower apparent Km with CycLuc2 
(Figure 7.11). 
 
Figure 7.11. Improved performance of FruitFire over wild-type CG6178 in 
live cells. Wild-type luc2 luciferase (A), wild-type CG6178 (B), and FruitFire (C) 
were each used to transfect Chinese hamster ovary (CHO) cells, then were 
imaged over a concentration range from 0.122 µM to 250 µM with either D-
luciferin or CycLuc2. Panel D shows the relative performance of all three 
enzymes with CycLuc2 on the same graph, which highlights the lower Km for 
FruitFire than wild type CG6178 in live cells. 
 
The lower Km and greater luminescence activity of FruitFire luciferase 
with CycLuc2 compared to wild type CG6178 suggests the former may be 
suitable for in vivo use. To test this hypothesis, we delivered both enzymes into 
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live mouse brain via stereotactic delivery of adeno-associated viral (AAV) 
vectors. Once the respective genes established expression in the mice’s brains, 
we injected them intraperitoneally with either D-luciferin, CycLuc2, or CycLuc2-
amide on separate imaging days to assess the enzymes’ relative performance 
with the substrates. CycLuc2-amide differs from the parent compound, CycLuc2, 
by addition of an amide group (Figure 7.12) (Mofford et al., 2014.). Presence of 
this amide group makes the compound a pro-luciferin which must be converted 
to CycLuc2 by endogenous enzymes present in mouse brain (Mofford et al., 
2014.). CycLuc2, despite requiring unmasking by a secondary enzymatic activity, 
greatly improves the access of the substrate to mouse brain following delivery 
and results in greater light emission (Mofford et al., 2014.). Wild-type CG6178 
expressed in mouse striatum was incapable of light emission when treated with 
D-luciferin, CycLuc2, or CycLuc2-amide. However, FruitFire emits measurable 
light when treated with CycLuc2-amide (Figure 7.12). FruitFire’s two mutated 
residues are sufficient to convert the fruit fly enzyme CG6178 to a luciferase 





Figure 7.12. FruitFire emits measurable light in live mouse brain when 
imaged with CycLuc2-amide. Fruitfire or wild-type CG6178 were delivered into 
live mice’s brains via stereotactic injection of viral vectors containing genes for 
the enzymes. Once expressing either of these enzymes, the mice were injected 
intraperitoneally with either D-luciferin, CycLuc2, or CycLuc2-amide on separate 
imaging days (compound structures for each substrate shown under the 
corresponding images) and imaged with an IVIS Spectrum imaging system. 
Measurable light emission was achieved with mice expressing Fruitfire following 
administration of CycLuc2-amide, but not with CycLuc2 or D-luciferin. Wild-type 
CG6178 did not catalyze measurable light emission with any of the substrates. 
 
Conclusion 
 Fluc is a bifunctional enzyme, acting as both a luciferase and an ACSL. 
The chemistry is dependent on what substrate the enzyme binds; luciferins are 
oxidized for light emission and long-chain fatty acids are attached to coenzyme 
A. The reverse is also true in some cases, with some ACSLs exhibiting luciferase 
activity with luciferins. One such bifunctional ACSL is the fruit fly enzyme 
CG6178 (Mofford et al., 2014.). CG6178 is capable of emitting light with the 
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synthetic luciferin CycLuc2, but not the natural D-luciferin substrate (Mofford et 
al., 2014.). We wanted to elucidate the nature of CG6178’s substrate 
discrimination and improve its luciferase activity. Once we determined the 
structure of CG6178, we generated mutants of multiple active-site residues and 
tested their relative performance. Of these mutants, changing one contiguous 
stretch of residues from 342-347 had the most impact. Taking a closer look at 
this region, we could see that residues 344-347 formed a loop that creates a 
unique protrusion via the sidechain of leucine 346. This leucine sidechain aligns 
with the sidechain of a serine residue responsible for binding the luciferin 
substrate via an intermediate hydrogen-bonded water molecule in Fluc (serine 
347 in Fluc). Previously, efforts were made to functionally convert CG6178 to a 
functional luciferase by mutating leucine 346 to a serine residue based on 
sequence alignments alone (Oba et al., 2009.). However, this single point 
mutation was not sufficient to permit light emission with D-luciferin (Oba et al., 
2009.). We mutated the leucine and surrounding residues that comprise the 
bump in CG6178 and found that mutating two residues was sufficient to improve 
light emission in CG6178 by 20-fold over the wild-type enzyme with CycLuc2, 
while also lowering the Km for CycLuc2 by approximately 7-fold. This same 
double-mutant also permits dose-dependent light emission in vitro with D-
luciferin. We named this mutant enzyme FruitFire luciferase. Further experiments 
with FruitFire luciferase showed that it also exhibits a lower apparent Km in live 
CHO cells than the wild-type enzyme with CycLuc2 and is capable of producing 
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measurable light emission in live mouse brain with CycLuc2-amide. The robust 
improvement of CG6178’s luciferase activity via structure-directed mutagenesis 
highlights the utility of enzymes homologous to Fluc to serve as alternative 
platforms for bioluminescent reporter engineering. 
Materials and Methods 
Contributions 
S.T.A. Jr. devised experiments, performed purified enzyme assays, performed 
live cell assays, crystallized CG6178, analyzed x-ray data and built structural 
model, performed all mouse experiments, and prepared the manuscript. Markus 
F. Bohn (formerly of Celia Schiffer’s lab in the department S.T.A. Jr. performed 
thesis research in) mentored S.T.A. Jr. for crystallography work leading to the 
structure. G.R.R. and G.S.K.K.R. designed and synthesized luciferins. S.C.M. 
helped devise experiments. Thanks to Celia Schiffer for providing a lab with 
immensely talented scientists to show me how to work with protein structures 
and for the Kelch lab for shooting my CG6178 crystal at the Synchotron. 
Plasmid Constructs: Plasmids for bacterial expression were prepared by 
cloning the target gene into pGex-6P1 vector. For live cell assays, luc2 and 
CG6178 were cloned into pcDNA3.1. CG6178 mutants, including FruitFire, were 
ordered as complete plasmids in pGex-6P1 and pcDNA3.1 from Genscript. 
Enzyme Expression and Purification: Enzymes were expressed as GST-
fusion proteins from pGex6P-1 vectors. Liter cultures of BL21-DE3 cells 
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transformed to express the protein of interest were grown at 37 °C until the 
culture’s OD600 reached between 0.5-1. The culture was cooled to room 
temperature, then induced with 0.1 mM IPTG, followed by incubation and 
shaking at 20 °C overnight. The following day, cells were pelleted at 5000 rpm 
and flash frozen with liquid nitrogen. The frozen pellets were kept on ice and 
resuspended in 25 mL lysis buffer (50 mM Tris [pH 7.4], 500mM NaCl, and 0.5% 
Tween 20) containing 1 mM phenymethylsulfonyl fluoride, and disrupted by 
sonication. Dithiothreitol (DTT) was added at 10 mM, followed by 
ultracentrifugation at 35k rpm for 1 hour at 4 °C. The supernatant was bound to 
immobilized glutathione beads (Thermo Scientific) in a Pierce column (Pierce 
Scientific) for 1 hour at 4 °C. The beads were washed with lysis buffer containing 
10 mM DTT, followed by wash buffer (50mM Trish [pH 8.1], 250 mM NaCl, and 
10 mM DTT) and storage buffer (50 mM Tris [pH 7.4], 0.1 mM EDTA, 150 mM 
NaCl, and 1 mM TCEP). Twenty units of PreScission Protease (GE Healthcare) 
were added, then the beads were incubated overnight at 4 °C on a Labquake 
tube rotator (Thermo Scientific) to cleave the GST-linkage, permitting elution of 
the untagged enzyme the following day. Protein concentrations were determined 
using the Nanodrop 100 (ThermoFisher) using the protein mass and molar 
extinction coefficient method (calculated using the Peptide Property Calculator at: 
biotools.nubic.northwestern.edu/proteincalc.html). 
For crystallographic use, CG6178 was further purified using size-exclusion 
chromatography with a Superdex 75 column (GE Life Sciences), where the 
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protein collected eluted as a single band and was collected for concentration. 
CG6178 enzyme for crystallography was concentrated to 30 mg/mL using 
cellulose Millipore Amicon® Ultra – 4 Ultracel – 30K centrifugal filters 
(MilliporeSigma). 
Crystallization of CG6178: To crystallize CG6178, a sitting drop method was 
used. Hampton Research Intelli-Plate 48-3 plates were used. After optimized hits 
following multiple screens, the following method reliably produced crystals within 
24 hours: 200 µl of crystallization solution (0.1M Tris pH 7.5, 0.2M (NH4)2SO4, 
28% PEG 3350, and 10 mM ATP disodium salt) was deposited into the reservoir 
of each well. Then, 2 µl of the crystallization solution was mixed 1:1 with 2 µl of 
30 mg/mL CG6178 in each of 3 sample drop drop wells within each well. Plates 
were immediately sealed with Hampton Research ClearSeal Film and stored at 
25 °C. 
Crystal Harvesting and Data Collection: Crystals were harvested from their 
drops with MiTeGen crystal mounts attached to goniometer bases using a 
MiTeGen wand and deposited immediately into liquid nitrogen. Cryopreserved 
crystals were transferred to magnetic cryovials and stored in at cryogenic 
temperatures for transport to the beamline. No cryoprotectant was used. Data 
was collected at the 23-IDB beamline at the Advanced Photon Source within the 
Argonne National Laboratory, Chicago, Illinois, U.S.A.  
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Data Processing: The crystal diffraction intensities were indexed, integrated, 
and scaled using HKL3000. Structures were solved using firefly luciferase (PDB 
4G36) as a search model in molecular replacement calculation. Model building 
and refinement were performed using Coot and Phenix. Ligand models were 
generated using eLBOW to generate .cif files that could be placed using Phenix 
LigandFit. 
Purified Protein Luminescence Assays – GloMax: 50 µL of purified luciferase 
in enzyme buffer (20 mM Tris [pH 7.4], 0.1 mM EDTA, 1 mM DTT, and 0.8 
mg/mL BSA) were added to 50 µL 2X substrate in substrate buffer (20 mM Tris 
[pH 7.4], 0.1 mM EDTA, 8 mM MgSO4, and 4 mM ATP) in a white 96-well plate 
(Costar 3912). Light was measured and integrated for each half second for 1 
minute after enzyme addition using a Promega GloMax at a final enzyme 
concentration of 40 nM and final substrate concentrations ranging from 0.122 µM 
to 250 µM. Data was exported into Excel for formatting, then pasted into 
Graphpad Prism for graphing. Data are reported as emission (relative light units, 
RLU) for each well of the 96-well plate. The values at the final 1 minute time point 
were plotted for each concentration to generate dosage-response curves. 
Graphs were fit to a sigmoidal dose-response curve by non-linear regression. 
Live Cell Assay: Chinese hamster ovary (CHO) cells were transduced with 
pcDNA3.1 vector backbone containing either luc2, wild type CG6178, or 
FruitFire. Cells were plated into 96-well black plates (Costar 3915) at 10k cells 
per well. After 24 hours, cells were transfected with 0.075 g DNA per well using 
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Lipofectamine 2000 (ThermoFisher). Prior to imaging the transfected cells, a 
master plate containing the substrates titrated from 250 µM to 0.122 µM over the 
12 columns was prepared at sufficient volume to supply substrate to the plates 
for all three enzymes being assayed. At 24 hours post-transfection, cells were 
imaged by removing the media containing the Lipofectamine, washing each well 
with 60 µl Hank’s Balanced Salt Solution (HBSS), aspirating the HBSS, then 
adding 60 µl per well of the appropriate substrate. After a 3 minute hold, the cells 
were imaged with the Perkin Elmer IVIS 100. Data collection and Regions of 
Interest (ROIs) were performed with Living Image Software, then data exported 
to Excel for formatting. The formatted data was plotted using Graphpad Prism as 
dosage response curves and analyzed using nonlinear regression models. 
AAV Vector Construction: Luc2, wild-type CG6178, and CG6178 mutants were 
cloned into the EcoRI-SalI sites of a pAAV-CMV plasmid. AAV-luciferase, AAV-
wild type CG6178, and AAV-FruitFire constructs were packaged into AAV9 
serotype viral vectors by the Viral Vector Core at the University of Massachusetts 
Medical School. 
Mice: FVB/N mice were purchased from the Jackson Laboratory. Mouse 
procedures were approved by the Institutional Animal Care and Use Committee 
(IACUC) at the University of Massachusetts Medical School (protocol A-2474). 
Striatal Delivery of AAV Vectors: Striatal injections of FVB/NJ mice were 
performed at 6 weeks of age. Each mouse was induced with isoflurane 
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anesthesia, then restrained in a stereotactic frame, fitted with isoflurane nose 
cones to maintain anesthesia. Mice were kept on a chemical hand warmer 
wrapped in autoclaved paper towels to maintain body temperature. Hair from the 
mice’s scalp was removed by applying superglue, followed by removing the 
glued hair with sterilized forceps. The denuded scalps were then washed three 
times alternately, using 70% ethanol and betadine, using a fresh sterile swab 
each time. Then, while holding up the scalp with sterilized forceps, a 1 cm 
anteroposterior incision was made in the middle of the scalp with sterile surgical 
scissors. The bregma suture was visualized and used as a reference for 
acquiring the injection site at the lateral edge of the striatum/cortex border 
(stereotactic coordinates: anterioposterior: +1 mm anterior, mediolateral: +3 mm 
right lateral, and dorsoventral: -2 mm ventral from bregma). A dental drill 
wrapped in sterile paper towel containing a sterilized bit was used to drill a hole 
through the skull at this site, then the needle lowered into the brain at the 
appropriate depth. After waiting 1 minute, the injection of 1 µl of 2.5e12 GC/ml 
AAV9 in PBS) was delivered at 125 nl/min using a micropump-controlled syringe 
(NanoFil, World Precision Instruments). After the injection completed, the needle 
was left in place for one minute before withdrawing. The scalp was sutured using 
3 simple interrupted sutures of dissolvable suture. The mice each then received 
the following subcutaneously prior to returning them to their cages: 4 mg/kg 
meloxicam SR, 0.05 mg/kg buprenorphine and 200 µl PBS. The cages remained 
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on heat pads at 37 °C until mice regained their righting reflexes. 
Bioluminescence imaging began at least 2 weeks after completing the surgeries.  
Preparation of Luciferins for Brain Imaging: D-luciferin (100 mM) and 
CycLuc2 (5 mM) were prepared by dissolving dry compound directly into PBS. 
CycLuc2-amide was prepared by first dissolving dry compound into DMSO to a 
concentration of 50 mM, followed by dilution in PBS to a final concentration of 
250 µM. Once dissolved, each substrate stock was filtered through a 0.2 µm filter 
(Millipore Millex GV) prior to injection in mice. 
Brain Imaging: Mice were imaged using the University of Massachusetts 
Medical School Small Animal Imaging Core using an IVIS Spectrum imaging 
system. Mice were induced with isoflurane anesthesia (2% in 1 L/min oxygen), 
then injected intraperitoneally with 4 µl of luciferin stock in PBS per gram of body 
mass. Images were acquired as 2 minute exposures at 15 minutes after 
intraperitoneal injection and analyzed using Living Image software. Regions of 
interest (ROIs) were drawn around the region covering the brain, and the total 
flux within each ROI was recorded. ROI sizes were identical across all images. 







Chimeras between Firefly Luciferase and Fatty Acyl-CoA Synthetases are 
Substrate-Selective Luciferases 
Spencer T. Adams, Jr., et al. Currently preparing for submission. 
Summary 
To create their luminous display, fireflies oxidize the small-molecule D-luciferin 
with their enzyme firefly luciferase (Fluc). In addition to this bioluminescent 
activity, Fluc can attach coenzyme A to fatty acids, making it also a long-chain 
fatty acyl-CoA synthetase (ACSL). The latter activity hearkens to Fluc’s 
evolutionary origins and, conversely, some ACSLs with homology to Fluc also 
emit light with synthetic luciferins. However, the relative intensity of light emission 
with these latent luciferases is much weaker than Fluc. To create luciferases with 
enhanced selectivity with synthetic luciferins and greater light emission, we 
created chimeras combining Fluc and ACSLs. These Fluc-ACSL chimeras were 
all capable of generating robust light output with synthetic luciferins, even when 
made with an ACSL that has no luciferase activity on its own. One of the 
chimeras generates greater light emission than Fluc in live cells and live mice. 
The chimeras detailed here highlight how ACSLs can augment bioluminescent 





Bioluminescence is the chemical production of light that results when a luciferase 
enzyme catalyzes the oxidation of a small-molecule luciferin to an excited-state 
product. This excited-state oxyluciferin next relaxes to the ground state, 
generating a photon. Bioluminescence’s use of chemistry to accomplish light 
emission creates a reporter with a great signal-to-noise ratio (Weissleder and 
Ntziachristos, 2003.). Over half a century of inquiry has unraveled the 
identification of numerous unique luciferases and luciferins (White et al.,1963.; 
White et al., 1965.; McElroy et al., 1969.). Each luciferase and luciferin 
contributes to our growing knowledge of how bioluminescence works, while 
creating reporters useful for illuminating biology. 
Fireflies are one of the best studied bioluminescent species. The broad emission 
spectra extending into red wavelengths and relative intensity of light emission 
make firefly bioluminescence an exceptional reporter for penetrating animal 
tissues (Zhao et al., 2005.). Elucidation of how firefly luciferase (Fluc) catalyzes 
light emission from the natural substrate D-luciferin thus becomes imperative to 
enhancing its utility through modifying the luciferase and luciferin. Fireflies emit 
light using a two-step reaction (Figure 8.1). D-luciferin is adenylated in the first 




Figure 8.1. Firefly luciferase (Fluc) and some long-chain fatty acyl-CoA 
synthetases (ACSL) are bifunctional. A) Fluc catalyzes light emission with D-
luciferin in a two-step reaction. D-luciferin is adenylated, then oxidized to make 
an excited-state oxyluciferin, which then relaxes to the ground-state to release a 
photon. B) Fluc and some homologous ACSLs catalyze light emission with 
synthetic luciferins, such as CycLuc2, following the same two-step reaction. C) 
Fluc and ACSLs catalyze the ligation of coenzyme A to fatty acids of appropriate 
length, such as arachidonic acid. The fatty acid is initially adenylated, then the 
AMP moiety is displaced to attach coenzyme A, yielding the fatty acyl-CoA 
product. 
 
Interrogation of Fluc’s enzymatic activity, coupled with the understanding of the 
enzyme’s shared evolutionary history with insect long-chain fatty acyl-CoA 
synthetases (ACSLs), has opened a new area of inquiry about how 
bioluminescence works and how we might make novel reporters to expand the 
bioluminescent palette (Oba et al., 2004.; Oba et al. 2006.; Oba et al., 2009.; 
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Mofford et al., 2014., Mofford et al., 2017.). In addition to emitting light with 
luciferins, Fluc can also catalyze the ligation of coenzyme A to long-chain fatty 
acids (Oba et al., 2004.). This makes Fluc bifunctional, possessing both 
luciferase and ACSL activities. Some of these ACSLs bearing significant 
homology to Fluc are also latent luciferases, catalyzing light emission from 
synthetic luciferins (Mofford et al., 2017.). Such ACSLs with latent luciferase 
activity are found in Drosophila menalogaster (CG6178) and Agrypnus binodulus 
(Agrypnus binodulus luciferase like protein, AbLL), while an ACSL with similar 
homology to Fluc from Pyrophorus angustus (Pyrophorus angustus luciferase-
like protein PaLL) exhibits no luciferase activity (Mofford et al., 2017.). The latent 
luciferase activity observed in CG6178 and AbLL are only revealed with synthetic 
luciferins, positioning them as candidates for creating orthogonal luciferases with 
suitable luciferins. However, their light output is poor compared to Fluc. 
To create novel luciferases with unique substrate selectivity and improved 
brightness, we created chimeric luciferase-ACSL proteins. Fluc is a two-domain 
protein with a larger N-terminal domain and smaller C-terminal domain (Figure 
8.2) (Conti, et al., 1996.). The N-terminal domain is primarily responsible for 
substrate binding, surrounding the substrate as seen in Figure 8.2. The C-
terminal domain rotates relative to the N-terminal domain, presenting two 
catalytic lysine residues in each of two conformations: lysines 529 and 443 in 
Fluc’s sequence, promoting adenylation and oxidation, respectively (Sundlov et 
al., 2012.).  
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Figure 8.2. Firefly luciferase is a two domain protein. Firefly luciferase (PDB 
ID: 4G36 (Sundlov et al., 2012.) is shown with its N-terminal domain in green and 
C-terminal domain in blue. The non-hydrolyzable bisubstrate analog DLSA is 
shown at the interface of the two domains, where the luciferin is adenylated and 
oxidized to emit light. Figure prepared with UCSF Chimera (Petterson et al., 
2004). 
 
Previous attempts to create chimeras with Fluc and CG6178 had demonstrated 
that modest luminescence with D-luciferin is achievable by splicing the C-
terminal domain of CG6178 to the N-terminal domain of Fluc at the linker region 
(Arginine 437 in Fluc’s sequence), while a chimera composed of CG6178’s N-
terminal domain and Fluc’s C-terminal domain was only able to function as an 
ACSL (Oba et al., 2006.). We hypothesized that replacing Fluc’s C-terminal 
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domain with the C-terminal domains from CG6178, AbLL, and PaLL would create 
unique luciferases selective for synthetic luciferins and with robust light emission.  
 
Results and discussion 
To gain a greater understanding of how the ACSLs homologous to Fluc might 
differ in their activity, we generated homology models of the enzymes to analyze 
how their active sites compare to Fluc (Figure 8.3) (Waterhouse et al., 2018.). 
Previous experiments had demonstrated that although AbLL shares greater 
homology with Fluc than CG6178, it has less luciferase activity when tested with 
a panel of synthetic luciferins (Figure 8.3) (Mofford et al., 2017.). PaLL also 
shares greater amino acid identity than CG6178 with Fluc but exhibits no 
luciferase activity with D-luciferin or synthetic luciferins (Table 8.1) (Mofford et al., 
2017). The SWISS model we used to generate the homology models had great 
predictive power when we compared its results to our previously unpublished 
structure of CG6178 (Adams Jr. et al., in preparation.). CG6178’s active site 
exhibits a unique protrusion that likely prevents proper alignment of D-luciferin 
relative to ATP for the adenylation step of bioluminescence chemistry (Adams Jr. 
et al., in preparation.). The SWISS model predicts this protrusion using only 
luciferase as a template to model CG6178’s sequence (Figure 8.4). Interestingly, 
the homology models we created predict that the active site of PaLL would not 
permit luciferin to fit, while the model for AbLL shows a similar active site to Fluc 
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(Table 8.1). This correlates with our experimental observations. The Models also 
predict conservation of the lysine residues the C-terminal domain must contribute 
for its role in bioluminescence. The model of AbLL shows an active site further 
constricted beyond what we saw in CG6178, possibly explaining its poorer 
performance as a luciferase. Additionally, the model of PaLL predicts an active 
site that would not permit luciferin to interact with ATP for the adenylation step. It 
is not clear if PaLL can even bind luciferin based on our model. The model 
predicts a small tunnel that would permit a fatty acid chain to bind and attack 






Figure 8.3. Comparison of homology models for AbLL and PaLL active 
sites with firefly luciferase and CG6178. The SWISS model was used to 
generate models of AbLL and PaLL for comparing their active sites with firefly 
luciferase and CG6178 (Waterhouse et al., 2018.). Firefly luciferase’s active site 
(Panel A) is less constricted than CG6178’s (panel B). AbLL’s active site (panel 
C) is predicted to be smaller than CG6178’s. PaLL’s active site (panel D) is only 
predicted to have a small tunnel that would accommodate a fatty-acid chain, but 
would prevent luciferin binding and/or adenylation. Images were produced using 








         
Table 8.1. Percent amino acid identity between firefly luciferase and the 
ACSLs used to make chimeras. 
 
 
Figure 8.4 SWISS Model predicts the protrusion in CG6178 we observed 
experimentally. The left panel shows our CG6178 structure determined using x-
ray crystallography (Adams et al. in preparation.). The right panel shows a 
homology model of CG6178 prepared using the SWISS model (Waterhouse et 
al., 2018.)with Fluc (PDB ID:4G36) as a template for CG6178’s sequence. The 
red arrows show the location of a protrusion that we predict is responsible for 
CG6178’s inability to emit light with D-luciferin. Images were produced using 
UCSF Chimera (Petterson et al., 2004). 
 
 
We aligned the sequence of Fluc with the sequences of AbLL, CG6178, and 
PaLL, then identified the residues forming the linker (Figure 8.5). The chimeric 
luciferases were created by attaching the C-terminal domain from each of the 
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ACSLs with the N-terminal domain of Fluc. We used Gibson assembly to create 
the chimeras following amplification of these domains (Figure 8.6). These 




Figure 8.5. Luciferase shares homology with insect ACSLs. Sequences for 
Photinus pyralis luciferase, Agrypnus binodulus luciferase-like protein (AbLL), 
Pyrophorus angustus luciferase-like protein (PaLL), and Drosophila 
melanogaster long-chain fatty acyl-CoA synthetase CG6178 (CG6178) were 
aligned using MUSCLE. Darker shades of blue represent greater homology. The 
junction where the N-terminal domains and C-terminal domains are represented 
by a red vertical line and red asterisk. Black asterisks indicate locations of the 






Figure 8.6. Chimera design strategy. The N-terminal domain of Fluc (residues 
1-436) were joined to C-terminal domains of Agrypnus binodulus luciferase-like 
protein (AbLL), Drosophila melanogaster CG6178 (CG6178), and Pyrophorus 
angustus luciferase-like protein (PaLL), at the junction indicated for the linker 
residues in alignments from Figure 8.5. 
 
Once the chimeras were made, we tested their in vitro activity. Purified enzyme 
was mixed with either D-luciferin or CycLuc1 (Figure 8.7) across a concentration 
range from 0.122 µM to 250 µM to measure the dose-response of luciferase 
activity with these substrates (Figure 8.8). The chimeras all emit measurable light 
in a dose-dependent manner with D-luciferin, albeit at lower intensity than Fluc. 
The best performing of these chimeras with D-luciferin was Fluc/CG6178, which 
emits 15-fold less light than WT luc2 at 250 µM substrate concentration. At this 
concentration of D-luciferin, Fluc/CG6178 emits about 5-fold greater flux than 
Fluc/AbLL, which emits slightly less than 3-fold greater flux than Fluc/PaLL. With 
250 µM CycLuc1, WT luc2 and Fluc/AbLL perform comparably and both emit 
about 2-fold greater flux than both Fluc/CG6178 and Fluc/PaLL. However, none 
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of these enzymes obey Michaelis-Menten kinetics with CycLuc1, rather exhibiting 
similar amounts of light emission at all concentrations measured. 
 
 
Figure 8.7. Luciferins used for experiments. D-luciferin and CycLuc1 were 




Figure 8.8. In vitro performance of luciferase-ACSL chimeras. Fluc and 
chimeras were tested in vitro for light emission with D-luciferin and CycLuc1. A) 
Dose-response of WT Fluc, Fluc/CG6178, Fluc/AbLL, and Fluc/PaLL with D-
luciferin. B) Same as A, but with WT Fluc removed for scale showing chimeras. 





Despite all of the C-terminal domains used to generate the chimeras contain the 
conserved catalytic lysines needed to promote adenylation and oxidation of 
luciferin, the chimeras vary in their activities with D-luciferin and CycLuc1. 
Though Figure 8.3 shows the differences in active sites for AbLL, CG6178, and 
PaLL, these models are for the whole protein. The luciferin is binding within the 
N-terminal domain (Figure 8.2), so we expect differences in activity would be the 
result of how the C-terminal domain promotes the adenylation and oxidation 
reactions.  The structures of AbLL and PaLL would be helpful in analyzing their 
C-terminal domains. The differences in activity between the chimeras may be a 
result of changes in domain-domain interactions between the different C-terminal 
domains from each ACSL with the N-terminal domain of Fluc. Though we 
achieved activity with all the chimeras, the differences in the ACSL C-terminal 
domains relative to Fluc represent divergent paths in evolution to specialize in 
acting on distinct substrates. 
Next, we tested the performance of the Fluc-ACSL chimeras in live cells (Figure 
8.9). We transfected Chinese hamster ovary (CHO) cells with vectors containing 
either WT luc2 or one of the three chimeras. Once expressing these enzymes, 
we tested the enzymes’ performance over a range of substrate concentrations by 
adding either D-luciferin or CycLuc1 from 0.122 µM to 250 µM and measuring 
light emission with an IVIS Spectrum instrument. D-luciferin generates greater 
radiance than CycLuc1 at saturating substrate concentration with WT luc2. 
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However, CycLuc1 yielded greater radiance at all measured concentrations with 
all three of the chimeras. Unexpectedly, Fluc/CG6178 generated greater 
radiance than WT luc2 with CycLuc1 at higher substrate concentrations. 
Additionally, the chimeras exhibit a lower apparent Km with CycLuc1 than with D-
luciferin. Western blots were used to gauge the relative expression of the 
chimeras relative to Fluc within CHO cells and showed that Fluc/CG6178 was 
present in greater quantities than the other two chimeras, possibly explaining its 
exceptional performance (Figure 8.10). 
 
Figure 8.9. Live cell performance of luciferase-ACSL chimeras. Dose-
response with D-luciferin and CycLuc1 in live CHO cells for: A) Luc2 (optimized 
version of Fluc) B) Fluc/CG6178 chimera C) Fluc/AbLL and D) Fluc/PaLL. 







Figure 8.10. Western blots of CHO cell lysates show Fluc/CG6178 chimera 
is present in greater quantities than the other two chimeras. A Western blot 
of CHO cell lysates showed that, controlling for beta-actin levels, Fluc/CG6178 
chimera was present in quantities similar to Fluc, while the Fluc/AbLL and 
Fluc/PaLL chimeras were present in approximately three to four-fold lower 
quantities. 
 
Encouraged by the unexpected robust light emission with Fluc/CG6178 and the 
other chimeras in live cells, we turned to using these enzymes for bioluminescent 
imaging in live mice (Figure 8.11). We employed an intranasal instillation of 
adeno-associated viral (AAV) vector containing either WT luc2 or one of the three 
chimeras to establish expression of each enzyme. Once the mice were 
expressing their respective enzymes, we administered either D-Luciferin or 
CycLuc1 on separate imaging days and measured light emission using an IVIS 
Spectrum instrument. Mice expressing WT luc2 produced more light with D-
Luciferin than with CycLuc1, which we would expect in peripheral tissues. Similar 
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to the preference for CycLuc1 in live cells, mice expressing the Fluc/AbLL 
chimera preferred CycLuc1 over D-Luciferin by about 2-fold. Mice expressing the 
Fluc/CG6178 chimera exhibited even more selectivity for CycLuc1 over D-
Luciferin, emitting about 7-fold greater radiance with the synthetic luciferin. 
Further, the mice expressing the Fluc/CG6178 chimera emit more light with 
CycLuc1 than WT luc2 with D-Luciferin. Mice expressing the Fluc/PaLL chimera 
emit measurable light with CycLuc1, but little to no light with D-luciferin. The 
exceptional performance of the Fluc/CG6178 chimera may be explained by its 
greater expression and/or stability leading to greater quantities of the enzyme in 
vivo, as we had seen with our Western blot data. However, all of the chimeras 
are capable of bioluminescence imaging in live mice, even when composed of 
the C-terminal domain from PaLL, an enzyme with no luciferase activity as a 











Figure 8.11. Luciferase-ACSL chimeras emit robust light in live mice with 
the synthetic luciferin CycLuc1. Codon-optimized wild-type firefly luciferase 
and the three chimeras were expressed in live mouse lung following intranasal 
instillation with adeno-associated viral vectors. Mice were then injected 
intraperitoneally with either D-luciferin (blue bars on graph) or CycLuc1 (red bars 
on graph) on separate days and imaged with an IVIS instrument to measure flux. 
All images are scaled the same. Flux was then compared mouse by mouse for 
each substrate to represent the relative performance with these two substrates 




Bioluminescence is a powerful tool for illuminating biology. As we gain a greater 
understanding of how bioluminescence works on a molecular level, we 
simultaneously open avenues for improved reporters. One application where 
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bioluminescence excels is in live animals, where a robust signal and lack of 
background improve the sensitivity of measurement (Prescher et al., 2010). 
Unfortunately, due to animal tissues’ light absorption properties, resolution of 
spectrally distinct signals is technically difficult (Weissleder and Ntziachristos, 
2003.; Jones et al., 2017.) However, orthogonal luciferase-Luciferin combinations 
that retain robust light emission can be temporally resolved for measurement of 
separate processes within the same animal. The chimeras detailed in this 
manuscript are selective for synthetic luciferins while still achieving bright 
emission, even outperforming the commercially-available luc2 with D-Luciferin as 
in the case of the luc2:CG6178 chimera with CycLuc1 in live mouse lung. The 
relative performance of luc2:CG6178 to WT luc2 was unexpected, but underlines 
the potential for improved bioluminescent reporters based on the emerging group 
of latent luciferases that share homology with Fluc. Homology modeling predicts 
that the N-terminal domains are different between the ACSLs we used to derive 
the chimeras. Though the C-terminal domains are interchangeable to make 
functional luciferases, the N-terminal domains appear to have diverged more in 
the evolution of Fluc, permitting the relatively bulky luciferin substrate to occupy a 
tunnel previously evolved to accommodate fatty acids. 
 




S.T.A. Jr. devised experiments, helped design chimeras, performed live cell 
experiments, performed all mouse experiments, and prepared the manuscript. 
D.M.M. devised experiments, designed chimeras, and performed purified 
enzyme experiments. G.R.R. and G.S.K.K.R. designed and synthesized 
luciferins. S.C.M. devised experiments. 
General  
Chemicals were purchased from Aldrich, Matrix Scientific, Oakwood, or TCI. ATP 
was purchased from both MP Biomedicals and Sigma. D-luciferin was obtained 
from Gold Bio. CycLuc1 was synthesized as previously described (Reddy et al., 
2010). Data were plotted with GraphPad Prism. Plasmid constructs The DNA 
sequences for long-chain fatty acyl-CoA synthetases CG6178, AbLL, and PaLL 
were codon optimized for mammalian expression, synthesized by GenScript, and 
cloned into the BamHI–NotI sites of pGEX6P-1. WT luc2 luciferase was used in 
pGEX6P-1 as previously described (Mofford et al., 2014). 
Plasmid constructs 
The DNA sequences for long-chain fatty acyl-CoA synthetases CG6178 and 
AbLL were codon optimized for mammalian expression, synthesized by 
GenScript, and cloned into pGEX6P-1. WT luc2 luciferase was used as 
previously described (Mofford et al., 2014). Plasmid constructs containing the 
chimeric enzymes were generated using Gibson Assembly (NEB). Fragments of 
each cDNA corresponding to the desired region of each enzyme were PCR 
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amplified and purified via agarose gel purification. PCR primers were designed to 
give overlapping ends of complementary DNA with the adjacent fragment of DNA 
for that chimera, per Gibson Assembly instructions. Each DNA fragment and 
pGEX6P-1 plasmid digested with BamHI and NotI were incubated with Gibson 
Assembly master mix per the manufacturer’s instructions to generate the final 
combined constructs. 
Enzyme expression and purification 
Luciferase and chimeras were expressed and purified as GST-fusion proteins 
from the pGEX6P-1 vector as previously described (Mofford et al., 2014). Briefly, 
JM109 cells were grown at 37 °C until the OD600 reached 0.5-1, induced with 
0.1 mM IPTG, and incubated with shaking at 20 °C overnight. Cells were pelleted 
at 5000 RPM, then flash frozen in liquid nitrogen. The E. coli pellets from 1 L of 
culture were thawed on ice, resuspended in 25 mL lysis buffer (50 mM Tris [pH 
7.4], 500 mM NaCl, and 0.5% Tween 20) containing 1 mM phenylmethylsulfonyl 
fluoride, and disrupted by sonification (Branson Sonifier). Dithiothreitol (DTT) was 
added at 10 mM, and the resulting cell lysate was clarified by centrifugation at 
35,000 RPM for 60 min at 4 °C. The supernatant was batch-bound to 
immobilized glutathione (Thermo Scientific) for 1 hr at 4 °C, and the beads were 
washed with lysis buffer containing 10 mM DTT, followed by wash buffer (50 mM 
Tris [pH 8.1], 250 mM NaCl, and 10 mM DTT) and storage buffer (50 mM Tris 
[pH 7.4], 0.1 mM EDTA, 150 mM NaCl, 1 mM TCEP). Twenty units of 
PreScission Protease (GE Healthcare) were added, and incubation continued 
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overnight at 4 °C to cleave the GST-fusion and elute the untagged enzyme. 
Protein concentrations were determined using Coomassie Plus (Thermo 
Scientific).  
Purified protein luminescence assays  
Luminescence assays were initiated by adding 30 μL of purified luciferase in 
enzyme buffer (20 mM Tris [pH 7.4], 0.1 mM EDTA, 1 mM TCEP, and 0.8 mg/mL 
BSA) to 30 μL 2x substrate in substrate buffer (20 mM Tris [pH 7.4], 0.1 mM 
EDTA, 8 mM MgSO4, and 4 mM ATP) in a black 96-well plate (Costar 3915). 
Imaging was performed one minute after enzyme addition using a Xenogen IVIS 
100 at a final enzyme concentration of 20 nM and final substrate concentrations 
ranging from 0.122 μM to 250 μM. Data acquisition and analysis was performed 
with Living Image software. Data are reported as total flux (p/s) for each ROI 
corresponding to each well of the 96-well plate. 
Cell culture  
Chinese hamster ovary (CHO) cells were grown in a CO2 incubator at 37°C with 
5% CO2 and were cultured in F-12K Nutrient Mixture (GIBCO) and Dulbecco's 
Modified Eagle's Medium (DMEM) (GIBCO), respectively. Both media were 




CHO cells were transfected with codon-optimized firefly luciferase (luc2) as 
previously described (Mofford et al., 2014). Transient transfections were 
performed at room temperature using Lipofectamine 2000 on cells plated at 
60%–75% confluency in 96-well black tissue culture treated plates (Costar 3916). 
0.075 μg DNA/well of pcDNA3.1-luc2 was transfected into CHO cells. Assays 
were performed in triplicate 24 hrs after transfection. 
Western blotting 
Media was aspirated from transfected wells in 6-well plates, then PBS added to 
wash. Ice-cold PBS was used to collect cells with a scraper and transferred to a 
conical tube. Cells were pelleted, then PBS supernatant removed. Lysis buffer 
was added and the pellet sonicated. Protein quantity was measured, then lysates 
were run with SDS-PAGE. Protein was transferred to a nitrocellulose membrane. 
After blocking the membrane (50:50 mix of Odyssey blocking buffer and TBS), 
the membrane was rinsed 3X with TBST. The membrane was incubated with 
primary antibodies for beta actin (Cell Signalling Technology 3700P anti-beta-
actin mouse 1:1000) and luciferase (Abcam ab21176 anti-luciferase rabbit, 
1:1000 in 1:1 TBST:Odyssey blocking buffer). The membrane was rinsed with 
TBST 3X. The membrane was incubated with secondary antibodies (LI-COR 
IRDye 680LT Goat anti-Rabbit 1:20000 and LI-COR IRDye 800CW Goat anti-
Mouse in 1:1 TBST:Odyssey blocking buffer), then rinsed 3X with TBST. Imaging 
was performed with a LI-COR Odyssey. 
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Live cell imaging 
Tissue culture media was removed from CHO cells 24 hrs post-transfection. 60 µl 
HBSS was added to each well to wash, then removed. 60 µl of substrate was 
added to each well. Substrate concentrations range from 250 µM to 0.122 µM 
across the twelve wells of a 96 well-plate, by two-fold dilutions in each 
successive column. Each substrate concentration was measured in triplicate for 
each enzyme. After a one minute hold, cells were imaged with an IVIS imaging 
system. Data acquisition and analysis were done using Living Image software to 
calculate radiance for each individual well. These values were then analyzed with 
Graphpad Prism. 
Mice  
All of the experiments involving mice were conducted in accordance with the 
Institutional Animal Care and Use Committee of The University of Massachusetts 
Medical School (docket #A-2474-14). FVB mice were ordered from Jackson 
Labs. AAV9 vectors containing each chimera and luc2 were prepared in sterile 
PBS in sufficient quantity to yield 1E11 viral particles in a 50 µl aliquot per 
mouse. Mice were anesthetized with ketamine/xylazine. Once mice no longer 
exhibited a toe-pinch response, these vectors were instilled dropwise into 
anesthetized mice’s noses, alternating between the two nostrils. This was 
achieved by holding the mice upright, with their heads at a 90 degree angle to 
their body (head parallel with the ground) to allow them to inhale the PBS-vector 
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solution. As the mice inhaled each drop of the PBS-vector solution, another drop 
was added to the alternate nostril until the full 50 µl dose was delivered. Once 
each mouse had inhaled their vector dose, they were kept warm in their cages on 
a heat mat until recovered. 
Mouse Imaging 
Prior to mouse imaging, luciferins were prepared in sterile saline at the 
appropriate concentration (100 mM for D-luciferin sodium salt and 5 mM 
CycLuc1). Mice were anesthetized using isoflurane, inducing in a chamber 
outside the IVIS imaging cabinet. Once anesthetized, they were placed into the 
IVIS imaging cabinet, which has a warmed stage (37 °C) and a manifold with 
nosecones dispensing isoflurane to maintain anesthesia. Mice were imaged prior 
to injection of luciferin to establish background signal, then injected 
intraperitoneally with either 100 mM D-luciferin or 5mM CycLuc1 (4 µl / gram 
body mass). Mice were subsequently imaged post-injection to measure light 
emission. The data acquisition and analysis were performed with Living Image 
software. Identical sized regions of interest were drawn over the lungs of mice to 
calculate the radiance. The same mice were imaged with both substrates for 








The glow of bioluminescent organisms has captivated the public’s imagination 
throughout history, illuminating landscapes from the night sky to the depths of the ocean. 
Bioluminescence is the chemical production of light by a luciferase enzyme oxidizing a 
small-molecule luciferin. Numerous divergent species have independently evolved the 
ability to make their own light chemically as selective pressures have fixated the feature 
for unique ecological benefits (Fallon et al.; 2018.; Petushkov et al., 2014.; Davis et al., 
2016.;. Kaskova et al., 2017.; Kaskova et al., 2016.). Many of these unique luciferins and 
luciferases have been characterized in the last century, while some are the subject of 
current investigation (Kaskova et al., 2016.). How all of these luciferases and luciferins 
work on a molecular basis is the subject of active research in an effort to create useful 
reporters for laboratory use. My thesis aims to expand the bioluminescent toolkit, 
focusing on two key areas: 1. Improving the in vivo bioluminescent toolkit by 
characterizing synthetic luciferins capable of producing more robust output than 
commercially available reporters and pro-luciferins that can report on secondary 
enzymatic activities in live animals and 2. Characterizing and enhancing the latent 
luciferase activity in fatty acyl-CoA synthetases that share homology with firefly 
luciferase as novel platforms for bioluminescent reporter development. 
Bioluminescence is frequently used in biological research to illuminate processes 
in vitro, in cells, and in live animals. Because bioluminescence employs chemistry to 
achieve light output, this circumvents the need for exogenous light sources. Therefore, 
bioluminescence can capitalize on this lack of extraneous light sources to improve its 
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signal to background ratio, providing a sensitive imaging modality (Prescher et al., 2010.; 
Dothager et al., 2009.; Zhao et al., 2010.). This is particularly useful in the context of live 
animal imaging, permitting measurement of processes within deep tissues (Prescher et 
al., 2010.; Dothager et al., 2009.; Zhao et al., 2010.). 
The chemical nature of bioluminescence also presents limitations. In live 
animals, luciferins must access the tissues that express luciferase to achieve light 
emission. For example, the firefly’s natural substrate D-luciferin is actively pumped out of 
the blood-brain barrier by ABCG2 pumps (Zhang et al., 2007.). In addition to the 
requirement for luciferins to access luciferase, the marine luciferin coelenterazine is 
prone to auto-oxidation, diminishing the lack of background that makes bioluminescence 
so attractive (Otto-Duessel et al., 2006.). 
My thesis research builds on the growing bioluminescent toolkit for research use, 
highlighting how synthetic luciferins, mutant luciferases, and specific long-chain fatty 
acyl-CoA synthetases work on a molecular level and how they can be employed for use 
in live animal research. In CHAPTER II, we see how the synthetic luciferin, CycLuc1, 
generates a signal greater than what is possible with D-luciferin in live mouse brain, 
even when administered at 20-fold lower substrate concentration (Evans et al., 2014.). 
We used multiple mouse models for complementary in vivo experiments to compare 
CycLuc1 to D-luciferin, including: mice expressing luciferase in brain striatum following 
adeno-associated viral delivery, mice expressing luciferase in xenografted cells, 
transgenic mice expressing luciferase ubiquitously, and transgenic mice expressing 
luciferase in only dopaminergic neurons contained within the substantia nigra. These 
experiments detail how CycLuc1 can outperform D-luciferin in tissues where substrate 
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access is a limiting factor. In transgenic mice expressing luciferase under control of the 
dopamine transporter promoter, CycLuc1 generated measurable light emission, 
demonstrating the ability for this synthetic luciferin to facilitate longitudinal 
bioluminescent experiments not previously possible with the natural D-luciferin 
substrate.  
 This is not to say that the synthetic luciferin CycLuc1 is superior to the natural D-
luciferin substrate for all in vivo imaging applications. In tissues more easily accessed by 
D-luciferin, such as superficial mouse tissues expressing luciferase, D-luciferin can 
generate a stronger signal than achievable with CycLuc1 (Evans, et al., 2014.; Mofford 
et al., 2015.). Thus, different imaging scenarios can benefit from a broad palette of 
bioluminescent reporters optimized for disparate conditions.  
In addition to providing more robust light emission than the natural substrate in 
some tissues, synthetic luciferins can also be modified to reveal secondary enzymatic 
activities (Miska et al., 1987.; Miska et al., 1988.; Geiger et al., 1992., Monsees et al., 
1994.; Wehrman et al., 2006.). We demonstrate this in CHAPTER III, where we created 
luciferin amides that serve as luminescent reporters of endogenous fatty-acid amide 
hydrolase (FAAH) activity in live mice (Mofford et al., 2015.). The FAAH enzyme is an 
important drug target that catalyzes the breakdown of anandamide. Inhibiting this 
enzyme has the potential to promote analgesia, but identifying selective inhibitors for in 
vivo use had historically required sacrificing animals to process tissues for analysis 
(Long et al., 2011.). By converting a luciferin’s carboxyl group to an amide, they become 
pro-luciferins that luciferase is unable to adenylate. We hypothesized such pro-luciferins 
would require FAAH’s activity for conversion into a luciferin that luciferase could then 
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adenylate and subsequently oxidize for light emission. In CHAPTER III, we show how 
these luciferin amides selectively report on FAAH activity and inhibition in live mice in 
real time (Mofford et al., 2015.). We tested luciferin amides in vitro and found that 
recombinant FAAH enzymes were capable of converting the pro-luciferins to luciferins. 
Cells that endogenously express FAAH also catalyzed light emission when supplied 
luciferin amides and responded to FAAH inhibitors via decreased light emission with 
luciferin amides. Interestingly, these luciferin amides achieved much greater light 
emission than the parent luciferins in live mouse brain, despite administration at much 
lower dosages. This reinforces the concept that chemical modification to luciferins can 
improve their access to some tissues in live animals. The luciferin amides behave like 
drugs, facilitating the transport of the parent compound into the brain. Considering 
FAAH’s association with membranes for internalizing endocannabinoids (Day et al., 
2001.), this presents a powerful paradigm for improved bioluminescent reporter design. 
The theme of chemical modification of synthetic luciferins to create prodrugs is not novel 
(Miska et al., 1987.; Miska et al., 1988.; Geiger et al., 1992., Monsees et al., 1994.; 
Wehrman et al., 2006.) and I expect that exploring more modifications holds promise for 
creating more selective reporters of endogenous enzymatic activities in cells and live 
animals. It would be helpful to test if pro-luciferins are impacting the native function of 
the protein they are interacting with, to avoid confounding variables with experiments. 
For example, measuring for analgesic phenotypes in mice following exposure to an 
amide prodrug would be helpful. 
In CHAPTERS IV and V (Sharma et al., 2017.; Sharma et al., 2019.), I detail a 
large panel of novel luciferin analogs that greatly expands the structure space we can 
explore with complementary luciferases and live animal models. These novel luciferins 
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help us to greater appreciate what constitutes a luciferin, a theme that depends on the 
corresponding luciferase we are testing with these compounds. Many of the luciferin 
analogs exhibit weak light emission, but what constituted a bright luciferin was not 
always intuitive. The approach of increasingly larger and varied functional groups 
attached to the core luciferin scaffold allows us to directly assay a luciferase, luciferase 
mutant, or latent luciferase for activity. A greater diversity of synthetic luciferins 
increases the capacity for identifying robust and selective reporters with complementary 
luciferase enzymes. Additionally, some of these luciferins behaved as inhibitors (Sharma 
et al., 2017.). As more enzymes with latent luciferase activity come to light, these 
luciferins can serve as tools for interrogating the biochemical intricacies of substrate 
preference. 
 Previous work in the lab had identified multiple mutants of firefly luciferase that 
selectively utililize synthetic luciferin analogs (Harwood et al., 2011.). The firefly 
luciferase mutants Arginine 218 to Lysine (R218K), Leucine 342 to Alanine (L342A), and 
the double mutant combining these two mutations had demonstrated selectivity for 
synthetic luciferins in experiments in vitro and in live cells (Harwood et al., 2011.). 
However, it was not clear how this selectivity would translate to use in live animal 
models. In CHAPTER IV, we tested these luciferase-luciferin pairs’ performance in vivo 
(Adams Jr. et al., 2016.). We used AAV delivery of these enzymes to mouse striatum 
and compared their relative performance with CycLuc1 and CycLuc2, as well as their 
amide derivatives to the natural D-luciferin substrate and with wild-type firefly luciferase. 
Despite emitting no measurable light output with D-luciferin, we found that the L342A 
mutant catalyzed light emission comparable to or greater than WT luciferase with 400 
μmol/kg D-luciferin when we administered 0.4 μmol/kg CycLuc2-amide (1000-fold lower 
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dose of luciferin amide) (Adams Jr. et al, 2016.). Alternatively, L342A emits virtually no 
light output with D-luciferin in live mouse brain. This highlights how in vivo conditions in 
mouse brain can enhance the selectivity observed with luciferase-luciferin pairs when 
translated from in vitro or live cell experiments, due to the threshold of light needed for 
measurable signal. Though selectivity was achieved by our reporters, they are still not 
orthogonal. Due to the shared evolutionary origins of Fluc and some insect long-chain 
fatty acyl-CoA synthetases (Oba et al., 2003.; Oba et al., 2004.), combined with their 
newfound latent luciferase activity only when provided synthetic luciferins (Mofford et al., 
2014.), we next considered them as a novel platform for selective luciferase-luciferin 
development. 
 Enzymes homologous to firefly luciferase from other insects can selectively 
catalyze light emission with synthetic luciferins (Mofford et al., 2014.; Mofford et al., 
2017.). One of the best characterized of these enzymes is the fruit fly long-chain fatty 
acyl-CoA synthetase CG6178, whose latent luciferase activity was revealed when our 
lab screened for activity with some of our synthetic luciferins (Oba et al., 2004.; Mofford 
et al., 2014.). CG6178 is unable to catalyze light emission with D-luciferin, but emits 
modest light output with the synthetic luciferin CycLuc2 (Mofford et al., 2014.). To 
interrogate CG6178’s discrimination between D-luciferin and CycLuc2, I determined the 
structure of the enzyme.  In CHAPTER VII, I report the first structure of CG6178. Efforts 
to co-crystallize CG6178 with CycLuc2 were not successful, but our CG6178 structure 
highlighted differences in the fatty-acid-binding tunnel that formed the basis of 
mutagenesis experiments. Initially, we performed mutagenesis to residues that 
surrounded the active site and found that one region spanning residues 342-347 
provided the greatest improvement of CG6178’s luciferase activity. When we compared 
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this region of CG6178’s active site with Fluc, we noticed CG6178 has a unique 
protrusion in its active site that we hypothesize prevents suitable alignment of D-luciferin 
with ATP for the adenylating step. This misalignment of the luciferin relative to ATP, 
should it prevent adenylation, would preclude its subsequent oxidation and light 
emission. Experiments had already established that CG6178 can oxidize pre-adenylated 
D-luciferin and emit light without the adenylation chemistry as a catalytic barrier, lending 
credence to this hypothesis (Mofford et al., 2014.). Why CG6178 is able to adenylate 
CycLuc2 is not clear, but I hypothesize that the rigid extra cyclic group acts as a handle 
to place the appropriate carboxyl group in proximity to the alpha phosphate of ATP for 
productive adenylation or that the CycLuc2 substrate may alter the N-terminal and C-
terminal domain interface, allowing CycLuc2 to align for adenylation undeterred by the 
bump.  
 To test the hypothesis that the bump I observe in the active site of CG6178 is 
preventing adenylation of D-luciferin, I mutated the residues that contribute to the bump. 
Fortuitously, one of the residues that contribute to this bump had already been mutated 
by Oba et al. to be the same residue as that in firefly luciferase, based on sequence 
alignment (Oba et al., 2009.). This mutation was made in an attempt to functionally 
convert CG6178 into a luciferase capable of emitting light with D-luciferin. This point 
mutation alone was not sufficient for light emission with D-luciferin. But with the structure 
of CG6178 now available, I surmised that extending mutagenesis to include more 
residues that comprise the bump in the active site would enhance CG6178’s luciferase 
activity with synthetic luciferins and permit the enzyme to also adenylate D-luciferin.  
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Mutating just two residues in this bump region transformed CG6178 from a weak 
luciferase incapable of emitting light with D-luciferin, to an enzyme capable of not only 
emitting significant light with D-luciferin, but measurable light output in live mouse brain 
with CycLuc2-amide. I dub this double-mutant of CG6178 “FruitFire” luciferase. It would 
still be illuminating to have co-crystal structures of CG6178 with CycLuc2 and D-luciferin, 
as well as Fruitfire with those substrates, to better understand CG6178’s substrate 
discrimination. Additionally, more mutagenesis experiments to further improve CG6178’s 
activity and selectivity for synthetic luciferins holds the potential for beetle-luciferase 
based orthogonal reporters. Considering the impact of mutating two residues on 
CG6178’s activity, saturating mutagenesis to these residues akin to the experiments 
performed by Harwood et al. (Harwood et al., 2011.) would be warranted to optimize 
CG6178 as a luciferase. Other ACSLs sharing homology with Fluc may also benefit from 
the same types of mutagenesis experiments. Determining the structures of other ACSLs, 
such as AbLL and PaLL could inform us in similar ways to enhance them as 
bioluminescent reporters as we have done with CG6178. 
Another example of characterizing selective luciferase reporters is detailed in 
CHAPTER VIII. Here, we report how generating chimeras that combine the N-terminal 
domain of firefly luciferase with the C-terminal domains of homologous insect ACSLs 
create novel luciferases, all capable of emitting light with D-luciferin and the synthetic 
luciferin CycLuc1. However, the chimeras prefer CycLuc1, emitting more light with this 
substrate. In live mouse lung, one of the chimeras (Fluc/PaLL) is only capable of 
emitting measurable light with CycLuc1. Unexpectedly, the Fluc/CG6178 chimera emits 
more robust light emission with CycLuc1 than even wild-type firefly luciferase with D-
luciferin in live mouse lung. This is not consistent with the in vitro performance of 
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Fluc/CG6178, where it does not rival WT Fluc with D-luciferin in light emission. The 
nature of the discrepancy between how these chimeras’ performance in vivo versus in 
vitro is not completely understood, but may be related to improved stability or expression 
of the Fluc/CG6178 chimera in vivo. We performed a western blot that supports this 
hypothesis. Testing the thermal stability and other measures of expression for these 
enzymes in vivo could help to determine the discrepancy between these conditions. 
Another interesting route to pursue in the pursuit of novel bioluminescencent reporters 
could improve AbLL and PaLL similar to Fruitfire using directed evolution. Select 
residues could be targeted based on structures and homology models for saturating 
mutagenesis and screened for selectivity and improved activity. 
The large assortment of synthetic luciferins, mutant luciferases, mutated latent 
luciferases homologous to firefly luciferase (such as our FruitFire luciferase), and 
chimeric luciferases have expanded our knowledge of both how bioluminescence works, 
improves the bioluminescent toolkit, and informs us on how to engineer future 
bioluminescent reporters. The synthetic luciferin CycLuc1 is useful for generating a 
robust signal in live mouse brain, an environment whose interrogation of such medically 
relevant processes as neurodegenerative and other brain processes can greatly benefit 
from such real-time, longitudinal reporting. The luciferin-amide CycLuc2-amide further 
improves on the strength of light emission in live mouse brain, even at exceedingly low 
imaging doses. CycLuc2-amide is also a selective reporter of FAAH activity. Using a pro-
drug approach, CycLuc2 is a useful reporter for this important drug target. Mutant firefly 
luciferase enzymes can selectively emit light with synthetic luciferins in mouse brain, 
providing an avenue for orthogonal reporters, as we demonstrate in CHAPTER IV. 
Expanding the luciferase enzyme repertoire was our goal in chapter VII, where we 
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transformed a fruit fly enzyme into a luciferase capable of use in live mouse brain 
imaging by just substituting two amino acids. Our structure-driven mutagenesis 
highlights how important structures are to unlocking the mysteries of enzyme 
engineering. We generated chimeras mixing ACSLs with Fluc in CHAPTER VIII, where 
we show how they are selective for synthetic luciferins and perform better than would be 
expected in vivo. In CHAPTERS V and VI, we detail a large panel of novel synthetic 
luciferins that enabled us to interrogate what constitutes a luciferin and provides a library 
of novel functionalities ripe for experimentation with different luciferases as they are 
engineered. The work embodied by this thesis has expanded our knowledge of how 
bioluminescence works and provided useful reporters already in use by other labs, 
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